SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE TO PROMOTE REMYELINATION - Patent application

Spirocyclic bicyclic modulators enhance Δ8,9-unsaturated sterol intermediates in oligodendrocytes to promote myelination and remyelination, addressing the lack of effective treatments for myelin-related disorders and improving neurological outcomes.

JP2024543237APending Publication Date: 2024-11-19GENENTECH INC +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024551885
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-23
Filing Date
2022-11-22
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Current treatments for myelin-related disorders, such as multiple sclerosis, lack a cure and effective therapeutic approaches to promote remyelination, leading to progressive neurological deterioration and disability.

Method used

Development of spirocyclic bicyclic modulators that enhance and induce the accumulation of Δ8,9-unsaturated sterol intermediates in oligodendrocyte progenitor cells, promoting their differentiation, survival, and maturation, thereby facilitating myelination and remyelination.

Benefits of technology

The compounds effectively promote myelination and remyelination in subjects with myelin-related disorders, potentially slowing disease progression and improving neurological function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543237000001
    Figure 2024543237000001
  • Figure 2024543237000002
    Figure 2024543237000002
  • Figure 2024543237000003
    Figure 2024543237000003
Patent Text Reader

Abstract

The subject matter described herein relates to myelin-promoting compounds of formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions containing the compounds, and methods of administering the compounds to treat disorders, such as myelin-related disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 282,357, filed November 23, 2021, the contents of which are incorporated herein by reference in their entirety for all purposes.

[0002] Field The subject matter described herein relates to myelin-promoting compounds of formula I, methods for making said compounds, pharmaceutical compositions thereof, and their use in the treatment of myelin-related disorders. [Background technology]

[0003] background Myelin-related disorders are disorders that result in abnormalities of the myelin sheath (e.g., dysmyelination, demyelination, and hypomyelination) in the nerve cells of a subject, e.g., CNS neurons, including their axons. The loss or degradation of the myelin sheath in such disorders results in slowing or cessation of neuronal conduction. The resulting myelin-related disorders are characterized by deficits in sensory, motor function, cognition, or other physiological functions. Myelin-related disorders include multiple sclerosis (MS), neuromyelitis optica (NMO), optic neuritis, childhood white matter dystrophies, neonatal white matter injury, age-related dementia, schizophrenia, progressive multifocal leukoencephalopathy (PML), encephalomyelitis pleuromyelitis (EPL), central pontine myelinolysis, and cerebral palsy. These include, but are not limited to, chronic myelolysis (CPM), adrenoleukodystrophy, Alexander disease, Perisaeus-Mersbacher disease (PMD), vanishing white matter disease, Wallerian degeneration, transverse myelitis, amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, Parkinson's disease, spinal cord injury, traumatic brain injury, post-radiation injury, neurological complications of chemotherapy, stroke, acute ischemic optic neuropathy, vitamin deficiency, isolated vitamin syndrome, Bassen-Kornzweig syndrome, Marchiafava-Bignami syndrome, metachromatic leukodystrophy, trigeminal neuralgia, acute disseminated encephalitis, Guillain-Barré syndrome, Charcot-Marie-Tooth disease, Bell's palsy, and radiation-induced demyelination.

[0004] MS is the most common myelin-related disorder affecting millions of people worldwide and is estimated to cause approximately 18,000 deaths per year. MS is a complex neurological disease characterized by the deterioration of central nervous system (CNS) myelin. Myelin, composed mostly of lipids (70% lipid, 30% protein), protects axons, allows saltatory conduction, and accelerates axonal electrical impulses. Demyelination of axons in chronic MS can lead to axonal degeneration and neuronal death. In addition, MS destroys oligodendrocytes, the highly specialized CNS cells that generate and maintain myelin. A repair process called remyelination occurs early in the disease, but over time, oligodendrocytes become unable to completely remodel and restore the myelin sheath. Repeated attacks result in successively less effective remyelination until scar-like plaques accumulate around damaged axons. These scars are the cause of the symptoms.

[0005] Currently, there is no cure for myelin-related disorders, and only a few disease-modifying therapies are available. Thus, there is a need for new therapeutic approaches to the treatment of myelin-related disorders, including promoting remyelination. The subject matter described herein addresses this unmet need. Summary of the Invention [Means for solving the problem]

[0006] overview In certain embodiments, the subject matter described herein pertains to a compound of formula I, or a pharma- ceutically acceptable salt thereof.

[0007] In certain embodiments, the subject matter described herein relates to a pharmaceutical composition comprising a compound of formula I, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0008] In certain embodiments, the subject matter described herein relates to a method of treating a disorder in a subject in need of treatment of said disorder, wherein the disorder is a myelin-related disorder, comprising administering to the subject an effective amount of a compound of formula I, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula I, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0009] In certain embodiments, the subject matter described herein relates to a compound of formula I, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula I, or a pharma- ceutically acceptable salt thereof, for use in treating a myelin-related disorder.

[0010] In certain embodiments, the subject matter described herein relates to a method of promoting myelination in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula I, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0011] In certain embodiments, the subject matter described herein relates to the use of a compound of formula I, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula I, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating a myelin-related disorder.

[0012] In certain embodiments, the subject matter described herein relates to a method of preparing a compound of formula I, or a pharma- ceutically acceptable salt thereof.

[0013] Other embodiments are also described. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Detailed Description Described herein are compounds of formula I, methods for producing the compounds, pharmaceutical compositions thereof, and their use in treating myelin-related disorders. In some embodiments, the compounds provided herein are pro-myelin.

[0015] Without wishing to be bound by theory, enhancing and / or inducing the accumulation of Δ8,9-unsaturated sterol intermediates of the cholesterol biosynthesis pathway in oligodendrocyte precursor cells (OPCs) can induce the generation of oligodendrocytes. Enhancement and / or induction of the accumulation of Δ8,9-unsaturated sterol intermediates can be provided, for example, by inhibiting the accumulation of Δ8,9-unsaturated sterol intermediates and / or regulating and / or inhibiting enzymes in the OPC cholesterol biosynthesis pathway in which Δ8,9-unsaturated sterol intermediates are substrates, and by administering Δ8,9-unsaturated sterol intermediates directly and / or indirectly to OPCs. Enhancement and / or induction of the accumulation of Δ8,9-unsaturated sterol intermediates can promote the differentiation, survival, proliferation and / or maturation of OPCs, which is believed to treat diseases and / or disorders in subjects in which myelination is beneficial to the subject.

[0016] Thus, in some embodiments, an agent capable of enhancing and / or inducing accumulation of Δ8,9-unsaturated sterol intermediates of the cholesterol biosynthetic pathway in OPCs, such as a compound of formula I or a pharma- ceutically acceptable salt thereof, can be administered to a subject and / or to OPCs in an amount effective to promote and / or induce differentiation, proliferation and / or maturation of OPCs, and oligodendrogenesis. In certain embodiments, the agent, such as a compound of formula I or a pharma- ceutically acceptable salt thereof, is a compound that inhibits enzyme-mediated synthesis of one or more sterol intermediates in the cholesterol biosynthetic pathway of OPCs and / or promotes accumulation of Δ8,9-unsaturated sterol intermediates.

[0017] In certain embodiments, the compound of formula I or a pharmaceutically acceptable salt thereof can regulate and / or inhibit one or more enzyme-mediated conversion steps (e.g., between lanosterol and / or lathosterol) of the cholesterol biosynthetic pathway, such as the lanosterol to cholesterol pathway, and regulating and / or inhibiting one or more of these steps in OPCs can promote and / or induce the generation of oligodendrocytes. For example, in some embodiments, the compound of formula I or a pharmaceutically acceptable salt thereof can inhibit CYP51, sterol 14-reductase (TM7SF2 and / or LBR), SC4MOL, NSDHL, and / or emopamil-binding protein (EBP) enzyme-mediated synthesis of sterol intermediates in the cholesterol biosynthetic pathway. In certain embodiments, the compound of formula I or a pharmaceutically acceptable salt thereof can inhibit CYP51, sterol 14-reductase, and / or EBP. In certain embodiments, the compound of formula I or a pharmaceutically acceptable salt thereof can inhibit EBP.

[0018] For example, in certain embodiments, the compound of formula I or a pharma- ceutically acceptable salt thereof used in the methods described herein can inhibit the enzyme-mediated conversion of zymostenol to lathosterol through inhibition of emopamil-binding protein (EBP) isomerase enzyme activity. Alternatively, in certain embodiments, the compound of formula I or a pharma-ceutically acceptable salt thereof used in the methods described herein can inhibit sterol C14 reductase enzyme activity or CYP51 enzyme activity in the cholesterol biosynthesis pathway.

[0019] Emopamil-binding protein (EBP) is an enzyme responsible for one of the final steps in the production of cholesterol. Specifically, EBP converts zymostenol to lathosterol, which is then modified by other enzymes to produce cholesterol. EBP is also called Δ8-Δ7-sterol isomerase, 3-β-hydroxysteroid-delta(8), delta(7)-isomerase, CDPX2, CHO2, CPX, or CPXD.

[0020] Without being bound to a particular theory, it is believed that the compound of formula I or a pharma- ceutically acceptable salt thereof can inhibit EBP-mediated conversion of zymostenol to lathosterol in the cholesterol biosynthesis pathway of OPCs, resulting in enhanced and / or induced accumulation of Δ8,9-unsaturated sterol intermediates. In some embodiments, enhanced and / or induced accumulation of Δ8,9-unsaturated sterol intermediates can promote OPC differentiation, survival, proliferation and / or maturation, and treat diseases and / or disorders in subjects in which myelination or myelin development is beneficial to the subject. This mechanism of promoting myelination is distinct from the primary action of immunomodulators that are often used to treat myelin-related disorders.

[0021] The subject matter disclosed herein will now be described more fully below. However, many modifications and other embodiments of the subject matter disclosed herein will occur to those skilled in the art to which the subject matter disclosed herein pertains having the benefit of the teachings presented in the description herein. Therefore, the subject matter disclosed herein should not be limited to the specific embodiments disclosed, and modifications and other embodiments should be considered as intended to be included within the scope of the appended claims. In other words, the subject matter described herein encompasses all alternatives, modifications and equivalents. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the event that one or more of the incorporated documents, patents, and similar materials differ from or conflict with this application, including but not limited to defined terms, usage of terms, techniques described, etc., this application shall control.

[0022] I. Definition As used herein, the following words, phrases and symbols are generally intended to have the meanings set forth below, except to the extent that the context in which they are used indicates otherwise.

[0023] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment of a substituent. For example, -C(O)NH2 is attached through a carbon atom. Dashes at the beginning or end of a chemical group are for convenience. Chemical groups may be shown with or without one or more dashes without losing their ordinary meaning. Wavy or dashed lines drawn vertically through or across the ends of lines in structures indicate designated points of attachment of a group. Unless chemically or structurally required, no directionality or stereochemistry is indicated or implied by the order in which chemical groups are described or named.

[0024] Prefix “C” u -C v " indicates that the group that follows has u to v carbon atoms. For example, "C1-C6 alkyl" indicates that the alkyl group has 1 to 6 carbon atoms.

[0025] Reference herein to a value or parameter followed by "about" includes (and describes) an embodiment directed to the value or parameter itself. In certain embodiments, the term "about" includes the indicated amount ±50%. In certain other embodiments, the term "about" includes the indicated amount ±20%. In certain other embodiments, the term "about" includes the indicated amount ±10%. In other embodiments, the term "about" includes the indicated amount ±5%. In certain other embodiments, the term "about" includes the indicated amount ±1%. In certain other embodiments, the term "about" includes the indicated amount ±0.5%, and in certain other embodiments, 0.1%. Such variations are appropriate for carrying out the disclosed methods or using the disclosed compositions. Also, the term "about x" includes the description of "x". Also, the singular forms "a" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to a "compound" includes a plurality of such compounds, and reference to an "assay" includes reference to one or more assays and equivalents thereof known to those of skill in the art.

[0026] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl refers to a group having 1 to 20 carbon atoms (i.e., C1 to C6 20 alkyl), 1 to 12 carbon atoms (i.e., C1 to C 12 alkyl), 1 to 8 carbon atoms (i.e., C1 to C8 alkyl), 1 to 6 carbon atoms (i.e., C1 to C6 alkyl), 1 to 4 carbon atoms (i.e., C1 to C4 alkyl), or 1 to 3 carbon atoms (i.e., C1 to C3 alkyl). Examples of alkyl groups include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a particular number of carbons is named by a chemical name or identified by a molecular formula, all positional isomers having that number of carbons can be encompassed, thus, for example, "butyl" includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2) and tert-butyl (i.e., -C(CH3)3), and "propyl" includes (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).

[0027] Certain commonly used alternative chemical names may be used. For example, divalent groups such as divalent "alkyl" groups, divalent "aryl" groups, etc. may also be referred to as "alkylene" groups, "alkylenyl" groups, "arylene" groups, and "arylenyl" groups, respectively. Also, unless otherwise noted, when a combination of groups is referred to herein as a single moiety, e.g., arylalkyl or aralkyl, the last-mentioned group includes the atom by which that moiety is attached to the remainder of the molecule.

[0028] "Alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond and having 2 to 20 carbon atoms (i.e., C 20alkenyl), alkyl groups having 2 to 8 carbon atoms (i.e., C2-C8 alkenyl), 2 to 6 carbon atoms (i.e., C2-C6 alkenyl), or 2 to 4 carbon atoms (i.e., C2-C4 alkenyl). Examples of alkenyl groups include, for example, ethenyl, propenyl, and butadienyl (including 1,2-butadienyl and 1,3-butadienyl).

[0029] "Alkynyl" means an alkyl group having 2 to 20 carbon atoms (i.e., C2-C6), unless otherwise specified. 20 It refers to an alkyl group containing at least one carbon-carbon triple bond, which may have from 2 to 8 carbon atoms (i.e., C2-C8 alkynyl), from 2 to 6 carbon atoms (i.e., C2-C6 alkynyl) or from 2 to 4 carbon atoms (i.e., C2-C4 alkynyl). The term "alkynyl" also includes groups having one triple bond and one double bond.

[0030] "Alkoxy" refers to the group "alkyl-O-" (e.g., C1-C3 alkoxy or C1-C6 alkoxy). Examples of alkoxy groups include, for example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0031] "Alkylthio" refers to the group "alkyl-S-".

[0032] "Acyl" is the group -C(O)R y In the formula, R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein. Examples of acyls include, for example, formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.

[0033] An "amide" is the group -C(O)NR y R z refers to the "C-amide" group, and the group -NR y C(O)R z and "N-amide" groups, where R y and R z is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein, or R y and R z taken together form a heterocyclyl, which may be optionally substituted as defined herein.

[0034] "Amino" is the group -NR y R z In the formula, R y and R z is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein.

[0035] "Amidino" is -C(NR y )(NR z 2), in which R y and R z is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein.

[0036] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic), including fused systems. As used herein, aryl refers to an aromatic carbocyclic group having 6 to 20 ring carbon atoms (i.e., C6 to C8). 20 aryl), 6 to 12 carbon ring atoms (i.e., C6 to C 12aryl), or 6 to 10 carbon ring atoms (i.e., C 10 aryl). Examples of aryl groups include, for example, phenyl, naphthyl, fluorenyl and anthryl. However, aryl does not encompass or in any way overlap with heteroaryl, as defined below. When one or more aryl groups are fused with a heteroaryl, the resulting ring system is a heteroaryl, regardless of the point of attachment. When one or more aryl groups are fused with a heterocyclyl, the resulting ring system is a heterocyclyl, regardless of the point of attachment.

[0037] "Arylalkyl" or "aralkyl" refers to the group "aryl-alkyl-", e.g. (C6-C 10 A non-limiting example of arylalkyl is benzyl.

[0038] "Carbamoyl" is the group -OC(O)NR y R z refers to the "O-carbamoyl" group and the group -NR y C(O)OR z "N-carbamoyl" refers to both the y and R z is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein.

[0039] "Carboxyl ester" or "ester" is -OC(O)R x and -C(O)OR x In the formula, R x is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein.

[0040] "Cycloalkyl" refers to saturated or partially unsaturated cyclic alkyl groups having single or multiple rings, which may include fused, bridged, and spiro ring systems. The term "cycloalkyl" refers to cycloalkenyl groups (i.e., cyclic groups having at least one double bond) and at least one sp 3 As used herein, cycloalkyl includes carbocyclic fused ring systems (i.e., at least one non-aromatic ring) having 3 to 20 ring carbon atoms (i.e., C3 to C4). 20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 10 Cycloalkyl) having 3 to 8 ring carbon atoms (i.e., C3-C8 cycloalkyl), 3 to 7 ring carbon atoms (i.e., C3-C7 cycloalkyl) or 3 to 6 ring carbon atoms (i.e., C3-C6 cycloalkyl). Monocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Additionally, the term cycloalkyl is intended to encompass any moiety containing a non-aromatic alkyl ring that may be fused to an aryl ring, regardless of attachment to the remainder of the molecule. Additionally, cycloalkyl also includes "spirocycloalkyl" when there are two positions for substitution on the same carbon atom (e.g., spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro[5.5]undecanyl). As used herein, "halocycloalkyl," e.g., C3-C7 halocycloalkyl, refers to a C3-C7 cycloalkyl group substituted with one or more halogens.

[0041] "Cycloalkylalkyl" refers to the group "cycloalkyl-alkyl-", e.g., (C3-C6 cycloalkyl)-C1-C3 alkyl.

[0042] "Guanidino" is -NR y C(=NR z )(NR y R z ) in which each R y and R z is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein.

[0043] "Hydrazino" refers to -NHNH2.

[0044] "Imino" is the group -C(NR y )R z In the formula, R y and R z Each is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein.

[0045] An "imide" is the group -C(O)NR y C(O)R z In the formula, R y and R z Each is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein.

[0046] "Halogen" or "halo" refers to atoms occupying Group VIIA of the periodic table, such as fluoro (fluorine), chloro (chlorine), bromo (bromine) or iodo (iodine).

[0047] "Haloalkyl" refers to an unbranched or branched alkyl, alkenyl, or alkynyl group as defined above in which one or more (e.g., 1-6, or 1-3) hydrogen atoms have been replaced with a halogen. For example, halo-C1-C3 alkyl refers to an alkyl group of 1-3 carbons in which at least one hydrogen atom has been replaced with a halogen. Halo-C1-C6 alkyl refers to an alkyl group of 1-6 carbons in which at least one hydrogen atom has been replaced with a halogen. Halo-C1-C6 alkenyl refers to an alkyl group containing at least one carbon-carbon double bond and having 1-6 carbon atoms in which at least one hydrogen atom has been replaced with a halogen. When a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to an alkyl substituted with two ("di") or three ("tri") halo groups, which are not necessarily the same halogen. Examples of haloalkyl include, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.

[0048] "Haloalkoxy" refers to an alkoxy group as defined above in which one or more (e.g., 1-6, or 1-3) hydrogen atoms are replaced with halogen. For example, halo-C1-C3alkoxy refers to an alkoxy group of 1-3 carbons in which at least one hydrogen atom is replaced with halogen. Halo-C1-C6alkoxy refers to an alkoxy group of 1-6 carbons in which at least one hydrogen atom is replaced with halogen. Non-limiting examples of haloalkoxy are -OCH2CF3, -OCF2H, and -OCF3.

[0049] "Hydroxyalkyl" refers to an alkyl group as defined above in which one or more (e.g., 1-6, or 1-3) hydrogen atoms have been replaced with a hydroxy group (e.g., hydroxy-C1-C3-alkyl, hydroxy-C1-C6-alkyl). The term "hydroxy-C1-C3-alkyl" refers to a 1-3 carbon alkyl chain in which one or more hydrogens on any carbon have been replaced with a hydroxy group, particularly one hydrogen on one carbon of the chain has been replaced with a hydroxy group. The term "hydroxy-C1-C6-alkyl" refers to a 1-6 carbon alkyl chain in which one hydrogen on any carbon has been replaced with a hydroxy group, particularly one hydrogen on one carbon of the chain has been replaced with a hydroxy group. Non-limiting examples of hydroxyalkyl include -CH2OH, -CH2CH2OH, and -C(CH3)2CH2OH.

[0050] "Heteroalkyl" refers to an alkyl group in which one or more carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatom groups, provided that the point of attachment to the remainder of the molecule is through a carbon atom. In certain embodiments, a heteroalkyl can have 1-3 carbon atoms (e.g., C1-C3 heteroalkyl) or 1-6 carbon atoms (e.g., C1-C6 heteroalkyl) and one or more (e.g., 1, 2, or 3) heteroatoms or heteroatom groups. The term "heteroalkyl" includes unbranched or branched saturated chains having carbon atoms and heteroatoms. By way of example, one, two, or three carbon atoms of the alkyl group in a "heteroalkyl" may be independently replaced with the same or different heteroatom groups. Heteroatom groups include, but are not limited to, -NR y -, -O-, -S-, -S(O)-, -S(O)2-, etc., in which R yis hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein. Examples of heteroalkyl groups include, for example, ethers (e.g., -CH2OCH3, -CH(CH3)OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, etc.), thioethers (e.g., -CH2SCH3, -CH(CH3)SCH3, -CH2CH2SCH3, -CH2CH2SCH2CH2SCH3, etc.), sulfones (e.g., -CH2S(O)2CH3, -CH(CH3)S(O)2CH3, -CH2CH2S(O)2CH3, -CH2CH2S(O)2CH2CH2OCH3, etc.), and amines (e.g., -CH2NR y CH3, -CH(CH3)NR y CH3, -CH2CH2NR y CH3 -CH2CH2NR y CH2CH2NR y CH3 etc. (in the formula, R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein. In certain embodiments, a heteroalkyl can have 1-20 carbon atoms, 1-15 carbon atoms, 1-12 carbon atoms, 1-10 carbon atoms, 1-8 carbon atoms, or 1-4 carbon atoms, and 1-3 heteroatoms, 1-2 heteroatoms, or 1 heteroatom.

[0051] "Heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl refers to an aromatic group having 1 to 20 ring carbon atoms (i.e., C1 to C6). 20 Heteroaryl), 3 to 12 ring carbon atoms (i.e., C3 to C 12Heteroaryl), or 3-8 carbon ring atoms (i.e., C3-C8 heteroaryl), and 1-5 ring heteroatoms, 1-4 ring heteroatoms, 1-3 ring heteroatoms, 1-2 ring heteroatoms, or 1 ring heteroatom, independently selected from nitrogen, oxygen, and sulfur. In certain cases, heteroaryl includes 9-10 membered ring systems (i.e., 9-10 membered heteroaryl), 5-10 membered ring systems (i.e., 5-10 membered heteroaryl), 5-7 membered ring systems (i.e., 5-7 membered heteroaryl), 5-6 membered ring systems (i.e., 5-6 membered heteroaryl), or 4-6 membered ring systems (i.e., 4-6 membered heteroaryl), each independently selected from 1-4 ring heteroatoms, 1-3 ring heteroatoms, 1-2 ring heteroatoms, or 1 ring heteroatom, independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include, for example, acridinyl, benzimidazolyl, benzothiazolyl, benzoindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, isothiophene, and the like. Azolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, isoquinolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, phenoazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinucinyl Examples of fused heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolinyl, isoquinolinyl, benzo[b]thiophenyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,5-a]pyridinyl, where the heteroaryl can be attached via either ring of the fused system.Any aromatic group having single or multiple fused rings containing at least one heteroatom is considered heteroaryl, regardless of attachment to the remainder of the molecule (i.e., through any one of the fused rings). Heteroaryl does not encompass or overlap with aryl, as defined above.

[0052] "Heteroarylalkyl" refers to the group "heteroaryl-alkyl-", e.g., (5-10 membered monocyclic heteroaryl)-C1-C3 alkyl.

[0053] "Heterocyclyl" refers to a saturated or partially unsaturated cyclic alkyl group having one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. The term "heterocyclyl" includes heterocycloalkenyl groups (i.e., heterocyclyl groups having at least one double bond), bridged heterocyclyl groups, fused heterocyclyl groups, and spiro-heterocyclyl groups. Heterocyclyls may be single rings or may have multiple rings fused, bridged, or spiro. Any non-aromatic ring containing at least one heteroatom is considered a heterocyclyl regardless of the bond (i.e., it may be bonded through a carbon atom or a heteroatom). In addition, the term heterocyclyl is intended to encompass moieties containing any non-aromatic ring containing at least one heteroatom, which may be fused to an aryl or heteroaryl ring, regardless of the bond to the rest of the molecule. The term heterocyclyl is also intended to encompass moieties containing a cycloalkyl ring fused to a heteroaryl ring, regardless of the bond to the rest of the molecule. Additionally, the term heterocyclyl is intended to encompass moieties containing a cycloalkyl ring fused to a heterocyclyl ring, regardless of attachment to the remainder of the molecule. As used herein, heterocyclyl refers to a ring having 2 to 20 ring carbon atoms (i.e., C2 to C6). 20 heterocyclyl), 2 to 12 ring carbon atoms (i.e., C2 to C 12 heterocyclyl), 2 to 10 ring carbon atoms (i.e., C2-C10 heterocyclyl), 2 to 8 ring carbon atoms (i.e., C2 to C8 heterocyclyl), 3 to 12 ring carbon atoms (i.e., C3 to C 12Heterocyclyls have 3 to 8 ring carbon atoms (i.e., C3-C8 heterocyclyl), or 3 to 6 ring carbon atoms (i.e., C3-C6 heterocyclyl), and have 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen. When the heterocyclyl ring contains 4 to 6 ring atoms, it is also referred to herein as a 4- to 6-membered heterocyclyl. Also disclosed herein are 5- or 6-membered heterocyclyls having 5 or 6 ring atoms, respectively, and 5- to 10-membered heterocyclyls having 5 to 10 ring atoms. Examples of heterocyclyl groups include, for example, azetidinyl, azepinyl, benzodioxolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxinyl, benzopyranonyl, benzofuranonyl, dioxolanyl, dihydropyranyl, hydropyranyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoquinol ... Examples of heterocyclyls include isoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, oxazolidinyl, oxiranyl, oxetanyl, phenothiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidinyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. In certain embodiments, the term "heterocyclyl" can include "spiroheterocyclyl" when there are two positions for substitution on the same carbon atom and at least one ring of the spiro system contains at least one heteroatom.Examples of spiro-heterocyclyl rings include bicyclic and tricyclic systems such as, for example, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl can be attached via either ring of the fused system.

[0054] "Heterocyclylalkyl" refers to the group "heterocyclyl-alkyl-".

[0055] "Oxime" is a group -CR y (=NOH), where R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein.

[0056] "Oxo" refers to the group (=O).

[0057] "Cyano" refers to the group (-CN).

[0058] "N-oxide" refers to the group (-N + -O - )

[0059] "Thiol" refers to the group (-SH).

[0060] "Sulfonyl" refers to the group -S(O)R y In the formula, R yis hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein. A non-limiting example of a sulfonyl group is -SO2(C1-C6 alkyl), referred to herein as alkylsulfonyl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.

[0061] "Sulfinyl" is the group -S(O)R y In the formula, R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein. Examples of sulfinyl are methylsulfinyl, ethylsulfinyl, phenylsulfinyl, and toluenesulfinyl.

[0062] "Sulfonamide" is the group -SONR y R z and -NR y SO2R z In the formula, R y and R z Each is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein.

[0063] The term "optionally" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not occur. Also, the term "optionally substituted" refers to any one or more (e.g., 1-5, 1-4, or 1-3) hydrogen atoms on a specified atom or group may or may not be replaced by a non-hydrogen moiety.

[0064] As used herein, the term "substituted" means any of the above groups (i.e., alkyl, alkenyl, alkynyl, alkylene, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl and / or heteroalkyl) in which at least one (e.g., 1-5, 1-4, or 1-3) hydrogen atom has been replaced by a bond to a non-hydrogen moiety. Unless otherwise specified, such non-hydrogen moieties may be alkyl, alkenyl, alkynyl, alkoxy, alkylthio, acyl, amido, amino, amidino, aryl, aralkyl, azide, carbamoyl, carboxyl, carboxyl ester, cyano, cycloalkyl, cycloalkylalkyl, guanidino, halo, haloalkyl, haloalkoxy, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -NHNH, =NNH, imino, imido, hydroxy, oxo, oxime, nitro, sulfonyl, sulfinyl, alkylsulfonyl, alkylsulfinyl, thiocyanate, -S(O)OH, -S(O)OH, sulfonamide, thiol, thioxo, N-oxide or -Si(R y )3(in the formula, each R y are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl.

[0065] In certain embodiments, "substituted" means that one or more (e.g., 1-5, 1-4, or 1-3) hydrogen atoms are independently replaced with deuterium, halo, cyano, nitro, azido, oxo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR g R h , -NR g C(=O)R h , -NR g C(=O)NR g R h , -NRg C(=O)OR h , -NR g S(=O) 1-2 R h , -C(=O)R g , -C(=O)OR g , -OC(=O)OR g , -OC(=O)R g , -C(=O)NR g R h , -OC(=O)NR g R h , -OR g , -SR g , -S(=O)R g , -S(=O)2R g , -OS(=O) 1-2 R g , -S(=O) 1-2 OR g , -NR g S(=O) 1-2 NR g R h , =NSO2R g , =NOR g , -S(=O) 1-2 NR g R h , -SF5, -SCF3, or -OCF3. In certain embodiments, "substituted" also means that one or more (e.g., 1-5, 1-4, or 1-3) hydrogen atoms are replaced with -C(=O)R g , -C(=O)OR g , -C(=O)NR g R h , -CH2SO2R g , or -CH2SO2NR g R h In the above, R g and R hare the same or different and are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and / or heteroarylalkyl. In certain embodiments, "substituted" also refers to one or more (e.g., 1-5, 1-4, or 1-3) hydrogen atoms being replaced by a bond to amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, and / or heteroarylalkyl, or R g and R h and R i means any of the above groups, wherein two of these, together with the atom to which they are attached, form a heterocyclyl ring optionally substituted with oxo, halo, or an alkyl optionally substituted with oxo, halo, amino, hydroxyl, or alkoxy.

[0066] Polymers or similar indefinite structures arrived at by defining a substituent with infinitely more additional substituents (e.g., substituted aryl with a substituted alkyl, which is itself substituted with a substituted aryl group, which is further substituted with a substituted heteroalkyl group, etc.) are not intended to be included herein. Unless otherwise stated, the maximum number of consecutive substitutions in the compounds described herein is three. For example, consecutive substitution of a substituted aryl group with two other substituted aryl groups is limited to ((substituted aryl) substituted aryl) substituted aryl. Similarly, the above definition is not intended to include impermissible substitution patterns (e.g., methyl substituted with five fluorines or heteroaryl groups with two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to those skilled in the art. When used to modify a chemical group, the term "substituted" can refer to other chemical groups as defined herein.

[0067] In certain embodiments, the phrase "one or more" as used herein refers to 1 to 5. In certain embodiments, the phrase "one or more" as used herein refers to 1 to 4. In certain embodiments, the phrase "one or more" as used herein refers to 1 to 3.

[0068] Any compound or structure provided herein is intended to represent unlabeled forms of the compound as well as isotopically labeled forms (isotopologues). These forms of compounds are also referred to as "isotopically enriched analogs", including "isotopically enriched analogs". Isotopically labeled compounds have structures as shown herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that may be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine and iodine, e.g., 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I. Various isotopically labeled compounds of the present disclosure include, for example, 3 H, 13 C and 14These include those incorporating radioactive isotopes such as C. Such isotopically labeled compounds may be useful in metabolism studies, reaction kinetic studies, detection or imaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or radioactive treatment of patients.

[0069] The term "isotopically enriched analog" includes "deuterated analogs" of the compounds described herein, in which one or more hydrogens are replaced with deuterium, such as hydrogen on a carbon atom. Such compounds exhibit increased resistance to metabolism and are therefore useful for increasing the half-life of any compound when administered to a mammal, particularly a human. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol.Sci.5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example, by using starting materials in which one or more hydrogens have been replaced with deuterium.

[0070] Deuterium-labeled or substituted therapeutic compounds of the present disclosure may have improved DMPK (drug metabolism and pharmacokinetic) properties with respect to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may provide certain therapeutic advantages resulting from greater metabolic stability, e.g., increased in vivo half-life, reduced dosage requirements and / or improved therapeutic index. 18 F, 3 H, 11C labeled compounds can be useful for PET or SPECT or other imaging studies.The isotopically labeled compounds of the present disclosure can generally be prepared by carrying out the procedures disclosed in the following schemes or examples and preparations, by using readily available isotopically labeled reagents instead of non-isotopically labeled reagents.In this context, it is understood that deuterium is considered as a substituent in the compounds described herein.

[0071] The concentration of such heavy isotopes, particularly deuterium, can be defined by the isotopic enrichment factor. In the compounds of the present disclosure, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise indicated, when a position is specifically designated as "H" or "hydrogen", the position is understood to have hydrogen at its natural abundance isotopic composition. Thus, in the compounds of the present disclosure, any atom specifically designated as deuterium (D) is meant to represent deuterium. Furthermore, in some embodiments, the corresponding deuterated analogs are provided.

[0072] In many cases, the compounds of the present disclosure are capable of forming acid and / or base salts by virtue of the presence of amino and / or carboxyl groups or groups similar thereto.

[0073] Pharmaceutically acceptable salts, isotopically enriched analogs, deuterated analogs, isomers (such as stereoisomers), and mixtures of isomers (such as mixtures of stereoisomers) of the compounds described herein are also provided.

[0074] "Pharmaceutically acceptable" or "physiologically acceptable" refers to compounds, salts, compositions, dosage forms and other materials useful in preparing pharmaceutical compositions suitable for veterinary or human pharmaceutical use. Generally, such materials are not biologically or otherwise undesirable, e.g., the substance can be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.

[0075] The term "pharmaceutically acceptable salts" of a given compound generally includes salts that are safe and not biologically or otherwise undesirable, including those that are acceptable for veterinary use as well as human pharmaceutical use, and "pharmaceutically acceptable salts" or "physiologically acceptable salts" include, for example, salts with inorganic acids and salts with organic acids. Furthermore, when a compound described herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, when the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional procedures for preparing acid addition salts from basic compounds. Those skilled in the art will recognize various synthetic methodologies that can be used to prepare non-toxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, for example, acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like. Similarly, pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts.Salts derived from organic bases include salts of primary, secondary, and tertiary amines, such as alkylamines (i.e., NH2(alkyl)), dialkylamines (i.e., HN(alkyl)2), trialkylamines (i.e., N(alkyl)3), substituted alkylamines (i.e., NH2(substituted alkyl)), di(substituted alkyl)amines (i.e., HN(substituted alkyl)2), tri(substituted alkyl)amines (i.e., N(substituted alkyl)3), alkenylamines (i.e., NH2(alkenyl)), dialkenylamines (i.e., HN(alkenyl)2), trialkenylamines (i.e., N(alkenyl)3), substituted alkenylamines (i.e., NH2(substituted alkenyl)), di(substituted alkenyl)amines (i.e., , HN(substituted alkenyl)2), tri(substituted alkenyl)amines (i.e., N(substituted alkenyl)3, mono-, di-, or tri-cycloalkylamines (i.e., NH2(cycloalkyl), HN(cycloalkyl)2, N(cycloalkyl)3), mono-, di-, or tri-arylamines (i.e., NH2(aryl), HN(aryl)2, N(aryl)3) or mixed amines, and the like. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(iso-propyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0076] The term "hydrate" refers to a complex formed by combining a compound described herein with water.

[0077] "Solvate" refers to an association or complex of one or more solvent molecules with a compound of the present disclosure. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethylsulfoxide, ethyl acetate, acetic acid, and ethanolamine. Solvates include hydrates.

[0078] Some of the compounds described herein may exist as tautomers. Tautomers are in equilibrium with each other. For example, an amide-containing compound may exist in equilibrium with an imidic acid tautomer. Regardless of which tautomer is shown and the nature of the equilibrium between the tautomers, it is understood by those skilled in the art that the compound includes both amide and imidic acid tautomers. Thus, amide-containing compounds are understood to include their imidic acid tautomers. Similarly, imidic acid-containing compounds are understood to include their amide tautomers. Another example of a compound with several tautomers is 1,4-thiazine. Tautomers are 1λ 4 ,4-thiazine, 2H-1,4-thiazine and 4H-1,4-thiazine, 4 ,4-Thiazine is the only one that is aromatic.

[0079] The compounds described herein or their pharma- ceutically acceptable salts may contain asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined in terms of absolute stereochemistry as (R)- or (S)-, or for amino acids as (D)- or (L)-. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for preparing / separating individual enantiomers include chiral synthesis from suitable optically pure precursors, or resolution of the racemates (or racemates of salts or derivatives), for example, using chiral high-performance liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, the compounds are intended to contain both E and Z geometric isomers.

[0080] "Stereoisomers" refer to compounds composed of the same atoms joined by the same bonds, but with different three-dimensional structures and are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof, and includes "enantiomers," which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.

[0081] "Diastereomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.

[0082] Relative centers of compounds depicted herein are indicated graphically using a "thick bond" style (bold or parallel lines) and absolute stereochemistry is indicated using wedge bonds (bold or parallel lines).

[0083] "Treatment" or "treating" is an approach to obtain beneficial or desired results, including but not limited to clinical results. Beneficial or desired results may include one or more of the following: a) inhibiting a disease or condition (e.g., reducing one or more symptoms caused by a disease or condition and / or reducing the severity of the disease or condition); b) delaying or halting the development of one or more clinical symptoms associated with a disease or condition (e.g., stabilizing a disease or condition, preventing or delaying the worsening or progression of a disease or condition, and / or preventing or delaying the spread (e.g., metastasis) of a disease or condition); and / or c) relieving a disease or condition, i.e., causing a regression of clinical symptoms (e.g., improving a disease state, providing partial or complete remission of a disease or condition, enhancing the effect of another drug, delaying the progression of a disease, improving quality of life, and / or prolonging survival). Reduction of the pathological consequences of demyelination is also encompassed by "treatment" or "treating".

[0084] "Prevention" or "preventing" refers to any treatment of a disease or condition that does not result in the development of clinical symptoms of the disease or condition. In some embodiments, the compounds may be administered to subjects (including humans) at risk for the disease or condition or who have a family history of the disease or condition.

[0085] "Subject" refers to an animal, e.g., a mammal, including a human, that has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful for human therapy and / or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human.

[0086] The term "therapeutically effective amount" or "effective amount" of a compound described herein or a pharma- ceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, or deuterated analogue thereof means an amount sufficient to effect treatment when administered to a subject to provide a therapeutic benefit, such as amelioration of symptoms or delay of disease progression. The therapeutically effective amount may vary depending on the subject and the disease or condition being treated, the subject's weight and age, the severity of the disease or condition, and the method of administration, which can be readily determined by one of skill in the art. An effective amount of a compound of the present disclosure in such a treatment method is, for example, about 0.01 mg / kg / day to about 1000 mg / kg / day, or about 0.1 mg / kg / day to about 100 mg / kg / day.

[0087] As used herein, the term "excipient" refers to an inert or inactive substance that may be used in the manufacture of a drug or pharmaceutical composition, such as a tablet, containing a compound (or a pharma- ceutically acceptable salt) described herein as an active ingredient. A variety of substances may be encompassed by the term excipient, including, but not limited to, any substance used as a diluent, filler or bulking agent, binder, disintegrant, wetting agent, coating, emulsifier or dispersing agent, compression / encapsulation aid, cream or lotion, lubricant, solution for parenteral administration, material for chewable tablets, sweetener or flavoring agent, suspending / gelling agent, or wet granulation agent. Binders include, for example, carbomer, povidone, xanthan gum, etc.; coating materials include, for example, cellulose acetate phthalate, ethyl cellulose, gellan gum, maltodextrin, enteric coatings, etc.; compression / encapsulation materials include, for example, calcium carbonate, glucose, fructose dc (dc--"directly compressible"), honey dc, lactose (anhydrous or monohydrate, optionally combined with aspartame, cellulose, or microcrystalline cellulose), starch dc, sucrose, etc.; disintegrants include, for example, croscarmellose sodium, gellan gum, sodium starch glycolate, etc.; creams or lotions include, for example, Examples of suitable excipients include maltodextrin, carrageenan, etc.; lubricants include magnesium stearate, stearic acid, sodium stearyl fumarate, etc.; chewable tablet materials include dextrose, fructose dc, lactose (monohydrate, optionally combined with aspartame or cellulose), etc.; suspending / gelling agents include carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners include dextrose, fructose dc, sorbitol, sucrose dc, etc.; wet granulating agents may include calcium carbonate, maltodextrin, microcrystalline cellulose, etc. In some cases, the term "excipient" does not include pharma- ceutically acceptable carriers.

[0088] Additional definitions may also be provided below as needed.

[0089] II. Compounds In certain embodiments, the subject matter described herein has formula I: [ka] or a pharma- ceutically acceptable salt thereof, wherein j1 and m1 are each independently 1, 2, or 3; j2 and m2 are each independently 0, 1, 2 or 3; The sum of j1 and j2 and the sum of m1 and m2 are each 5 or less, the sum of j1, j2, m1, and m2 is 9 or less, and when one of m2 and j2 is 0, the other is 1, 2, or 3; Ring A is a 5-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from the group consisting of O, N and S; R y is, when present, independently selected at each occurrence from the group consisting of halogen, C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkoxy, halo-C1-C6 alkoxy, C3-C7 cycloalkyl, C3-C7 halocycloalkyl, and -CN; n is 0, 1, 2, or 3; R x is halogen, C1-C 10 Alkyl, halo-C1-C6 alkyl, C1-C 10 Alkenyl, halo-C1-C6 alkenyl, C1-C6 alkoxy, halo-C1-C6 alkoxy, 5-7 membered heterocyclyl, C3-C7 cycloalkyl, C6-C 10 selected from the group consisting of aryl, 5- to 6-membered heteroaryl, and -CN; The heterocyclyl, cycloalkyl, aryl or heteroaryl is selected from the group consisting of (R xA ) q (wherein q is 0, 1, 2, 3, 4, or 5; Each R xAare optionally substituted with independently selected from the group consisting of halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halo-C1-C6 alkoxy and halo-C1-C6 alkyl, SO2(C1-C6 alkyl), and -CN.

[0090] In certain embodiments, the compound comprises a compound of formula I, or a pharma- ceutically acceptable salt thereof, wherein ring A contains 1, 2, or 3 N. In certain embodiments, the compound comprises a compound of formula I, or a pharma- ceutically acceptable salt thereof, wherein ring A is selected from the group consisting of pyrazolyl, triazolyl, and imidazolyl.

[0091] In certain embodiments of compounds of Formula I, or a pharma- ceutically acceptable salt thereof, the central bicyclic 3.1.0 ring is [ka] It is.

[0092] In some embodiments of formula I, the sum of j1 and j2 and the sum of m1 and m2 are each 5 or less, and the sum of j1, j2, m1, and m2 is 7 or less. In other embodiments, the sum of j1 and j2 and the sum of m1 and m2 are each 5 or less, and the sum of j1, j2, m1, and m2 is 6 or less. In some embodiments, one of m1 and m2 is 1 and the other is 2. Both j1 and j2 are 1. In some other embodiments, one of m1 and m2 is 1 and the other is 2, and one of j1 and j2 is 1 and the other is 2. In some other embodiments, each of m1 and m2 is 1 and each of j1 and j2 is 2. In further embodiments, one of m1 and m2 is 1 and the other is 2, j2 is 0, and j1 is 3. In some other embodiments, one of m1 and m2 is 3 and the other is 1, and one of j1 and j2 is 1 and the other is 2. In further embodiments, m1 and m2 are each 2, and j2 and j1 are each 1. In further embodiments, m2 is 0, m1 is 3, and j2 and j1 are each 1. Particular embodiments are shown in Table A. [Table A]

[0093] In still further embodiments of the compound of Formula I or a pharma- ceutically acceptable salt thereof, m1 and m2 are independently 1 or 2; and j1 and j2 are independently 1 or 2.

[0094] In certain embodiments of a compound of Formula I or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 1 and the other is 2; and j1 and j2 are both 1.

[0095] In certain embodiments of a compound of Formula I or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 2 and the other is 1; one of j1 and j2 is 2 and the other is 1.

[0096] In other embodiments of the compound of Formula I or a pharma- ceutically acceptable salt thereof, m1 and m2 are both 2 and j1 and j2 are both 1.

[0097] In other embodiments of the compound of Formula I or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 3 and the other is 1; one of j1 and j2 is 2 and the other is 1.

[0098] In other embodiments of the compound of Formula I or a pharma- ceutically acceptable salt thereof, m1 and m2 are both 1 and j1 and j2 are both 2.

[0099] In other embodiments of the compound of Formula I or a pharma- ceutically acceptable salt thereof, m2 is 0, m1 is 3, and j1 and j2 are both 1.

[0100] In other embodiments of the compound of Formula I or a pharma- ceutically acceptable salt thereof, one of m2 and m1 is 2 and the other is 1; j1 is 3; and j2 is 0.

[0101] In some embodiments of the compound of Formula I or a pharma- ceutically acceptable salt thereof, R y is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, halo-C1-C6 alkyl, C3-C7 cycloalkyl, and C3-C7 halocycloalkyl. y is independently C1-C6 alkyl or C3-C7 cycloalkyl. In certain embodiments, the compound is y is independently selected from the group consisting of methyl, ethyl, propyl, butyl, and cyclobutyl. y is, in each instance, propyl. In certain embodiments, the compound includes compounds where R y In certain embodiments, the compound includes compounds where R y In certain embodiments, the compound includes compounds where R y includes compounds which are, in each occurrence, selected from the group consisting of methyl, ethyl, propyl, butyl, cyclobutyl, trifluoromethyl, difluoromethyl, difluoroethyl, and difluoropropyl.

[0102] In certain embodiments of the compound of Formula I, or a pharma- ceutically acceptable salt thereof, R x is C1-C6 alkyl, halo-C1-C6 alkyl, C1-C 10 Alkenyl, halo-C1-C6 alkenyl, halo-C1-C6 alkoxy, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 6-membered heteroaryl, wherein the cycloalkyl, aryl or heteroaryl is selected from the group consisting of (R xA ) q wherein q is 0, 1, 2, or 3, and, if present, each R xA is substituted with independently selected from the group consisting of halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halo-C1-C6 alkoxy, and halo-C1-C6 alkyl. xis selected from the group consisting of C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkenyl, halo-C1-C6 alkenyl, halo-C1-C6 alkoxy, C3-C6 cycloalkyl, C6 aryl, and 5-6 membered heteroaryl, and the cycloalkyl, aryl, or heteroaryl is selected from the group consisting of (R xA ) q (wherein q is 0 or 1; R xA is substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, halo-C1-C6 alkoxy, or halo-C1-C6 alkyl. xA is halo-C1-C6 alkyl or C1-C6 alkyl. In certain embodiments, the compound is x In certain embodiments, the compound includes compounds where R x In certain embodiments, the compounds include those in which R is selected from the group consisting of trifluoromethyl, difluoromethyl, fluoromethyl, trifluoroethyl, difluoroethyl, and fluoroethyl. x In certain embodiments, the compound includes compounds where R x C6~C 10 Aryl or (R xA ) q q is 0, 1, 2, or 3; and, if present, each R xA is independently selected from the group consisting of halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halo-C1-C6 alkoxy, and halo-C1-C6 alkyl. x is phenyl or (R xA ) q In some embodiments, q is 0 or 1 and R xA is halo-C1-C6 alkyl or C1-C6 alkyl. In certain embodiments, the compound is x (R xA ) qand q is 0, 1, 2, or 3; and, if present, each R xA is independently selected from the group consisting of halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halo-C1-C6 alkoxy, and halo-C1-C6 alkyl.

[0103] In still further embodiments of the compound of formula I or a pharma- ceutically acceptable salt thereof, n is 0, 1 or 2, and each R y are independently halogen, C1-C6 alkyl, halo-C1-C6 alkyl, C3-C7 cycloalkyl, or C3-C7 halocycloalkyl; R x is selected from the group consisting of C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkenyl, halo-C1-C6 alkenyl, halo-C1-C6 alkoxy, C3-C6 cycloalkyl, C6 aryl, and 5-6 membered heteroaryl, and the cycloalkyl, aryl, or heteroaryl is selected from the group consisting of (R xA ) q (wherein q is 0 or 1; R xA is substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, halo-C1-C6 alkoxy or halo-C1-C6 alkyl).

[0104] In certain embodiments, the compound of formula I has formula Ia: [ka] or a pharma- ceutically acceptable salt thereof, wherein X1, X2, X3, and X4 are each independently N, NH, R x Or R y N, R substituted with x Or R y or CH, and one, two or three of X1, X2, X3 and X4 are N, NH or substituted N; j1, j2, m1, m2, R x , R yand n is as defined for formula (I).

[0105] One R x It should be apparent to one of skill in the art that only one of X1, X2, X3, and X4 is present in a compound of formula Ia or a pharma- ceutically acceptable salt thereof; thus, for example, only one of X1, X2, X3, and X4 is CR x or NR x Similarly, one or more of X1, X2, X3, and X4 may be CR y Or NR y Whether X1, X2, X3, and X4 are CR depends on the value of n. If n is 0, X1, X2, X3, and X4 are CR y or NR y If n is 1, then one of X1, X2, X3, and X4 is not a CR y or NR y When n is 2, two of X1, X2, X3, and X4 are independently CR y or NR y And each R y are independently selected, and so on.

[0106] In some embodiments of the compound of formula Ia, three of X1, X2, X3, and X4 are independently NH, N, or substituted N. In other embodiments, two of X1, X2, X3, and X4 are independently NH, N, or substituted N. In still further embodiments, one of X1, X2, X3, and X4 is NH, N, or substituted N. In certain embodiments, the compound is one in which X2 is CR xIn certain embodiments, the compound includes a compound of formula Ia, or a pharma- ceutically acceptable salt thereof, wherein X3 is N. In certain embodiments, the compound includes a compound where n is 1. In some embodiments of the compound of formula Ia, or a pharma- ceutically acceptable salt thereof, the sum of j1 and j2 and the sum of m1 and m2 are each 5 or less, and the sum of j1, j2, m1, and m2 is 7 or less. In other embodiments, the sum of j1 and j2 and the sum of m1 and m2 are each 5 or less, and the sum of j1, j2, m1, and m2 is 6 or less.

[0107] In certain embodiments of compounds of formula Ia or a pharma- ceutically acceptable salt thereof, the central bicyclic 3.1.0 ring is [ka] It is.

[0108] In some embodiments of formula Ia, one of m1 and m2 is 1 and the other is 2. j1 and j2 are both 1. In some other embodiments, one of m1 and m2 is 1 and the other is 2, one of j1 and j2 is 1 and the other is 2. In some other embodiments, m1 and m2 are each 1 and j1 and j2 are each 2. In further embodiments, one of m1 and m2 is 1 and the other is 2, j2 is 0, and j1 is 3. In some other embodiments, one of m1 and m2 is 3 and the other is 1, one of j1 and j2 is 1 and the other is 2. In further embodiments, m1 and m2 are each 2 and j2 and j1 are each 1. In further embodiments, m2 is 0, m1 is 3, and j2 and j1 are each 1.

[0109] In still further embodiments of the compound of formula Ia or a pharma- ceutically acceptable salt thereof, m1 and m2 are independently 1 or 2; and j1 and j2 are independently 1 or 2.

[0110] In certain embodiments of a compound of Formula Ia or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 1 and the other is 2; and j1 and j2 are both 1.

[0111] In certain embodiments of a compound of formula Ia or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 2 and the other is 1; one of j1 and j2 is 2 and the other is 1.

[0112] In other embodiments of the compounds of formula Ia or pharma- ceutically acceptable salts thereof, m1 and m2 are both 2; and j1 and j2 are both 1.

[0113] In other embodiments of the compound of formula Ia or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 3 and the other is 1; one of j1 and j2 is 2 and the other is 1.

[0114] In other embodiments of the compounds of formula Ia or pharma- ceutically acceptable salts thereof, m1 and m2 are both 1; and j1 and j2 are both 2.

[0115] In other embodiments of the compounds of formula Ia or pharma- ceutically acceptable salts thereof, m2 is 0, m1 is 3, and j1 and j2 are both 1.

[0116] In other embodiments of the compound of Formula Ia or a pharma- ceutically acceptable salt thereof, one of m2 and m1 is 2 and the other is 1; j1 is 3; and j2 is 0.

[0117] In some embodiments of the compound of formula Ia or a pharma- ceutically acceptable salt thereof, R y is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, halo-C1-C6 alkyl, C3-C7 cycloalkyl, and C3-C7 halocycloalkyl. y is independently C1-C6 alkyl or C3-C7 cycloalkyl. In certain embodiments, the compound isy is independently selected from the group consisting of methyl, ethyl, propyl, butyl, and cyclobutyl. y is, in each instance, propyl. In certain embodiments, the compound includes compounds where R y In certain embodiments, the compound includes compounds where R y In certain embodiments, the compound includes compounds where R y includes compounds which are, in each occurrence, selected from the group consisting of methyl, ethyl, propyl, butyl, cyclobutyl, trifluoromethyl, difluoromethyl, difluoroethyl, and difluoropropyl.

[0118] In certain embodiments of the compound of formula Ia or a pharma- ceutically acceptable salt thereof, R x is C1-C6 alkyl, halo-C1-C6 alkyl, C1-C 10 Alkenyl, halo-C1-C6 alkenyl, halo-C1-C6 alkoxy, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 6-membered heteroaryl, wherein the cycloalkyl, aryl or heteroaryl is selected from the group consisting of (R xA ) q wherein q is 0, 1, 2, or 3, and, if present, each R xA is substituted with independently selected from the group consisting of halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halo-C1-C6 alkoxy, and halo-C1-C6 alkyl. x is selected from the group consisting of C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkenyl, halo-C1-C6 alkenyl, halo-C1-C6 alkoxy, C3-C6 cycloalkyl, C6 aryl, and 5-6 membered heteroaryl, and the cycloalkyl, aryl, or heteroaryl is selected from the group consisting of (R xA ) q (wherein q is 0 or 1; R xAis substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, halo-C1-C6 alkoxy, or halo-C1-C6 alkyl. xA is halo-C1-C6 alkyl or C1-C6 alkyl. In certain embodiments, the compound is x In certain embodiments, the compound includes compounds where R x In certain embodiments, the compounds include those where R is selected from the group consisting of trifluoromethyl, difluoromethyl, fluoromethyl, trifluoroethyl, difluoroethyl, and fluoroethyl. x In certain embodiments, the compound includes compounds where R x C6~C 10 Aryl or (R xA ) q q is 0, 1, 2, or 3; and, if present, each R xA is independently selected from the group consisting of halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halo-C1-C6 alkoxy, and halo-C1-C6 alkyl. x is phenyl or (R xA ) q In some embodiments, q is 0 or 1 and R xA is halo-C1-C6 alkyl or C1-C6 alkyl.

[0119] In still further embodiments of the compound of formula Ia or a pharma- ceutically acceptable salt thereof, n is 0, 1 or 2, and each R y are independently halogen, C1-C6 alkyl, halo-C1-C6 alkyl, C3-C7 cycloalkyl, or C3-C7 halocycloalkyl; R xis selected from the group consisting of C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkenyl, halo-C1-C6 alkenyl, halo-C1-C6 alkoxy, C3-C6 cycloalkyl, C6 aryl, and 5-6 membered heteroaryl, and the cycloalkyl, aryl, or heteroaryl is selected from the group consisting of (R xA ) q (wherein q is 0 or 1; R xA is substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, halo-C1-C6 alkoxy or halo-C1-C6 alkyl).

[0120] In certain embodiments, the compound of formula (I) has formula Ib: [ka] or a pharma- ceutically acceptable salt thereof, wherein X1 is CH or N, and R y is C1-C6 alkyl or C3-C5 cycloalkyl; j1, j2, m1, m2, and R x is as defined for formula (I).

[0121] In certain embodiments of compounds of formula Ib or a pharma- ceutically acceptable salt thereof, the central bicyclic 3.1.0 ring is [ka] It is.

[0122] In some embodiments of formula Ib, one of m1 and m2 is 1 and the other is 2. j1 and j2 are both 1. In some other embodiments, one of m1 and m2 is 1 and the other is 2, one of j1 and j2 is 1 and the other is 2. In some other embodiments, m1 and m2 are each 1 and j1 and j2 are each 2. In further embodiments, one of m1 and m2 is 1 and the other is 2, j2 is 0, and j1 is 3. In some other embodiments, one of m1 and m2 is 3 and the other is 1, one of j1 and j2 is 1 and the other is 2. In further embodiments, m1 and m2 are each 2 and j2 and j1 are each 1. In further embodiments, m2 is 0, m1 is 3, and j2 and j1 are each 1.

[0123] In still further embodiments of the compound of formula Ib or a pharma- ceutically acceptable salt thereof, m1 and m2 are independently 1 or 2; and j1 and j2 are independently 1 or 2.

[0124] In certain embodiments of the compound of formula Ib or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 1 and the other is 2; and j1 and j2 are both 1.

[0125] In certain embodiments of a compound of formula Ib or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 2 and the other is 1; one of j1 and j2 is 2 and the other is 1.

[0126] In other embodiments of the compound of formula Ib or a pharma- ceutically acceptable salt thereof, m1 and m2 are both 2; and j1 and j2 are both 1.

[0127] In other embodiments of the compound of formula Ib or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 3 and the other is 1; one of j1 and j2 is 2 and the other is 1.

[0128] In other embodiments of the compound of formula Ib or a pharma- ceutically acceptable salt thereof, m1 and m2 are both 1; and j1 and j2 are both 2.

[0129] In other embodiments of the compound of formula Ib or a pharma- ceutically acceptable salt thereof, m2 is 0, m1 is 3, and j1 and j2 are both 1.

[0130] In other embodiments of the compound of Formula Ib or a pharma- ceutically acceptable salt thereof, one of m2 and m1 is 2 and the other is 1; j1 is 3; and j2 is 0.

[0131] In some embodiments of the compound of formula Ib or a pharma- ceutically acceptable salt thereof, R y is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, halo-C1-C6 alkyl, C3-C7 cycloalkyl, and C3-C7 halocycloalkyl. y is independently C1-C6 alkyl or C3-C7 cycloalkyl. In certain embodiments, the compound is y is independently selected from the group consisting of methyl, ethyl, propyl, butyl, and cyclobutyl. y is, in each instance, propyl. In certain embodiments, the compound includes compounds where R y In certain embodiments, the compound includes compounds where R y In certain embodiments, the compound includes compounds where R y includes compounds which are, in each occurrence, selected from the group consisting of methyl, ethyl, propyl, butyl, cyclobutyl, trifluoromethyl, difluoromethyl, difluoroethyl, and difluoropropyl.

[0132] In certain embodiments of the compound of formula Ib or a pharma- ceutically acceptable salt thereof, R x is C1-C6 alkyl, halo-C1-C6 alkyl, C1-C 10Alkenyl, halo-C1-C6 alkenyl, halo-C1-C6 alkoxy, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 6-membered heteroaryl, wherein the cycloalkyl, aryl or heteroaryl is selected from the group consisting of (R xA ) q wherein q is 0, 1, 2, or 3, and, if present, each R xA is substituted with independently selected from the group consisting of halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halo-C1-C6 alkoxy, and halo-C1-C6 alkyl. x is selected from the group consisting of C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkenyl, halo-C1-C6 alkenyl, halo-C1-C6 alkoxy, C3-C6 cycloalkyl, C6 aryl, and 5-6 membered heteroaryl, and the cycloalkyl, aryl, or heteroaryl is selected from the group consisting of (R xA ) q (wherein q is 0 or 1; R xA is substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, halo-C1-C6 alkoxy, or halo-C1-C6 alkyl. xA is halo-C1-C6 alkyl or C1-C6 alkyl. In certain embodiments, the compound is x In certain embodiments, the compound includes compounds where R x In certain embodiments, the compounds include those where R is selected from the group consisting of trifluoromethyl, difluoromethyl, fluoromethyl, trifluoroethyl, difluoroethyl, and fluoroethyl. x In certain embodiments, the compound includes compounds where R x C6~C 10 Aryl or (R xA ) q q is 0, 1, 2, or 3; and, if present, each R xAis independently selected from the group consisting of halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halo-C1-C6 alkoxy, and halo-C1-C6 alkyl. x is phenyl or (R xA ) q In some embodiments, q is 0 or 1 and R xA is halo-C1-C6 alkyl or C1-C6 alkyl.

[0133] In still further embodiments of the compound of formula Ib or a pharma- ceutically acceptable salt thereof, n is 0, 1 or 2, and each R y are independently halogen, C1-C6 alkyl, halo-C1-C6 alkyl, C3-C7 cycloalkyl, or C3-C7 halocycloalkyl; R x is selected from the group consisting of C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkenyl, halo-C1-C6 alkenyl, halo-C1-C6 alkoxy, C3-C6 cycloalkyl, C6 aryl, and 5-6 membered heteroaryl, and the cycloalkyl, aryl, or heteroaryl is selected from the group consisting of (R xA ) q (wherein q is 0 or 1; R xA is substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, halo-C1-C6 alkoxy or halo-C1-C6 alkyl).

[0134] In still further embodiments of the compound of formula Ib or a pharma- ceutically acceptable salt thereof, R x are (R xA ) q wherein q is 0, 1, 2, or 3, and, if present, each R xA is a C-C cycloalkyl substituted with independently selected from the group consisting of halogen, C-C alkyl, hydroxy, C-C alkoxy, halo-C-C alkoxy, and halo-C-C alkyl, such as cyclopentyl or cyclohexyl.xA is independently selected from the group consisting of methyl, ethyl, propyl, butyl, hydroxyl, fluoro (including gem difluoro), trifluoromethyl, difluoromethyl, difluoroethyl, and difluoropropyl. In certain embodiments, q is 1 or 2.

[0135] In certain embodiments, the compound of formula (I) has formula (Ic): [ka] or a pharma- ceutically acceptable salt thereof, wherein E1, E2, E3, E4, and E5 are each independently N, CR XA or CH, up to three of E1, E2, E3, E4, and E5 are N, q is 1 or 2, and j1, j2, m1, and m2 are as defined for formula (I).

[0136] One or two of E1, E2, E3, E4, and E5 are CR XA It should be clear to one skilled in the art that whether E1, E2, E3, E4, or E5 is CR depends on the value of q. If q is 1, then one of E1, E2, E3, E4, and E5 is CR XA If q is 2, then two of E1, E2, E3, E4, and E5 are CRs. XA And each R XA are independently selected.

[0137] In certain embodiments, the compound is a compound in which E1 is CH, E2 is N, and E3 is CR XA and E4 is CR XA and E5 is CH, or a pharma- ceutically acceptable salt thereof. In certain embodiments, E1, E2, E3, and E5 are CH, and E4 is CR XA In certain embodiments, E1 is CH, E2 is N, E3 is CH, and E4 is CR. XA and E5 is CH. In certain embodiments, E1, E2, E4, and E5 are CH and E3 is CR XAIn certain embodiments, E1 is CH, E2 is N, and E3 is CR XA and E4 is N and E5 is CH. In certain embodiments, E1, E2, and E3 are CH and E4 is CR XA and E5 is N. In certain embodiments, E1 is CH, E2 is N, and E3 is CR XA and E4 and E5 are CH. In certain embodiments, E1 is CH, E2 is CH, E3 is N, and E4 is CR XA and E5 is N. In certain embodiments, E1 is CH, E2 is CH, E3 is N, and E4 is CR XA and E5 is CH. In certain embodiments, E1 is N, E2 is CH, E3 is CH, and E4 is CR XA and E5 is CH. In certain embodiments, the compound is XA In certain embodiments, R is halo-C1-C6 alkyl, or a pharma- ceutically acceptable salt thereof. XA is selected from the group consisting of trifluoromethyl, difluoromethyl, fluoromethyl, trifluoroethyl, difluoroethyl, and fluoroethyl. XA is trifluoromethyl. In certain embodiments, R XA is halo-C1-C6 alkoxy. In certain embodiments, R XA is difluoromethoxy.

[0138] In certain embodiments of compounds of formula Ic or a pharma- ceutically acceptable salt thereof, the central bicyclic 3.1.0 ring is [ka] It is.

[0139] In some embodiments of formula Ic, one of m1 and m2 is 1 and the other is 2. j1 and j2 are both 1. In some other embodiments, one of m1 and m2 is 1 and the other is 2, one of j1 and j2 is 1 and the other is 2. In some other embodiments, m1 and m2 are each 1 and j1 and j2 are each 2. In further embodiments, one of m1 and m2 is 1 and the other is 2, j2 is 0, and j1 is 3. In some other embodiments, one of m1 and m2 is 3 and the other is 1, one of j1 and j2 is 1 and the other is 2. In further embodiments, m1 and m2 are each 2 and j2 and j1 are each 1. In further embodiments, m2 is 0, m1 is 3, and j2 and j1 are each 1.

[0140] In still further embodiments of the compound of formula Ic or a pharma- ceutically acceptable salt thereof, m1 and m2 are independently 1 or 2; and j1 and j2 are independently 1 or 2.

[0141] In certain embodiments of a compound of Formula Ic or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 1 and the other is 2; and j1 and j2 are both 1.

[0142] In certain embodiments of a compound of formula Ic or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 2 and the other is 1; one of j1 and j2 is 2 and the other is 1.

[0143] In other embodiments of the compound of formula Ic or a pharma- ceutically acceptable salt thereof, m1 and m2 are both 2 and j1 and j2 are both 1.

[0144] In other embodiments of the compound of formula Ic or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 3 and the other is 1; one of j1 and j2 is 2 and the other is 1.

[0145] In other embodiments of the compound of formula Ic or a pharma- ceutically acceptable salt thereof, m1 and m2 are both 1; and j1 and j2 are both 2.

[0146] In other embodiments of the compound of formula Ic or a pharma- ceutically acceptable salt thereof, m2 is 0, m1 is 3, and j1 and j2 are both 1.

[0147] In other embodiments of the compound of Formula Ic or a pharma- ceutically acceptable salt thereof, one of m2 and m1 is 2 and the other is 1; j1 is 3; and j2 is 0.

[0148] In certain further embodiments of formula Ic or a pharma- ceutically acceptable salt thereof described herein, E1, E2, E3, E4, and E5 are each independently N, R XA is C, or CH when bonded to E1, E2, E3, E4, and E5, and up to three of E1, E2, E3, E4, and E5 are N; X1 is N or CH; q is 1 or 2; Each R XA is independently selected from the group consisting of halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halo-C1-C6 alkoxy, and halo-C1-C6 alkyl; one of m1 and m2 is 2 and the other is 1, or m1 and m2 are each 1, or m1 and m2 are each 2; j1 and j2 are each 1, or one of j1 and j2 is 2 and the other is 1, or j1 and j2 are each 2.

[0149] In some such embodiments of a compound of Formula Ic or a pharma- ceutically acceptable salt thereof, one of m1 and m2 is 2 and the other is 1. In other embodiments, m1 and m2 are each 1. In still further embodiments, m1 and m2 are each 2. In still further embodiments, j1 and j2 are each 1. In other embodiments, one of j1 and j2 is 2 and the other is 1. In certain embodiments, j1 and j2 are each 2.

[0150] In certain embodiments, the compound comprises a compound of formula Ia, Ib, or Ic, or a pharma- ceutically acceptable salt thereof, wherein X1 is CH.

[0151] In certain embodiments of a compound of formula I or a pharma- ceutically acceptable salt thereof, such as a compound of formula Ia, Ib, or Ic, or any of the foregoing pharma- ceutically acceptable salts, the compound includes a compound in which the sum of j1 and j2 and the sum of m1 and m2 are each equal to or less than 4, and the sum of j1, j2, m1, and m2 is equal to or less than 7. In certain embodiments of a compound of formula I or a pharma- ceutically acceptable salt thereof, such as a compound of formula Ia, Ib, or Ic, or any of the foregoing pharma- ceutical acceptable salts, the sum of j1 and j2 and the sum of m1 and m2 are each equal to or less than 3, and the sum of j1, j2, m1, and m2 is equal to or less than 5. In certain embodiments, one of m1 and m2 is 1 and the other is 2. In certain embodiments, m1 and m2 are each 1. In certain embodiments, one of m1 and m2 is 3 and the other is 1. In certain embodiments, m1 and m2 are each 2. In certain embodiments, m1 is 3 and m2 is 0. In certain embodiments, one of j1 and j2 is 1 and the other is 2. In certain embodiments, one of j1 and j2 is 3 and the other is 1. In certain embodiments, j1 and j2 are each 1. In certain embodiments, j1 and j2 are each 2. In certain embodiments, j1 is 3 and j2 is 0.

[0152] In certain embodiments of compounds of Formula I or a pharma- ceutically acceptable salt thereof, such as compounds of Formula Ia, Ib, or Ic, or a pharma- ceutically acceptable salt of any of the foregoing, the central bicyclic 3.1.0 ring is [ka] It is.

[0153] The subject matter described herein includes the following compounds in Table 1 or pharma- ceutically acceptable salts thereof. Individual enantiomers and diastereomers are included in the table below by compound name, and their corresponding structures can be readily determined therefrom. In Table 1, an asterisk (*) denotes an isolated isomer or group of isolated isomers, but no stereochemistry has been assigned. In some cases, the enantiomers or diastereomers of the present disclosure can be identified by their respective properties, such as retention time by chiral HPLC, NMR peaks, and / or biological activity (e.g., as further described in the Examples), but the absolute configuration of one or more chiral centers has not been assigned. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14]

[0154] III. Pharmaceutical Compositions and Modes of Administration The compounds provided herein can be administered in the form of pharmaceutical compositions.Therefore, pharmaceutical compositions comprising one or more of the compounds described herein, or their pharma-ceutically acceptable salts, stereoisomers, or mixtures of stereoisomers, and one or more pharma-ceutically acceptable excipients are also provided herein.Suitable pharma-ceutically acceptable excipients can include, for example, inert solid diluents and fillers, liquid diluents including sterile aqueous solutions and various organic solvents, permeation enhancers, solubilizers, and adjuvants.Such compositions are prepared by methods well known in the pharmaceutical field.See, for example, Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (GS Banker & C.T. Rhodes, Eds.).

[0155] In some embodiments, the pharmaceutical composition comprises a compound of formula I or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises a compound of formula Ia or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises a compound of formula Ib or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises a compound of formula Ic or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises a compound of Table 1 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient.

[0156] The pharmaceutical composition can be administered in either a single dose or multiple doses.The pharmaceutical composition can be administered by various methods, including, for example, rectal, buccal, intranasal and transdermal routes.In certain embodiments, the pharmaceutical composition can be administered by intraarterial injection, intravenous, intraperitoneal, parenteral, intramuscular, subcutaneous, oral, topical, or inhalant.

[0157] One mode of administration is parenterally, for example by injection.The form in which the pharmaceutical composition described herein can be incorporated for administration by injection includes, for example, aqueous suspension or oil suspension, or emulsion containing sesame oil, corn oil, cottonseed oil or peanut oil, as well as elixir, mannitol, dextrose or sterile aqueous solution, and similar pharmaceutical vehicles.

[0158] Oral administration may be another route for administering the compounds described herein. Administration may be via capsules or tablets, such as enteric coated tablets. In preparing pharmaceutical compositions containing at least one compound described herein or its pharma-ceutically acceptable salts, stereoisomers, or mixtures of stereoisomers, the active ingredient is usually diluted by an excipient and / or enclosed within such a carrier, which may be in the form of a capsule, sachet, paper, or other container. When an excipient serves as a diluent, it may be in the form of a solid, semi-solid, or liquid material that acts as a vehicle, carrier, or medium for the active ingredient. Thus, the composition may be in the form of a tablet, pill, powder, lozenge, sachet, cachet, elixir, suspension, emulsion, solution, syrup, aerosol (as a solid or liquid medium), for example, ointment containing up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable liquid, and sterile packaged powder.

[0159] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methylcellulose.The formulation may further include lubricants such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preservatives such as methyl and propyl hydroxybenzoates; sweeteners; and flavoring agents.

[0160] Compositions comprising at least one compound described herein or its pharma- ceutically acceptable salt, stereoisomer, or mixture of stereoisomers can be formulated to provide rapid, sustained, or delayed release of active ingredient after administration to a subject by using procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolution systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. Nos. 3,845,770, 4,326,525, 4,902,514, and 5,616,345. Another formulation for use in the methods disclosed herein uses a transdermal delivery device ("patch"). Such transdermal patches can be used to provide continuous or discontinuous infusion of the compounds described herein in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, for example, U.S. Patent Nos. 5,023,252, 4,992,445 and 5,001,139.Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

[0161] To prepare solid compositions such as tablets, the principal active ingredient can be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogenous mixture of the compound described herein or a pharma- ceutically acceptable salt, stereoisomer, or mixture of stereoisomers. When these preformulation compositions are referred to as homogenous, the active ingredient can be evenly dispersed throughout the composition such that the composition can be readily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules.

[0162] The tablets or pills of the compounds described herein can be coated or otherwise compounded to provide a dosage form that provides the advantage of long-acting action or to protect against the acidic conditions of the stomach.For example, the tablet or pill can comprise an inner dosage component and an outer dosage component, the latter being in the form of an envelope that covers the former.The two components can be separated by an enteric layer, which serves to resist disintegration in the stomach and allows the inner component to pass intact to the duodenum or to be delayed in release.Various materials can be used for such enteric layers or coatings, including a number of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.

[0163] Compositions for inhalation or insufflation may include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents or mixtures thereof, as well as powders. Liquid or solid compositions may contain suitable pharma- ceutically acceptable excipients as described herein. In some embodiments, compositions are administered by oral or nasal respiratory routes for local or systemic effect. In other embodiments, compositions in pharma- ceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device, or the nebulizing device may be attached to a face mask tent or intermittent positive pressure respirator. Solution, suspension, or powder compositions may be administered from a device that delivers the formulation in an appropriate manner, preferably orally or nasally.

[0164] The specific dose level of the compounds of the present application for any particular subject will depend on a variety of factors, including the activity of the particular compound used, age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination, and the severity of the particular disease in the subject being treated. For example, dosages may be expressed as milligrams of the compounds described herein per kilogram of subject body weight (mg / kg). Doses of about 0.1-150 mg / kg may be appropriate. In some embodiments, between about 0.1 mg / kg and 100 mg / kg may be appropriate. In other embodiments, doses of 0.5-60 mg / kg may be appropriate. Normalizing according to subject body weight is particularly useful when adjusting dosages between subjects of widely differing sizes, such as when using drugs in both children and adults, or when converting effective dosages in non-human subjects, such as dogs, to dosages appropriate for human subjects. Doses may be administered once daily (QID), twice daily (BID), or more frequently, depending on the pharmacokinetic and pharmacodynamic properties, including absorption, distribution, metabolism, and excretion, of the particular compound. In addition, toxicity factors may affect the dosage and administration regimen. When administered orally, pills, capsules, or tablets may be taken orally every day or more frequently for a specified period of time. This regimen can be repeated for a given number of treatment cycles.

[0165] IV. Method of Treatment Described herein is a method for promoting myelination of central nervous system neurons in a subject suffering from a myelin-related disorder, comprising administering to the subject a therapeutically effective amount of a compound of formula I or a pharmaceutical composition comprising the same. In certain embodiments, the subject matter disclosed herein relates to a compound of formula I or a pharma- ceutically acceptable salt thereof for promoting myelination of central nervous system neurons in a subject suffering from a myelin-related disorder. In another embodiment, the subject matter described herein relates to the use of a compound of formula I or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for promoting myelination of central nervous system neurons in a subject suffering from a myelin-related disorder. In some embodiments, the compound of formula I is a compound of Table 1 or a pharma- ceutically acceptable salt thereof.

[0166] In certain embodiments, in a method of promoting myelination of central nervous system neurons in a subject suffering from a myelin-related disorder, a compound of formula I or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising same, inhibits enzyme-mediated synthesis of one or more sterol intermediates in the cholesterol biosynthetic pathway.

[0167] In certain embodiments, in a method for promoting myelination of central nervous system neurons in a subject suffering from a myelin-related disorder, a compound of formula I or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising same, promotes accumulation of Δ8,9-unsaturated sterol intermediates in the cholesterol biosynthetic pathway.

[0168] In certain embodiments, in a method of promoting myelination of central nervous system neurons in a subject suffering from a myelin-related disorder, the compound of formula I or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising same, inhibits one or more of CYP51, sterol-14-reductase, or EBP enzyme-mediated synthesis of sterol intermediates in the cholesterol biosynthetic pathway.

[0169] In certain embodiments, in a method of promoting myelination of central nervous system neurons in a subject suffering from a myelin-related disorder, a compound of formula I or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising same, induces, promotes and / or modulates the differentiation, proliferation and / or maturation of oligodendrocyte precursor cells (OPCs). In certain embodiments, the induction of OPC differentiation is characterized by an increase in myelin basic protein (MBP) expression.

[0170] In certain embodiments, the subject matter described herein relates to a method of treating a disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of formula I, or a pharma- ceutically acceptable salt thereof, to a subject in need thereof. In certain embodiments, the subject has a myelin-related disorder. In some embodiments, the compound of formula I is a compound of formula Ia, or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ib, or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ic, or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula I is a compound of Table 1, or a pharma- ceutically acceptable salt thereof.

[0171] In certain embodiments, the subject matter disclosed herein relates to a compound of formula I or a pharma- ceutically acceptable salt thereof for use in treating a disorder in a subject in need of such treatment. In certain embodiments, the subject has a myelin-associated disorder. In some embodiments, the compound of formula I is a compound of formula Ia or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ib or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ic or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula I is a compound of Table 1 or a pharma- ceutically acceptable salt thereof.

[0172] In certain embodiments, the subject matter disclosed herein relates to the use of a compound of formula I or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for treating a disorder in a subject in need of such treatment. In certain embodiments, the subject has a myelin-related disorder. In some embodiments, the compound of formula I is a compound of formula Ia or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ib or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ic or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula I is a compound of Table 1 or a pharma- ceutically acceptable salt thereof.

[0173] In certain embodiments, the subject matter disclosed herein relates to a method of promoting myelination in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharma- ceutically acceptable salt thereof. In certain embodiments, the subject has a myelin-related disorder. In some embodiments, the compound of formula I is a compound of formula Ia, or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ib, or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ic, or a pharma- ceutically acceptable salt thereof.

[0174] In certain embodiments, the subject matter disclosed herein relates to a compound of formula I or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound, for use in promoting myelination in a subject in need thereof. In certain embodiments, the subject has a myelin-related disorder. In some embodiments, the compound of formula I is a compound of formula Ia or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ib or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ic or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula I is a compound of Table 1 or a pharma- ceutically acceptable salt thereof.

[0175] In certain embodiments, the subject matter disclosed herein relates to the use of a compound of formula I or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising said compound, in the manufacture of a medicament for promoting myelination in a subject in need thereof. In certain embodiments, the subject has a myelin-related disorder. In some embodiments, the compound of formula I is a compound of formula Ia, or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ib, or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ic, or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula I is a compound of Table 1, or a pharma- ceutically acceptable salt thereof.

[0176] In certain embodiments, the subject matter disclosed herein relates to a method of inducing differentiation of endogenous oligodendrocyte precursor cells (OPCs) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising the same. In certain embodiments, the subject is suffering from a myelin-associated disorder. In certain embodiments, the myelin-associated disorder is multiple sclerosis.

[0177] Such myelin-related disorders include multiple sclerosis (MS), neuromyelitis optica (NMO), optic neuritis, childhood leukodystrophies, neonatal white matter injury, age-related dementia, schizophrenia, progressive multifocal leukoencephalopathy (PML), encephalomyelitis (EPL), central pontine myelinolysis (CPM), adrenoleukodystrophy, Alexander disease, Pelizaeus-Mersbacher disease (PMD), vanishing white matter disease, Wallerian degeneration, transverse myelitis, amyotrophic lateral sclerosis (ALS), Huntington's disease, These include, but are not limited to, Alzheimer's disease, Parkinson's disease, spinal cord injury, traumatic brain injury, post-radiation injury, neurological complications of chemotherapy, stroke, acute ischemic optic neuropathy, vitamin deficiency, isolated vitamin D syndrome, Bassen-Kornzweig syndrome, Marchiafava-Bignami syndrome, metachromatic leukodystrophy, trigeminal neuralgia, acute disseminated encephalitis, Guillain-Barré syndrome, Charcot-Marie-Tooth disease, Bell's palsy, and radiation-induced demyelination.

[0178] The compound of formula I or a pharma- ceutically acceptable salt thereof, alone or in combination with another agent, can be administered to a subject suffering from a myelin-related disorder to promote myelination of neurons (e.g., neuronal axons). Myelin-related disorders can include any disease, condition (e.g., those resulting from traumatic spinal cord injury and cerebral infarction), or disorder that results in abnormalities in the myelin sheath. The abnormalities can be caused by loss of myelin, referred to as demyelination, malfunction of myelin, referred to as dysmyelination, or failure to form sufficient myelin, referred to as hypomyelination. The myelin-related disorders described herein can result from genetic disorders or one or more of a variety of neurotoxic insults. In some embodiments, the compound of formula I is a compound of formula Ia, or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ib, or a pharma- ceutically acceptable salt thereof. In other embodiments, the compound of formula I is a compound of formula Ic, or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula I is a compound of Table 1, or a pharma- ceutically acceptable salt thereof.

[0179] As used herein, "demyelination" refers to the activity of demyelination, or damage or loss of some or all of the myelin sheath that insulates nerves, and is a hallmark of myelin-related disorders. In certain embodiments, demyelination refers to damage or loss of some or all of the myelin sheath that insulates a subset of an individual's nerves, such as, for example, one or more nerves localized in a particular region of the body (e.g., the brain or spinal cord, or neurons of both the brain and spinal cord, or the optic nerve).

[0180] Oligodendrocytes are required for myelination of neurons. As used herein, the term "myelination" refers to the generation of myelin sheath of nerves by replacing or restoring the function of myelin-producing cells. The neurons undergoing remyelination may be in the brian, spinal cord, or both the brain and spinal cord. Restoring the function of myelin-producing cells may include, for example, increasing the myelin production rate in a cell or cells that have a lower than average production level. Such an increase may include increasing the myelin production rate to or above the average production level, but may also include increasing the myelin production rate to a level that is still lower than average but higher than the previous level.

[0181] As used herein, "promoting myelination" refers to increasing the rate of myelin production, rather than merely a net increase in the amount of myelin, compared to a baseline level of myelin production in a subject. The increase in myelin production rate can be determined using imaging techniques or functional measurements. In some embodiments, myelination is promoted by increasing the differentiation of OPCs, increasing the accumulation of 8,9-unsaturated sterol intermediates in biosynthetic pathways, increasing the formation of OPCs, or any combination thereof. Such activities can be assessed, for example, using one or more in vitro assays, such as those described herein or known to those of skill in the art.

[0182] As used herein, "baseline level of myelin production rate" refers to the myelin production rate in a subject being treated prior to the start of treatment.

[0183] V. Methods of Preparing Compounds of Formula I and Their Pharmaceutically Acceptable Salts The compounds can be synthesized by synthetic routes that include processes similar to those known in the chemical arts, particularly in light of the description contained herein, as well as processes for other heterocycles described in: Comprehensive Heterocyclic Chemistry II, Editors Katritzky and Rees, Elsevier, 1997, e.g., Volume 3; Liebigs Annalen der Chemie, (9): 1910-16, (1985); Helvetica Chimica Acta, 41: 1052-60, (1958); Arzneimittel-Forschung, 40(12): 1328-31, (1990), each of which are expressly incorporated by reference. Starting materials are generally available from commercial sources, such as Aldrich Chemicals (Milwaukee, Wis.), or are readily prepared using methods well known to those of skill in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-23, Wiley, NY (1967-2006 ed.), or prepared by methods generally described in Beilstein's Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)).

[0184] Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful for synthesizing the compounds as well as the requisite reagents and intermediates are known in the art and can be found, for example, in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. Muts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley and Sons (1999); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

[0185] The compounds may be prepared singly or as a compound library comprising at least two, for example 5-1,000 compounds, or 10-100 compounds. Libraries of compounds of formula I or pharma- ceutically acceptable salts thereof may be prepared by procedures known to those skilled in the art, by combinatorial "split and mix" approaches, or by multiple parallel syntheses using either solution phase or solid phase chemistry. Thus, according to a further aspect, there is provided a compound library comprising at least two compounds or pharma- ceutically acceptable salts thereof. EXAMPLES

[0186] Working Example The examples provide exemplary methods for preparing the compounds. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the compounds. Although specific starting materials and reagents are shown and discussed in the schemes, general procedures, and examples, other starting materials and reagents can be readily substituted to provide a variety of derivatives and / or reaction conditions. In addition, many of the exemplary compounds prepared by the methods described can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art. An asterisk (*) denotes an isolated isomer or a group of isolated isomers, but no stereochemistry has been assigned.

[0187] Synthesis of intermediates Intermediate Example I-1: (1R,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka] Step 1: Synthesis of ethyl 4-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-2,4-dioxobutanoate [ka]

[0188] To a solution of 1-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)ethanone (27 g, 71 mmol) in anhydrous tetrahydrofuran (300 mL) was added lithium bis(trimethylsilyl)amide (106 mL, 106 mmol, 1 M in tetrahydrofuran) slowly at −78° C. under nitrogen. After 0.5 h, diethyl oxalate (15.63 g, 107.0 mmol) was added and the reaction mixture was allowed to warm to room temperature. After 6 h, the reaction mixture was quenched with 3 M aqueous hydrochloric acid until the solution reached a pH of about 3. The mixture was extracted with ethyl acetate (2×200 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated to give ethyl 4-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-2,4-dioxobutanoate (40 g), which was used without further purification. LCMS: [M+H] + 479.0, [M+Na] + 501.0, [M+Na+CH3CN] + 542.0

[0189] Step 2: Synthesis of ethyl 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazole-3-carboxylate [ka]

[0190] To a solution of ethyl 4-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-2,4-dioxobutanoate (0.40 kg, 84 mmol) in ethanol (500 mL) was added N-isopropylhydrazine hydrochloride (9.7 g, 84 mmol) at room temperature. After 16 h, triethylamine was added and the resulting mixture was concentrated in vacuo. Purification of the residue by flash column chromatography (9% ethyl acetate in petroleum ether) afforded ethyl 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazole-3-carboxylate (19.5 g, 45%). LRMS: [M+H] + =517.1.

[0191] Step 3: Synthesis of 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazole-3-carboxylic acid [ka]

[0192] To a stirred solution of ethyl 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazole-3-carboxylate (19.5 g, 37.7 mmol) in ethanol (200 mL) was added a solution of sodium hydroxide (6.30 g, 151 mmol) in water (50 mL) at room temperature. After 6 h, the reaction mixture was concentrated in vacuo and the resulting aqueous solution was diluted with water (10 mL). 2 M aqueous hydrochloric acid was added until the solution reached a pH of about 3. The aqueous mixture was extracted with ethyl acetate (2×100 mL). The combined organic extracts were washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated to give crude 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazole-3-carboxylic acid (18 g, 92%).

[0193] Step 4: Synthesis of benzyl (5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazol-3-yl)carbamate [ka]

[0194] A 500 mL three-neck flask was charged with 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazole-3-carboxylic acid (26 g, 53 mmol), diisopropylethylamine (14 mL, 0.080 mol), benzyl alcohol (17.26 g, 159.6 mmol) and anhydrous toluene (300 mL). The reaction mixture was purged with nitrogen for 2 minutes and heated to 100° C. Diphenyl phosphoroazidate (17.2 mL, 79.85 mmol) was added dropwise to the reaction mixture and the reaction was maintained at 100° C. After 16 h, the reaction mixture was concentrated in vacuo. The resulting residue was purified by flash column chromatography (20:1 petroleum ether / ethyl acetate) to give benzyl (5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazol-3-yl)carbamate (28 g, 89%). LRMS: [M+H] + 594.0.

[0195] Step 5: Synthesis of 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-3-iodo-1-isopropyl-1H-pyrazole [ka]

[0196] To a solution of benzyl (5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazol-3-yl)carbamate (28 g, 47 mmol) in methanol (200 mL) was added 10% palladium on carbon (2.8 g). The reaction mixture was stirred at room temperature under 1 atm of hydrogen. After 16 h, the reaction mixture was filtered through Celite. The filtrate was concentrated in vacuo to give crude 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazol-3-amine, which was dissolved in acetonitrile (200 mL). A solution of 4-methylbenzenesulfonic acid monohydrate (22.34 g, 117.5 mmol) in water (25 mL) was added at room temperature. After 30 min at room temperature, the reaction mixture was cooled to 0° C. A solution of sodium nitrite (5.4 g, 78 mmol) and sodium iodide (1174 g, 78.31 mmol) in water (25 mL) was added dropwise to the reaction mixture. After 30 min, saturated aqueous sodium sulfite was added to the reaction and the resulting aqueous mixture was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash column chromatography (3-5% ethyl acetate in petroleum ether) to give 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-3-iodo-1-isopropyl-1H-pyrazole (11.2 g, 50%). LRMS: [M+H] + 570.9.

[0197] Step 6: Synthesis of 6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol [ka]

[0198] A solution of 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-3-iodo-1-isopropyl-1H-pyrazole (11.2 g, 19.7 mmol) and triethylamine trihydrofluoride (63 g, 391 mmol) in anhydrous tetrahydrofuran (100 mL) was heated at 70° C. for 6 h. Saturated aqueous sodium bicarbonate was added until the solution reached pH=7. The resulting aqueous mixture was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated. Purification by flash column chromatography (5:1 petroleum ether / ethyl acetate) afforded crude 6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol (6.6 g, 100%). LRMS: [M+H] + 332.9.

[0199] Step 7: Synthesis of the title compound. To a solution of 6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol (6.0 g, 18 mmol) in dichloromethane (200 mL) was added Dess-Martin periodinane (11.5 g, 27.1 mmol) at room temperature. After 2 hours, saturated aqueous sodium bicarbonate (100 mL) and saturated aqueous sodium sulfite (100 mL) were added sequentially to the reaction mixture. The heterogeneous solution was stirred for 0.5 hours. The organic layer was separated and the aqueous layer was extracted with dichloromethane (2×100 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated. Purification by flash column chromatography (5:1 petroleum ether / ethyl acetate) gave (1R,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one (3.5 g). LRMS: [M+H] + 330.7; 1H NMR (400 MHz, CDCl3): δ 6.03 (s, 1H), 4.59-4.49 (m, 1H), 2.78-2.72 (m, 2H), 2.42 (s, 1H), 2.37 (s, 1H), 1.89 (t, J = 3.6 Hz, 2H), 1.49 (s, 6H), 1.33 (t, J = 3.2 Hz, 1H). (1R,5S,6s)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one (1.5 g) was also isolated.

[0200] Intermediate Example I-2: 1-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)ethan-1-one [ka] Step 1: Synthesis of tert-butyl(cyclopent-3-en-1-yloxy)diphenylsilane [ka]

[0201] To an ice-cold solution of 4-hydroxycyclopentene (50.0 g, 0.594 mol) and imidazole (80.9 g, 1.19 mol) in N,N-dimethylformamide (300 mL) was slowly added tert-butyldiphenylsilyl chloride (180 g, 0.65 mmol). The reaction mixture was allowed to warm to room temperature. After 16 h, the reaction mixture was diluted with water (1 L) and ethyl acetate (500 mL). The aqueous layer was extracted with ethyl acetate (2×200 mL). The combined organic layers were washed successively with water (3×300 mL) and saturated aqueous sodium chloride solution (2×200 mL). The collected organics were dried over anhydrous sodium sulfate, filtered, and concentrated. Purification by flash column chromatography (15:1 petroleum ether / ethyl acetate) afforded tert-butyl(cyclopent-3-en-1-yloxy)diphenylsilane (188 g, 98%). 1H NMR (400MHz, CDCl3): δ 7.69-7.66(m,4H),7.43-7.38(m,6H),5.63-5.60(m,2H),4.58-4.53(m,1H),2.46-2.38(m,4H),1.61(s,9H).

[0202] Step 2: Synthesis of ethyl 3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carboxylate [ka]

[0203] To a stirred solution of tert-butyl(cyclopent-3-en-1-yloxy)diphenylsilane (0.100 kg, 310 mmol) and rhodium acetate dimer (1.37 g, 3.10 mmol) in anhydrous dichloromethane (1.2 L) at room temperature was added a solution of ethyl 2-diazoacetate (63.68 mmol) in dichloromethane (300 mL) over 8 h. After an additional 12 h. the reaction mixture was filtered through Celite. The filtrate was concentrated to give crude ethyl 3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carboxylate (140 g), which was used without further purification.

[0204] Step 3: Synthesis of 3-((tert-butyldiphenylsilyl)oxy)-N-methoxy-N-methylbicyclo[3.1.0]hexane-6-carboxamide [ka]

[0205] To a solution of ethyl 3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carboxylate (70.0 g, 171 mmol) in ethanol (400 mL) was slowly added a solution of sodium hydroxide (20.56 g, 513.94 mmol) in water (100 mL). After 20 h, the reaction mixture was concentrated and the resulting residue was diluted with water (200 mL). 3 M aqueous hydrochloric acid was added dropwise to adjust pH=3. The aqueous mixture was extracted with ethyl acetate (2×200 mL). The combined organic layers were washed with saturated aqueous sodium chloride (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give 3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carboxylic acid (53 g). To an ice-cold suspension of the crude acid in dichloromethane (600 mL) was added carbonyldiimidazole (25.5 g, 158 mmol). After 2 h, N,O-dimethylhydroxylamine hydrochloride (32 g, 0.33 mmol) was added. After 3 h, the reaction mixture was filtered and the filtrate was concentrated and purified by flash column chromatography (6:1 petroleum ether / ethyl acetate) to give 3-((tert-butyldiphenylsilyl)oxy)-N-methoxy-N-methylbicyclo[3.1.0]hexane-6-carboxamide (37 g, 60%). 1 H NMR(400MHz,CDCl3):δ 7.63-7.61(m,4H),7.42-7.33(m,6H),4.33-4.31(m,1H),3.74(s,2H),3.57(s,1H), 3.21(s,2H),3.10(s,1H),2.21-2.18(m,1H),2.00-1.80(m,6H),1.06-1.01(m,9H).

[0206] Step 4: Synthesis of the title compound. To an ice-cold solution of 3-((tert-butyldiphenylsilyl)oxy)-N-methoxy-N-methylbicyclo[3.1.0]hexane-6-carboxamide (37 g, 87 mmol) in anhydrous tetrahydrofuran (500 mL) was added dropwise methylmagnesium bromide (87 mL, 262 mmol, 3.0 M in diethyl ether). After 3 hours, saturated aqueous ammonium chloride was added to the reaction mixture. The resulting aqueous solution was extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated to give crude 1-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-yl)ethanone (30.0 g, 91%), which was used without further purification.

[0207] Synthesis of Compounds of Formula I Example A: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 1), and 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 2) [ka] In general, the title compound was synthesized following the procedures described for compounds 3 and 4 using 4,4,5,5-tetramethyl-2-(3-(trifluoromethyl)phenyl)-1,3,2-dioxaborolane. The crude mixture was purified by reverse phase chromatography (acetonitrile / water gradient with 0.05% NH3+10 mM NH4HCO3) to give compound 1 as the first eluting peak and compound 2 as the second eluting peak. The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0208] Compound 1: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide LCMS (ESI) [M+H] + =494.1. 1 H NMR(400MHz,CD3OD)δ 8.01(s,1H),7.98-7.90(m,1H),7.54(d,J=5.2Hz,2H),6.25(s,1H),4 .76-4.73(m,1H),4.09(s,4H),3.06-2.93(m,1H),2.88-2.80(m,1H),2 .84(s,1H),2.72(t,J=7.2Hz,2H),2.25-2.11(m,5H),1.95(d,J=4.4Hz,1H),1.92(d,J=4.4Hz,1H),1.74-1.70(m,2H),1.54(d,J=6.8Hz,6H).

[0209] Compound 2: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide LCMS (ESI) [M+H] + =494.1. 1 H NMR(400MHz,CD3OD)δ 8.02(s,1H),7.98-7.93(m,1H),7.54(d,J=5.2Hz,2H),6.29(s,1H),4.80-4.72(m,1H),4.18-4.07(m,4H),2.86(s,2H),2 .71(t,J=7.2Hz,2H),2.62-2.50(m,1H),2.31-2.16(m,4H),1.91-1.81(m,2H),1.78-1.70(m,3H),1.53(d,J=6.8Hz,6H).

[0210] Example B: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 3), and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 4) [ka] Step 1: (1R,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0211] To a mixture of (1R,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one (2.0 g, 6.1 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)pyridine (2.5 g, 9.2 mmol) in 1,4-dioxane (32 mL) and water (8 mL) was added Cs2CO3 (6 g, 18.4 mmol) and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (460 mg, 0.65 mmol). The reaction mixture was placed under nitrogen atmosphere and stirred at 100 °C for 4 h. The reaction was quenched with water (30 mL) and extracted with ethyl acetate (100 mL x 2). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica column chromatography (0-30% ethyl acetate in petroleum ether) to give the title compound (2.1 g, 96.3% yield). LCMS (ESI) [M+H] + =350.2.

[0212] Step 2: 6-((1R,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0213] To a solution of (1R,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one (60 mg, 0.171 mmol) and 2-thia-6-azaspiro[3.4]octane 2,2-dioxide hydrochloride (50 mg, 0.25 mmol) in anhydrous methanol (2 mL) was added NaBH3CN (55 mg, 0.88 mmol) at 20°C. The reaction mixture was heated to 70°C and stirred for 16 h. The reaction was quenched with aqueous NaHCO3 solution (5 mL), extracted with dichloromethane (30 mL x 3). The combined organic phase was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo.

[0214] The residue was purified by reverse phase chromatography (acetonitrile / water gradient + 0.05% NH3 + 10 mM NH4HCO3) to give the first eluting peak, compound 3, as a pure single stereoisomer of the title compound (37.9 mg, 44.6% yield). The second eluting peak, compound 4, was obtained as a pure single stereoisomer of the title compound (33.0 mg, 32.7% yield).

[0215] Compound 3: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide LCMS (ESI) [M+H] + =495.4. 1 H NMR(400MHz,CDCl3)δ 9.11(s,1H),8.75(s,1H),8.29(s,1H),6.19(s,1H),4.68-4.60(m,1H),4.09(s,4H),2.93-2.69(m, 4H),2.46(brs,1H),2.25-2.11(m,4H),1.92-1.84(m,2H),1.72-1.66(m,3H),1.55(d,J=6.4Hz,6H).

[0216] Compound 4: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide. LCMS (ESI) [M+H] + =495.4. 1 H NMR(400MHz,CDCl3)δ 9.11(s,1H),8.74(s,1H),8.29(s,1H),6.14(s,1H),4.72-4.55(m,1H),4.10-3.98(m,4H),2.93(brs,1H),2.81(s,2 H),2.65-2.75(m,2H),2.20-2.10(m,4H),2.08(s,1H),1.98-1.86(m,2H),1.72-1.66(m,2H),1.55(d,J=6.8Hz,6H).

[0217] Example C: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 5) [ka] (The relative stereochemistry is 1 (Assigned based on H NMR analysis) Step 1: 6-((1R,3r,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0218] To (1R,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one (750 mg, 2.27 mmol) in m-xylene (9.1 mL) was added 2-thia-6-azaspiro[3.4]octane 2,2-dioxide hydrochloride (674 mg, 3.41 mmol), sodium triacetoxyborohydride (1444 mg, 6.82 mmol) and acetic acid (1.56 mL, 27.26 mmol). The reaction mixture was stirred at 60° C. for 18 hours. Additional 2-thia-6-azaspiro[3.4]octane 2,2-dioxide hydrochloride (209 mg, 1.07 mmol) was added and the reaction mixture was stirred at 75° C. for 18 hours. Additional 2-thia-6-azaspiro[3.4]octane 2,2-dioxide hydrochloride (209 mg, 1.07 mmol) and sodium triacetoxyborohydride (720 mg, 3.40 mmol) were added and the reaction mixture was stirred at 75° C. for 6 h. The reaction mixture was diluted with 1N aqueous NH4Cl (5 mL), 1N aqueous NaHCO3 (40 mL) and 10% methanol in dichloromethane (25 mL). The aqueous layer was extracted with 10% methanol in dichloromethane (2×25 mL). The combined organic layers were concentrated under reduced pressure. The mixture was diluted with DMSO and purified by preparative HPLC (acetonitrile / water gradient + 0.1% NH4OH) to give the second eluting peak as a pure single stereoisomer of the title compound (110 mg, 10% yield). LCMS (ESI) [M+H] + =476.1. 1 H NMR(400MHz,DMSO-d6)δ 6.00(s,1H),4.64-4.52(m,1H),4.16-4.03(m,4H),2.84-2.76(m,1H),2.69(s,2H),2.56(t,J=7.3Hz,2H),2.18(t,J=3.4 Hz,1H),2.05(t,J=7.2Hz,2H),2.02-1.93(m,2H),1.89(dd,J=14.0,3.3Hz,2H),1.59-1.53(m,2H),1.36(d,J=6.5Hz,6H).

[0219] Step 2: Synthesis of the title compound. A solution of 6-((1R,3r,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (35.7 mg, 0.075 mmol), potassium phosphate (32 mg, 0.15 mmol), SPhos Pd G3 (2.9 mg, 0.004 mmol) and (4-(trifluoromethyl)phenyl)boronic acid (21 mg, 0.11 mmol) in 1,4-dioxane (0.38 mL) and water (0.094 mL) was stirred at 60° C. for 18 hours. The reaction mixture was diluted with 1N aq. NH4Cl (0.5 mL) and DMSO, filtered, and purified by preparative HPLC (acetonitrile / water gradient + 0.1% TFA) to give the title compound (31.2 mg, 84% yield).

[0220] Compound 5:LCMS(ESI)[M+H] + =494.2. 1 H NMR(400MHz,DMSO-d6)δ 7.93(d,J=8.0Hz,2H),7.71(d,J=8.2Hz,2H),6.41(s,1H),4.74-4.60(m,1H),4.18-4.05(m,4H),2.88-2.80(m,1H),2.72(s,2H),2.5 9(t,J=7.2Hz,2H),2.24(t,J=3.4Hz,1H),2.11-1.98(m,4H),1.92(dd,J=13.6,3.3Hz,2H),1.68-1.61(m,2H),1.46(d,J=6.6Hz,6H).

[0221] Example D: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 6) [ka] The title compound was generally synthesized following the procedure described for compound 5 using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyrimidine.

[0222] Compound 6:LCMS(ESI)[M+H] + =496.2. 1 H NMR(400MHz,DMSO-d6)δ 9.31(s,2H),6.65(s,1H),4.79-4.66(m,1H),4.18-4.05(m,4H),2.89-2.79(m,1H),2.72(s,2H),2.59(t,J=7.3Hz,2 H),2.29(t,J=3.3Hz,1H),2.11-1.99(m,4H),1.95(dd,J=13.8,3.2Hz,2H),1.68-1.62(m,2H),1.48(d,J=6.6Hz,6H).

[0223] Example E-Compounds 7* to 10*: (R)-7-((1R,3s,5S,6R)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.4]nonane 2,2-dioxide; (S)-7-((1R,3s,5S,6S)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.4]nonane 2,2 -dioxide;(R)-7-((1R,3r,5S,6R)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.4]nonane 2,2-dioxide;and(S)-7-((1R,3r,5S,6S)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.4]nonane 2,2-dioxide [ka] Step 1: 7-((1R,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.4]nonane 2,2-dioxide [ka]

[0224] In step 2, 7-((1R,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.4]nonane 2,2-dioxide was synthesized using 2-thia-7-azaspiro[4.4]nonane 2,2-dioxide according to the same procedure as for compound 3.

[0225] Compound 7*: The crude mixture was purified by chiral preparative HPLC (Daicel Chiralpak AS, 0.1% NH3 in HO / EtOH 95:5 to 75:25) to give the first eluting peak as a pure single undefined enantiomer of the title compound (10.8 mg, 6% yield). LCMS (ESI) [M+H] + =509.2. 1 H NMR(400MHz,CD3OD)δ 9.15(s,1H),8.74(s,1H),8.41(s,1H),6.39(s,1H),4.82-4.74(m,1H),3.26-3.07(m,4H),3.00-2.90(m,1H),2.89-2.84(m,1H),2.8 2-2.75(m,1H),2.66-2.56(m,1H),2.54-2.46(m,1H),2.33-2.12(m,5H),2.06-1.83(m,4H),1.79-1.64(m,2H),1.55(d,J=4.8Hz,6H).

[0226] Compound 8*: The crude mixture was purified by chiral preparative HPLC (Daicel Chiralpak AS, 0.1% NH3 in HO / EtOH 95:5 to 75:25) to give the second eluting peak as a pure single undefined enantiomer of the title compound (7.7 mg, 4.2% yield). LCMS (ESI) [M+H] + =509.2. 1 H NMR(400MHz,CD3OD)δ 9.15(s,1H),8.73(s,1H),8.41(s,1H),6.39(s,1H),4.83-4.76(m,1H),3.26-3.06(m,4H),2.95-2.87(m,1H),2.85-2.81(m,1H),2.7 9-2.73(m,1H),2.63-2.54(m,1H),2.51-2.45(m,1H),2.30-2.13(m,5H),2.03-1.85(m,4H),1.80-1.65(m,2H),1.55(d,J=6.4Hz,6H).

[0227] Compound 9*: The crude mixture was purified by chiral preparative HPLC (Daicel Chiralpak AS, 0.1% NH in HO / EtOH 95:5 to 75:25) to give the third eluting peak as a pure single undefined enantiomer of the title compound (12.9 mg, 7.2% yield). LCMS (ESI) [M+H] + =509.2. 1 H NMR(400MHz,CD3OD)δ 9.15(s,1H),8.74(s,1H),8.41(s,1H),6.44(s,1H),4.82-4.77(m,1H) ,3.25-3.09(m,4H),2.81-2.76(m,1H),2.76-2.70(m,1H),2.69-2.63(m ,1H),2.61-2.56(m,1H),2.54-2.46(m,1H),2.33-2.19(m,4H),2.08-1. 98(m,1H),1.94-1.85(m,3H),1.80-1.75(m,3H),1.53(d,J=6.8Hz,6H).

[0228] Compound 10*: The crude mixture was purified by chiral preparative HPLC (Daicel Chiralpak AS, 0.1% NH3 in HO / EtOH 95:5 to 75:25) to give the fourth eluting peak as a pure single undefined enantiomer of the title compound (15.3 mg, 8.5% yield). LCMS (ESI) [M+H] + =509.2. 1 H NMR(400MHz,CD3OD)δ 9.15(s,1H),8.74(s,1H),8.41(s,1H),6.45(s,1H),4.82-4.75(m,1H),3.25-3.10(m,4H),2.81-2.70(m,2H),2.69-2.60(m,1H),2.5 9-2.55(m,1H),2.53-2.47(m,1H),2.34-2.20(m,4H),2.08-1.98(m,1H),1.96-1.87(m,3H),1.80-1.75(m,3H),1.53(d,J=6.4Hz,6H).

[0229] Example F: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 11), and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 12) [ka] Step 1: 1-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-3-(6-(trifluoromethyl)pyridin-2-yl)propane-1,3-dione [ka]

[0230] To a solution of 1-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)ethan-1-one (25.0 g, 66.0 mmol) in tetrahydrofuran (300 mL) was added NaH (4.0 g, 100 mmol, 60% in mineral oil) in portions at 0° C. under nitrogen and stirred for 1 h. A solution of methyl 6-(trifluoromethyl)picolinate (25.0 g, 121.9 mmol) in THF (100 mL) was added at 0° C. under nitrogen. The reaction mixture was then stirred at 20° C. for 2 h. The reaction mixture was quenched with saturated aqueous NH4Cl (80 mL) and extracted with ethyl acetate (500 mL×3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica column chromatography (0-10% ethyl acetate in petroleum ether) to give the title compound (35 g, 59.64 mmol, 90.3% yield). LCMS (ESI) [M+H] + =552.2.

[0231] Step 2: 2-(5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazol-3-yl)-6-(trifluoromethyl)pyridine [ka]

[0232] To a solution of 1-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-3-(6-(trifluoromethyl)pyridin-2-yl)propane-1,3-dione (26.0 g, 47.13 mmol) in ethanol (250 mL) was added dropwise isopropylhydrazine hydrochloride (5.44 g, 49.22 mmol) and triethylamine (6.83 mL, 49.1 mmol). The mixture was stirred at 25 °C for 15 h. The mixture was concentrated, diluted with ethyl acetate (100 mL) and washed with brine (60 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica column chromatography (0-10% EtOAc in petroleum ether) to give the title compound and a mixture of its pyrazole regioisomers (24 g, 86.4% yield). LCMS(ESI)[M+H] + =590.2.

[0233] Step 3: (1R,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol [ka]

[0234] To 2-(5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazol-3-yl)-6-(trifluoromethyl)pyridine (24.0 g, 40.69 mmol) was added 1 M tetrabutylammonium fluoride in tetrahydrofuran (212.5 mL, 212.5 mmol) and the mixture was stirred at 25° C. for 15 h. The reaction was quenched with saturated aqueous NH4Cl solution (100 mL) and extracted with ethyl acetate (350 mL×3). The combined organic layers were washed with brine (100 mL×2), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica column chromatography (0-50% ethyl acetate in petroleum ether) to give the title compound and a mixture of its pyrazole regioisomers (13.0 g, 90.9% yield). LCMS (ESI) [M+H] + =352.1

[0235] Step 4: (1R,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0236] To a solution of (1R,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol (10.5 g, 29.88 mmol) in anhydrous dichloromethane (70 mL) was added DMP (25.35 g, 59.77 mmol) at 0° C. under nitrogen. The reaction mixture was stirred at 25° C. for 1 h. The mixture was filtered and washed with dichloromethane (100 mL). The organic layer was washed with brine (50 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography (10-20% ethyl acetate in petroleum ether) to give the title compound as the first eluting peak (5000 mg, 48% yield). LCMS (ESI) [M+H] + =350.1. 1 H NMR(400MHz,CD3OD)δ 8.17(d,J=8.0Hz,1H),7.98(t,J=7.6Hz,1H),7.63(d,J=7.6Hz,1H),6.61(s,1H),4.83-4.76(m,1H) ,2.80-2.71(m,2H),2.42-2.35(m,2H),2.02-1.99(m,2H),1.61-1.56(m,1H),1.48(d,J=6.4Hz,6H).

[0237] Step 5: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 11) [ka]

[0238] To a solution of 6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one (5 g, 14.3 mmol) and 2-thia-6-azaspiro[3.4]octane 2,2-dioxide (3 g, 18.6 mmol) in anhydrous methanol (100 mL) was added NaBH3CN (3.2 g, 50.9 mmol) and acetic acid (2.4 mL, 41.9 mmol) dropwise at 20° C. The reaction mixture was heated to 50° C. and stirred for 2 h. The reaction was quenched with saturated aqueous NaHCO3 (20 mL) and extracted with dichloromethane (300 mL×3). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (acetonitrile / water gradient containing 0.05% NH3+10 mM NH4HCO3) to give the second eluting peak as a pure single stereoisomer of the title compound (2.88 g, 39.8% yield).

[0239] Compound 11:LCMS(ESI)[M+H] + =495.1. 1 H NMR(400MHz,CDCl3)δ 8.17(d,J=8.0Hz,1H),7.84-7.80(m,1H),7.51(d,J=7.2Hz,1H),6.56(s,1H),4.70-4.59(m,1H),4.08(s,4H),2.78(s,2H),2.68-2. 66(m,2H),2.42-2.35(m,1H),2.21-2.16(m,4H),1.86-1.76(m,2H),1.73(s,2H),1.58-1.56(m,1H),1.54(d,J=6.4Hz,6H).The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0240] 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 12) [ka]

[0241] The residue from step 6 was purified by preparative reverse-phase HPLC (acetonitrile / water gradient containing 0.05% NH3+10 mM NH4HCO3) to give the first eluting peak as a pure single stereoisomer of the title compound (3.60 g, 49.4% yield).

[0242] Compound 12:LCMS(ESI)[M+H] + =495.1. 1 H NMR(400MHz,CDCl3)δ 8.17(d,J=8.0Hz,1H),7.84-7.80(m,1H),7.51(d,J=7.2Hz,1H),6.52(s,1H),4.70-4.60(m,1H),4.05(s,4H),3.00-2.92(m,1H),2.79( The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0243] Example G: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 13), and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 14) [ka] Following a similar procedure for compounds 3 and 4, 6-((1R,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide was synthesized using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyridine. The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0244] The crude mixture was purified by reverse phase chromatography (acetonitrile / water gradient containing 0.05% NH3+10 mM NH4HCO3) to give compound 13 as the first eluting peak and compound 14 as the second eluting peak.

[0245] Compound 13: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide. LCMS (ESI) [M+H] + =495.2. 1 H NMR(400MHz,CDCl3)δ 9.03(s,1H),8.23(d,J=8.4Hz,1H),7.66(d,J=8.0Hz,1H),6.19(s,1H),4.68-4.61(m,1H),4.08(s,4H),2.79(s,2H),2.66(d,J =6.8Hz,2H),2.45-2.42(m,1H),2.24-2.16(m,4H),1.88-1.86(m,2H),1.71(brs,2H),1.61-1.59(m,1H),1.56(d,J=6.8Hz,6H).

[0246] Compound 14: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide. LCMS (ESI) [M+H] + =495.2. 1 H NMR(400MHz,CDCl3)δ 9.02(s,1H),8.24(d,J=8.4Hz,1H),7.66(d,J=8.0Hz,1H),6.15(s,1H),4.68-4.61(m,1H),4.09-4.00(m,4H),2.98-2 .89(m,1H),2.80(s,2H),2.70-2.68(m,2H),2.17-2.08(m,5H),1.94-1.90(m,2H),1.67(s,2H),1.55(d,J=6.8Hz,6H).

[0247] Example H: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 15) [ka] The title compound was synthesized using (2-(trifluoromethyl)pyrimidin-4-yl)boronic acid following a procedure similar to that for compound 5. The relative stereochemistry is: 1 Assigned based on 1 H NMR analysis.

[0248] Compound 15:LCMS(ESI)[M+H] + =496.2. 1H NMR(400MHz,DMSO-d6)δ 8.95(d,J=5.3Hz,1H),8.11(d,J=5.3Hz,1H),6.56(s,1H),4.82-4.67(m,1H),4.19-4.04(m,4H),2.90-2.78(m,1H),2.72(s,2H),2.59(t, Relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0249] Example I: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 16), and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 17) [ka] Step 1: (E)-Benzyl (amino(methylthio)methylene)carbamate [ka]

[0250] To an ice-cold mixture of 2-methylisothiourea sulfite (10.0 g, 58.06 mmol) and 2N aqueous sodium hydroxide (34.8 mL, 69.6 mmol) in dichloromethane (100 mL) was added benzyl chloroformate (7.0 mL, 52.26 mmol). The mixture was stirred at 25 °C for 1 h. The mixture was extracted with ethyl acetate (500 mL x 2). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica column chromatography (0-50% ethyl acetate in petroleum ether) to give the title compound (10 g, 76.8% yield). LCMS (ESI) [M+H] + =225.1. 1 H NMR(400MHz,DMSO-d6)δ 8.74(brs,2H),7.39-7.29(m,5H),5.04(s,2H),2.33(s,3H).

[0251] Step 2: Benzyl ((Z)-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carboxamide)(methylthio)methylene)carbamate [ka]

[0252] To a solution of (1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carboxylic acid 1.97 mL, 62.42 mmol), N,N-diisopropylethylamine (19.4 mL, 111.4 mmol) and (E)-benzyl(amino(methylthio)methylene)carbamate (10.0 g, 44.59 mmol) in tetrahydrofuran (80 mL) was added HATU (25.4 g, 66.88 mmol) at 20 °C. The reaction mixture was stirred at 20 °C for 2 h. The mixture was diluted with ethyl acetate (200 mL) and washed with brine (50 mL). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica column chromatography (0-20% ethyl acetate in petroleum ether) to give the title compound (22 g, 84.1% yield). LCMS(ESI)[M+H] + =587.1.

[0253] Step 3: 5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-1,2,4-triazol-3-amine [ka]

[0254] To a stirred solution of benzyl ((Z)-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carboxamide)(methylthio)methylene)carbamate (20.0 g, 34.08 mmol) in N,N-dimethylformamide (200 mL) was added isopropylhydrazine hydrochloride (18.9 g, 170.4 mmol) and trimethylamine (47.4 mL, 340.8 mmol). The reaction mixture was stirred at 160° C. for 2.5 h. The reaction mixture was quenched with water (200 mL) and extracted with 10% methanol in ethyl acetate (100 mL×3). The combined organic layers were washed with brine (100 mL×3), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica column chromatography (0-50% ethyl acetate in petroleum ether) to give the title compound (10 g, 63.7% yield). LCMS (ESI) [M+H] + =461.3.

[0255] Step 4: 5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-3-iodo-1-isopropyl-1H-1,2,4-triazole [ka]

[0256] To an ice-cold solution of 5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-1,2,4-triazol-3-amine (5.0 g, 10.85 mmol) in acetonitrile (50 mL) and water (10 mL) was added a solution of 4-methylbenzenesulfonic acid (9331 mg, 54.3 mmol) and sodium nitrite (1498 mg, 21.71 mmol) in water (5 mL). The reaction mixture was stirred at 0 °C for 30 min. Sodium iodide (4067.0 mg, 27.13 mmol) was added quickly and the solution was stirred at 0 °C for 3 h. The reaction was poured into water (50 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography (0-20% ethyl acetate in petroleum ether) to give the title compound (3800 mg, 61.3% yield). LCMS (ESI) [M+H] + =572.0.

[0257] Step 5: (1R,5S,6r)-6-(3-iodo-1-isopropyl-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-ol [ka]

[0258] To a stirred solution of 5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-3-iodo-1-isopropyl-1H-1,2,4-triazole (3800.0 mg, 6.65 mmol) in tetrahydrofuran (38 mL) was added triethylamine trihydrofluoride (21.7 mL, 132.97 mmol). The reaction mixture was stirred at 70 °C for 16 h. The reaction was quenched with saturated aqueous NaHCO3 solution (100 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography (0-25% ethyl acetate in petroleum ether) to give the title compound (2000 mg, 83.1% yield). LCMS(ESI)[M+H] + =334.0.

[0259] Step 6: (1R,5S,6r)-6-(3-iodo-1-isopropyl-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0260] To a stirred solution of (1R,5S,6r)-6-(3-iodo-1-isopropyl-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-ol (2000 mg, 6 mmol) in dichloromethane (20 mL) was added Dess-Martin periodinane (3055 mg, 7.2 mmol). The reaction mixture was stirred at 25 °C for 16 h. The reaction was quenched with saturated aqueous NaHCO3 solution (80 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography (0-50% ethyl acetate in petroleum ether) to give the title compound (1200 mg, 58.6% yield). LCMS (ESI) [M+H] +=332.0.

[0261] Step 7: (1R,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0262] A suspension of K2CO3 (626 mg, 4.53 mmol), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (106.9 mg, 0.15 mmol), (1R,5S,6r)-6-(3-iodo-1-isopropyl-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-one (500 mg, 1.51 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)pyridine (495 mg, 1.81 mmol) in 1,4-dioxane (10 mL) and water (2 mL) was stirred at 80 °C for 2 h under N2 atmosphere. The mixture was diluted with water (25 mL) and extracted with ethyl acetate (40 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography (0-50% ethyl acetate in petroleum ether) to give the title compound (200 mg, 26.5% yield). LCMS (ESI) [M+H] + =351.1.

[0263] Step 8: 6-((1R,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0264] To a solution of (1R,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-one (50 mg, 0.14 mmol) and 2-thia-6-azaspiro[3.4]octane 2,2-dioxide hydrochloride (28.2 mg, 0.14 mmol) in methanol (3 mL) was added NaBH3CN (45 mg, 0.71 mmol) at 25° C. The reaction mixture was stirred at 80° C. for 4 h. The reaction mixture was concentrated and the residue was purified by preparative reverse-phase HPLC (acetonitrile / water gradient + 0.05% NH3 + 10 mM NH4HCO3) to give the first eluting peak as a pure single stereoisomer of the title compound (27.5 mg, 39% yield) (compound 16).

[0265] Compound 16: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0266] LCMS(ESI)[M+H] + =496.1. 1 H NMR(400MHz,CD3OD)δ 9.33(d,J=1.6Hz,1H),8.83(d,J=1.2Hz,1H),8.55(s,1H),4.79-4.72(m,1H),4.08-4.05(m,4H),2.94-2.88(m,1H),2. 71-2.66(m,2H),2.44-2.43(m,1H),2.19-2.12(m,4H),2.02-1.96(m,4H),1.85(s,2H),1.53(d,J=6.8Hz,6H).The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0267] Compound 17: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0268] The residue from step 8 was purified by preparative reverse phase HPLC (acetonitrile / water gradient with 0.05% NH3 + 10 mM NH4HCO3) to give the second eluting peak as a pure single stereoisomer of the title compound (24.4 mg, 35% yield). LCMS (ESI) [M+H] + =496.1. 1 H NMR(400MHz,CD3OD)δ 9.34(d,J=1.2Hz,1H),8.83(d,J=1.2Hz,1H),8.55(s,1H),4.21-4.12(m,1H),4.11-4.07(m,4H),3.58-3.55(m,1H),3.26-3.07( m,1H),2.85(s,1H),2.71-2.69(m,2H),2.66-2.58(m,1H),2.29-2.15(m,5H),2.06-1.96(m,3H),1.51(d,J=6.8Hz,6H).The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0269] Example J: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 18), and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 19) [ka] The title compound was synthesized using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyridine following a similar procedure to compounds 3 and 4. The crude mixture was purified by reverse phase chromatography (acetonitrile / water gradient with 0.05% NH3+10 mM NH4HCO3) to give compound 19 as the first eluting peak and compound 18 as the second eluting peak.

[0270] Compound 18: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide. LCMS (ESI) [M+H] + =495.2. 1 H NMR(400MHz,CDCl3)δ 8.66(d,J=5.2Hz,1H),8.03(s,1H),7.79(d,J=5.2Hz,1H),6.24(s,1H),4.72-4.60(m,1H),4.11-4.05(m,4H),2.78(s,2H),2 .66(t,J=7.2Hz,2H),2.47-2.39(m,1H),2.22-2.15(m,4H),1.88-1.65(m,4H),1.59(t,J=3.2Hz,1H),1.55(d,J=6.4Hz,6H).

[0271] Compound 19: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide. LCMS (ESI) [M+H] + =495.2. 1H NMR(400MHz,CDCl3)δ 8.66(d,J=5.2Hz,1H),8.03(s,1H),7.80(d,J=5.2Hz,1H),6.20(s,1H),4.70-4.60(m,1H),4.08-4.00(m,4H),2.96-2.90(m,1H),2.80 (s,2H),2.70(t,J=7.2Hz,2H),2.20-2.12(m,4H),2.08(t,J=3.2Hz,1H),1.94-1.90(m,2H),1.75-1.60(m,2H),1.55(d,J=6.8Hz,6H).

[0272] Example K: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 20), and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 21) [ka] Step 1: 6-((1R,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0273] 6-((1R,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide was synthesized following a similar procedure for compounds 3 and 4 using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyridine. The crude mixture was purified by chiral SFC (Daicel Chiralcel OD, 0.1% NH3 in HO / EtOH 65:45) to give compound 20 as the first eluting peak and compound 21 as the second eluting peak. The relative stereochemistry of both compounds was confirmed as follows: 1 Assigned based on 1 H NMR analysis.

[0274] Compound 20: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide. LCMS (ESI) [M+H] + =495.1. 1 H NMR(400MHz,CD3OD)δ 8.68(d,J=5.2Hz,1H),8.13(s,1H),7.49(d,J=4.0Hz,1H),6.49(s,1H),4.76-4.73(m,1H),4.08-4.05(m,4H),2 .83(s,2H),2.70-2.66(m,2H),2.49-2.42(m,1H),2.25-2.15(m,4H),1.85-1.69(m,5H),1.50(d,J=6.4Hz,6H).

[0275] Compound 21: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide. LCMS (ESI) [M+H] + =495.1. 1H NMR(400MHz,CD3OD)δ 8.68(d,J=5.2Hz,1H),8.13(s,1H),7.49(d,J=4.4Hz,1H),6.44(s,1H),4.77-4.72(m,1H),4.09-4.06(m,4H),2.95-2.93 (m,1H),2.79(s,2H),2.70-2.66(m,2H),2.15-2.11(m,5H),1.92-1.90(m,2H),1.67-1.66(m,2H),1.51(d,J=6.4Hz,6H).

[0276] Example L: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 22), and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 23) [ka] Step 1: 1-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-4,4,4-trifluorobutane-1,3-dione [ka]

[0277] To a solution of ethyl trifluoroacetate (0.52 mL, 4.22 mmol) in THF (10 mL) was added NaH (0.19 g, 4.65 mmol) in portions at 0 °C under N2. The reaction mixture was stirred at 0 °C for 0.5 h. A solution of 1-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)ethan-1-one (1.28 g, 3.38 mmol) in THF (20 mL) was added at 0 °C under N2. The reaction mixture was stirred at 20-30 °C for 2 h, quenched with saturated NH4Cl solution (50 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (50 mL × 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography (0-10% ethyl acetate in petroleum ether) to give the title compound (1.2 g, 75% yield). LCMS (ESI) [M+H] + =475.1.

[0278] Step 2: 5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-3-(trifluoromethyl)-1H-pyrazole [ka]

[0279] To a solution of 1-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-4,4,4-trifluorobutane-1,3-dione (400 mg, 0.84 mmol) in ethanol (15 mL) was added isopropylhydrazine hydrochloride (93 mg, 0.84 mmol) and triethylamine (0.12 mL, 0.84 mmol). The mixture was stirred at 25 °C for 15 h. The mixture was concentrated under reduced pressure and purified by silica column chromatography (0-5% ethyl acetate in petroleum ether) to give the title compound as a mixture of stereoisomers (350 mg, 81% yield). LCMS (ESI) [M+H] + =513.2.

[0280] Step 3: (1R,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol [ka]

[0281] To 5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-3-(trifluoromethyl)-1H-pyrazole (350 mg, 0.68 mmol) was added 1M tetrabutylammonium fluoride in tetrahydrofuran (5 mL, 5 mmol). The reaction mixture was stirred at 25° C. for 5 h. The mixture was diluted with water (20 mL) and extracted with ethyl acetate (30 mL×2). The combined organic layers were concentrated under reduced pressure. The residue was purified by silica column chromatography (0-30% ethyl acetate in petroleum ether) to give the title compound as a mixture of stereoisomers (170 mg, 85.3% yield). LCMS (ESI) [M+H] + =275.1.

[0282] Step 4: (1R,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0283] To a solution of (1R,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol (170 mg, 0.62 mmol) in anhydrous dichloromethane (6 mL) was added Dess-Martin periodinane (394 mg, 0.93 mmol). The reaction mixture was stirred at 25 °C for 4 h. The mixture was diluted with H2O (5 mL), saturated aqueous Na2SO3 (5 mL) and saturated aqueous NaHCO3 (5 mL). The mixture was extracted with ethyl acetate (25 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography (0-40% ethyl acetate in petroleum ether) to give the title compound (150 mg, 74.7% yield). LCMS (ESI) [M+H] + =273.1. 1 H NMR(400MHz,CD3OD)δ 6.27(s,1H),4.84-4.74(m,1H),2.78-2.72(m,2H),2.44-2.31(m,2H),2.03-1.96(m,2H),1.62(t,J=3.6Hz,1H),1.48(d,J=6.8Hz,6H).

[0284] Step 5: 6-((1R,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0285] To a solution of (1R,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one (100 mg, 0.37 mmol) in methanol (5 mL) was added 2-thia-6-azaspiro[3.4]octane 2,2-dioxide hydrochloride (87.5 mg, 0.44 mmol), acetic acid (0.11 mL) and NaBH3CN (115 mg, 1.84 mmol). The mixture was stirred at 70° C. for 2 h. The reaction mixture was diluted with saturated aqueous solution. Sodium bicarbonate (10 mL) was added and extracted with dichloromethane (50 mL×3). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (acetonitrile / water gradient containing 0.05% NH3+10 mM NH4HCO3) to afford the first eluting peak as a pure single stereoisomer of the title compound (30 mg, 19.5% yield) (Compound 22).

[0286] Compound 22: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0287] LCMS(ESI)[M+H] + =418.2. 1 H NMR(400MHz,CDCl3)δ 6.04(s,1H),4.68-4.60(m,1H),4.12-4.01(m,4H),2.77(s,2H),2.65(t,J=7.2Hz,2H),2.45-2.36(m,1 H),2.20-2.14(m,4H),1.87-1.81(m,2H),1.66-1.65(m,2H),1.56-1,55(m,1H),1.51(d,J=6.4Hz,6H).

[0288] Compound 23: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0289] The crude mixture from step 5 was purified by preparative reverse-phase HPLC (acetonitrile / water gradient + 0.05% NH3 + 10 mM NH4HCO3) to give the second eluting peak as a pure single stereoisomer of the title compound (30.5 mg, 19.5% yield). 1 H NMR(400MHz,CDCl3)δ 6.00(s,1H),4.68-4.60(m,1H),4.09-3.97(m,4H),2.96-2.86(m,1H),2.79(s,2H),2.68(t,J=7.2Hz,2H),2 .18-2.10(m,4H),2.07-2.06(m,1H),1.92-1.86(m,2H),1.62-1,61(m,2H),1.51(d,J=6.8Hz,6H).The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0290] Example M: ​​6-((1R,3s,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 24), and 6-((1R,3r,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 25) [ka] Step 1: 3-(5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyridine [ka]

[0291] To a solution of tert-butyl-[[(1R,5S)-6-(3-iodo-1H-pyrazol-5-yl)-3-bicyclo[3.1.0]hexanyl]oxy]-diphenyl-silane (2.0 g, 3.78 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)pyridine (1.6 g, 5.86 mmol) in 1,4-dioxane (20 mL) and water (4 mL) was added K2CO3 (1.6 g, 11.58 mmol) and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (0.28 g, 0.40 mmol). The reaction mixture was placed under a nitrogen atmosphere and stirred at 75 °C for 5 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica column chromatography (0-30% ethyl acetate in petroleum ether) to give the title compound (2.0 g, 3.32 mmol, 87.8% yield). LCMS (ESI) [M+H] + =548.3.

[0292] Step 2: 3-(5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-ethyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyridine [ka]

[0293] To a stirred mixture of 3-(5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyridine (1.2 g, 2.19 mmol) and Cs2CO3 (1.4 g, 4.3 mmol) in N,N-dimethylformamide (12 mL) was added iodoethane (0.9 mL, 11.25 mmol) dropwise. The mixture was stirred at 25 °C for 3 h. The reaction was quenched with water (50 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated. The residue was purified by silica column chromatography (0-15% ethyl acetate in petroleum ether) to give the title compound (890 mg, 70.6% yield). LCMS (ESI) [M+H] + =576.2.

[0294] Step 3: (1R,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol [ka]

[0295] To 3-(5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-ethyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyridine (870 mg, 1.51 mmol) was added tetrabutylammonium fluoride in tetrahydrofuran (12.0 mL, 12 mmol, 1 M) and the mixture was stirred at 25 °C for 5 h. The reaction was quenched with saturated aqueous NH4Cl (50 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica column chromatography (0-50% ethyl acetate in petroleum ether) to give the title compound (500 mg, 98.1% yield). LCMS (ESI) [M+H]+ =338.1.

[0296] Step 4: (1R,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0297] To a solution of (1R,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol 500 mg, 1.48 mmol) in anhydrous dichloromethane (12 mL) was added Dess-Martin periodinane (1000 mg, 2.36 mmol). The reaction mixture was stirred at 25 °C for 4 h. The mixture was quenched with aqueous Na2SO3 (20 mL). Saturated aqueous NaHCO3 (10 mL) was added and the mixture was extracted with dichloromethane (100 mL × 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica column chromatography (0-40% ethyl acetate in petroleum ether) to give the title compound (410 mg, 82.5% yield). LCMS(ESI)[M+H] + =336.3.

[0298] Step 5: 6-((1R,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0299] To a solution of (1R,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one (130 mg, 0.38 mmol) and 2-thia-6-azaspiro[3.4]octane 2,2-dioxide hydrochloride (100 mg, 0.504 mmol) in anhydrous methanol (4 mL) was added NaBH3CN (120 mg, 1.92 mmol) and acetic acid (0.02 mL, 0.35 mmol) at 20 °C. The reaction mixture was then heated to 70 °C and stirred for 5 h. The reaction was quenched with saturated aqueous NaHCO3 (5 mL) and extracted with dichloromethane (30 mL × 3). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified by reverse phase HPLC (acetonitrile / water gradient + 0.05% NH3 + 10 mM NH4HCO3) to give the second eluting peak as a pure single stereoisomer of the title compound (51.5 mg, 27.6% yield) (Compound 24).

[0300] Compound 24: 6-((1R,3s,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0301] LCMS(ESI)[M+H] + =481.4. 1H NMR(400MHz,CDCl3)δ 9.11(d,J=1.6Hz,1H),8.76(s,1H),8.28(s,1H),6.19(s,1H),4.27-4.23(m,2H),4.09(s,4H),2.82-2.78(m,1H),2.69-2.65(m ,2H),2.46-2.42(m,1H),2.22-2.18(m,4H),2.00-1.85(m,1H),1.75-1.72(m,3H),1.58(s,2H),1.51(t,J=7.2Hz,3H).The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0302] Compound 25: 6-((1R,3r,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0303] The residue from step 5 was purified by preparative reverse phase HPLC (acetonitrile / water gradient with 0.05% NH3+10 mM NH4HCO3) to give the first eluting peak as a pure single stereoisomer of the title compound (46.1 mg, 25% yield). LCMS (ESI) [M+H] + =481.4. 1 H NMR(400MHz,CDCl3)δ 9.10(s,1H),8.76(s,1H),8.28(s,1H),6.14(s,1H),4.30-4.20(m,2H),4.13-3.99(m,4H),2.95-2.90(m,1H),2.82-2.79(m,2H) ,2.72-2.68(m,2H),2.43-2.11(m,3H),2.09-2.06(m,1H),1.98-1.90(m,2H),1.67-1.64(m,2H),1.50(t,J=7.2Hz,3H). 1 Assigned based on 1 H NMR analysis.

[0304] Example N: 6-((1R,3s,5S,6r)-6-(1-ethyl-3-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 26) and 6-((1R,3r,5S,6r)-6-(1-ethyl-3-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 27) [ka] The title compound was synthesized using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyridine following a similar procedure to compounds 24 and 25. The relative stereochemistry of both compounds is as follows: 1 Assigned based on 1 H NMR analysis.

[0305] Compound 26: 6-((1R,3s,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide. LCMS (ESI) [M+H] + =481.2. 1 H NMR(400MHz,CDCl3)δ 8.68(d,J=5.2Hz,1H),8.02(s,1H),7.77(d,J=5.2Hz,1H),6.25(s,1H),4.24(q,J=7.2Hz,2H),4.19-4.08(m,4H),2.87-2.65( m,3H),2.52-2.41(m,1H),2.29-2.18(m,4H),2.10-1.80(m,2H),1.79-1.61(m,3H),1.58-1.56(m,1H),1.51(t,J=7.2Hz,3H).

[0306] Compound 27: 6-((1R,3r,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide. LCMS (ESI) [M+H] + =481.2. 1 H NMR(400MHz,CDCl3)δ 8.68(d,J=5.2Hz,1H),8.01(s,1H),7.78(d,J=4.4Hz,1H),6.20(s,1H),4.24(q,J=7.2Hz,2H),4.09-4.01(m,4H),2.98-2.91(m,1H) ,2.80(s,2H),2.73-2.67(m,2H),2.16-2.09(m,4H),1.98-1.91(m,2H),1.73-1.62(m,2H),1.61-1.58(m,1H),1.50(t,J=7.2Hz,3H).

[0307] Example O: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 28) [ka] The title compound was synthesized using (2-(trifluoromethyl)pyrimidin-4-yl)boronic acid following a procedure similar to that for compound 5. The relative stereochemistry is: 1 Assigned based on 1 H NMR analysis.

[0308] Compound 28:LCMS(ESI)[M+H] + =496.2. 1H NMR(400MHz,DMSO-d6)δ 8.96(d,J=5.3Hz,1H),8.11(d,J=5.4Hz,1H),6.60(s,1H),4.90-4.76(m,1H),4.19-4.07(m,4H),2.68(s ,2H),2.59-2.51(m,3H),2.16-2.04(m,4H),1.87-1.82(m,1H),1.77-1.67(m,4H),1.46(d,J=6.5Hz,6H).

[0309] Example P: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(3,3,3-trifluoroprop-1-en-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 31) [ka] Step 1: 6-((1R,3r,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0310] Step 2: The title compound was prepared following the procedure described for compound 5. A solution of 6-((1R,3r,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (75 mg, 0.16 mmol), potassium phosphate (67 mg, 0.32 mmol), Cataxium Pd G4 (5.9 mg, 0.008 mmol) and 4,4,6,6-tetramethyl-2-(3,3,3-trifluoroprop-1-en-2-yl)-1,3,2-dioxaborinane (56 mg, 0.24 mmol) in 1,4-dioxane (0.79 mL) and water (0.20 mL) was stirred at 50° C. for 18 hours. The reaction mixture was diluted with 1N aqueous NH4Cl (0.5 mL) and filtered DMSO and purified by preparative HPLC (acetonitrile / water gradient + 0.1% TFA) to give the title compound (38 mg, 54% yield). The relative stereochemistry is: 1 Assigned based on 1 H NMR analysis.

[0311] Compound 31:LCMS(ESI)[M+H] + =444.3. 1 H NMR(400MHz,DMSO-d6)δ 6.09(s,1H),6.02(s,1H),5.81(s,1H),4.69-4.57(m,1H),4.16-4.04(m,4H),2.85-2.78(m,1H),2.70(s,2H),2.57(t,J= 7.2Hz,2H),2.23-2.17(m,1H),2.10-1.96(m,4H),1.90(dd,J=13.7,3.2Hz,2H),1.62-1.57(m,2H),1.40(d,J=6.5Hz,6H).

[0312] Example Q: 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(1-(trifluoromethyl)cyclopropyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 32) [ka] To a 0 °C cooled solution of 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(3,3,3-trifluoroprop-1-en-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (36 mg, 0.081 mmol) and diphenyl(methyl)sulfonium tetrafluoroborate (30 mg, 0.11 mmol) in tetrahydrofuran (0.54 mL), sodium bis(trimethylsilyl)amide (0.13 mL, 0.13 mmol, 1 mol / L in tetrahydrofuran) was added. The reaction mixture was stirred at 0-25 °C for 1 h. The reaction mixture was cooled to 0° C. and additional diphenyl(methyl)sulfonium tetrafluoroborate (25 mg, 0.092 mmol) and sodium bis(trimethylsilyl)amide (0.090 mL, 0.090 mmol, 1 mol / L in tetrahydrofuran) were added. The reaction mixture was stirred at 0-25° C. for 2 h. The reaction mixture was diluted with 1N aqueous NH4Cl (0.5 mL) and DMSO, filtered, and purified by preparative HPLC (acetonitrile / water gradient + 0.1% TFA) to give the title compound (6.1 mg, 16% yield).

[0313] Compound 32:LCMS(ESI)[M+H] + =458.2. 1 H NMR(400MHz,DMSO-d6)δ 5.82(s,1H),4.63-4.48(m,1H),4.16-4.02(m,4H),2.85-2.75(m,1H),2.69(s,2H),2.56(t,J=7.3Hz,2H),2.15(t,J=3.4Hz,1H),2.09 -1.93(m,4H),1.88(dd,J=13.8,3.2Hz,2H),1.58-1.52(m,2H),1.35(d,J=6.6Hz,6H),1.24-1.20(m,2H),1.15-1.08(m,2H).The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0314] Example R: 7-((1R,3s,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 38) [ka] The title compound was synthesized following a similar procedure to compound 3 using 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide. The crude mixture was purified by silica column chromatography (0-12% ethanol in ethyl acetate) to give compound 38 as the first eluting peak. The relative stereochemistry is: 1 Assigned based on 1 H NMR analysis.

[0315] Compound 38:LCMS(ESI)[M+H] + =509.2. 1 H NMR(400MHz,CDCl3)δ 9.11(d,J=2.0Hz,1H),8.75(d,J=1.2Hz,1H),8.29(s,1H),6.13(s,1H),4.69-4.59(m,1H),3.86(s,4H),2.58-2.33(m ,4H),2.27-2.22(m,2H),1.95-1.92(m,4H),1.88-1.83(m,2H),1.72(s,2H),1.66-1.56(m,2H),1.55(d,J=6.4Hz,6H).

[0316] Example S: 7-((1R,3r,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 40) [ka] The title compound was synthesized following a similar procedure to compound 4 using 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide. The crude mixture was purified by silica column chromatography (0-12% ethanol in ethyl acetate) to give compound 40 as the second eluting peak. The relative stereochemistry is: 1 Assigned based on 1 H NMR analysis.

[0317] Compound 40:LCMS(ESI)[M+H] + =509.2. 1 H NMR(400MHz,CDCl3)δ 9.10(d,J=1.6Hz,1H),8.74(d,J=1.2Hz,1H),8.28(s,1H),6.13(s,1H),4.72-4.62(m,1H),3.85(s,4H),2.96-2 .88(m,1H),2.56-2.25(m,5H),1.92-1.89(m,4H),1.71-1.64(m,4H),1.61-1.58(m,2H),1.55(d,J=6.8Hz,6H).

[0318] Example T - Compounds 43* and 44*: 7-((1R,3s,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide, and 7-((1R,3r,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide [ka] Step 1: 1-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-4,4,4-trifluorobutane-1,3-dione [ka]

[0319] To a solution of ethyl trifluoroacetate (0.52 mL, 4.22 mmol) in THF (10 mL) was added NaH (0.19 g, 4.65 mmol) portionwise under N2 at 0 °C and stirred for 0.5 h. A solution of 1-[3-[tert-butyl(diphenyl)silyl]oxy-6-bicyclo[3.1.0]hexanyl]ethanone (1.28 g, 3.38 mmol) in THF (20 mL) was added under N2 at 0 °C. The reaction mixture was then stirred at 20-30 °C for 2 h. The reaction mixture was quenched with saturated NH4Cl solution (50 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (50 mL × 3), dried over anhydrous Na2SO4, filtered, and concentrated in vacuum. The resulting residue was purified by silica flash chromatography (0-10% ethyl acetate in petroleum ether) to give the title compound (1.2 g, 2.53 mmol, 75% yield). LCMS (ESI) [M+H] + =475.1.

[0320] Step 2: 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-3-(trifluoromethyl)-1H-pyrazole [ka]

[0321] To a solution of 1-[3-[tert-butyl(diphenyl)silyl]oxy-6-bicyclo[3.1.0]hexanyl]-4,4,4-trifluoro-butane-1,3-dione (400 mg, 0.84 mmol) in ethanol (15 mL) was added isopropylhydrazine hydrochloride (93 mg, 0.84 mmol) and triethylamine (0.12 mL, 0.84 mmol). The reaction mixture was stirred at 25 °C for 15 h. The mixture was concentrated in vacuo and purified by silica flash chromatography (0-5% ethyl acetate in petroleum ether) to give the title compound (350 mg, 0.683 mmol, 81% yield). LCMS (ESI) [M+H] + =513.2.

[0322] Step 3: 6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol [ka]

[0323] To tert-butyl-[[6-[2-isopropyl-5-(trifluoromethyl)pyrazol-3-yl]-3-bicyclo[3.1.0]hexanyl]oxy]-diphenyl-silane (350 mg, 0.68 mmol) in a flask was added tetrabutylammonium fluoride (5 mL, 5 mmol, 1 M) in tetrahydrofuran. The reaction mixture was stirred at 25 °C for 5 h. The mixture was diluted with water (20 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic layers were concentrated in vacuo. The resulting residue was purified by silica flash chromatography (0-30% ethyl acetate in petroleum ether) to give the title compound (170 mg, 0.5826 mmol, 85.3% yield). LCMS (ESI) [M+H] + =275.1.

[0324] Step 4: (1R,5S,6r)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0325] To a solution of 6-[2-isopropyl-5-(trifluoromethyl)pyrazol-3-yl]bicyclo[3.1.0]hexan-3-ol (170 mg, 0.62 mmol) in anhydrous dichloromethane (6 mL) was added Dess-Martin periodinane (394 mg, 0.93 mmol). The reaction mixture was stirred at 25 °C for 4 h. The reaction mixture was then diluted with H2O (5 mL), saturated Na2SO3 solution (5 mL) and saturated NaHCO3 solution (5 mL). The mixture was extracted with ethyl acetate (25 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The resulting residue was purified by silica flash chromatography (0-40% ethyl acetate in petroleum ether) to give the title compound (150 mg, 0.463 mmol, 75% yield). LCMS (ESI) [M+H] + =273.1; 1 H NMR(400MHz,CD3OD)δ 6.27(s,1H),4.84-4.74(m,1H),2.78-2.72(m,2H),2.44-2.31(m,2H),2.03-1.96(m,2H),1.62(t,J=3.6Hz,1H),1.48(d,J=6.8Hz,6H).

[0326] Step 5: Synthesis of the title compound. To a mixture of (1R,5S)-6-[2-isopropyl-5-(trifluoromethyl)pyrazol-3-yl]bicyclo[3.1.0]hexan-3-one (600.0 mg, 2.2 mmol), 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide hydrochloride (564 mg, 2.66 mmol) and acetic acid (662 mg, 11.02 mmol) in methanol (8 mL) was added sodium cyanoborohydride (692 mg, 11.0 mmol). The reaction mixture was stirred at 70° C. for 2 hours, diluted with saturated sodium bicarbonate (10 mL) and extracted with dichloromethane (50 mL×3). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (water (0.05% NH3H2O ​​+ 10 mM NH4HCO3)-ACN) to give the title compound 43* (first peak by HPLC, 349 mg, 0.80 mmol, 36.4% yield) and the title compound 44* (second peak by HPLC, 273 mg, 0.62 mmol, 28.2% yield). LCMS (ESI) [M+H] + = 432.3. Relative stereochemistry has been arbitrarily assigned for both compounds.

[0327] Compound 43*: 1 H NMR(400MHz,CDCl3)δ 6.03(s,1H),4.66-4.62(m,1H),3.85(s,4H),2.38-2.30(m,3H),2.21-2.19(m,2H),1. 94-1.91(m,4H),1.78-1.72(m,2H),1.67(s,2H),1.60-1.62(m,1H),1.56-1.51(m,8H).

[0328] Compound 44*: 1 H NMR(400MHz,CDCl3)δ 5.99(s,1H),4.69-4.62(m,1H),3.85(s,4H),2.94-2.88(m,1H),2.34-2.3 0(m,5H),1.91-1.90(m,4H),1.68(s,1H),1.62(s,3H),1.57-1.50(m,8H).

[0329] Example U - Compounds 45* and 46*: 7-((1R,3s,5S,6r)-6-(3-(5-(difluoromethoxy)pyridin-3-yl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide, and 7-((1R,3r,5S,6r)-6-(3-(5-(difluoromethoxy)pyridin-3-yl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide [ka] Step 1: (5-(difluoromethoxy)pyridin-3-yl)boronic acid [ka]

[0330] A solution of potassium acetate (657 mg, 6.7 mmol), Pd(dppf)Cl2 (163 mg, 0.22 mmol), 3-bromo-5-(difluoromethoxy)pyridine (500 mg, 2.23 mmol), and bis(pinacolato)diboron (2.3 g, 8.93 mmol) in 1,4-dioxane (20 mL) was stirred at 100 °C under N2 atmosphere for 4 h. The reaction mixture was used directly in the next step without further purification. LCMS (ESI) [M+H] + =190.1

[0331] Step 2: (1R,5S,6r)-6-(3-(5-(difluoromethoxy)pyridin-3-yl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0332] To a mixture of potassium carbonate (500 mg, 3.62 mmol) and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (85 mg, 0.12 mmol) in 1,4-dioxane (20 mL) and water (8 mL) was added (1R,5S)-6-(5-iodo-2-isopropyl-1,2,4-triazol-3-yl)bicyclo[3.1.0]hexan-3-one (400 mg, 1.21 mmol) and 3-(difluoromethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (655 mg, 2.42 mmol). The reaction mixture was then stirred at 75° C. for 3 h under nitrogen atmosphere. The mixture was extracted with ethyl acetate (20 mL×3). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica flash chromatography (0-50% ethyl acetate in petroleum ether) to give the title compound (420 mg, 1.21 mmol, 99.8% yield). LCMS (ESI) [M+H] + =348.2.

[0333] Step 5: Synthesis of the title compound. To a mixture of 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide hydrochloride (62 mg, 0.35 mmol), acetic acid (0.1 mL) and sodium cyanoborohydride (72 mg, 1.15 mmol) in methanol (5 mL) was added (1S,5R)-6-[5-[5-(difluoromethoxy)-3-pyridyl]-2-isopropyl-pyrazol-3-yl]bicyclo[3.1.0]hexan-3-one (100 mg, 0.29 mmol). The reaction mixture was stirred at 60° C. for 6 hours. The mixture was concentrated in vacuum and the residue was diluted with ethyl acetate (50 mL) and washed with water (30 mL) and brine (30 mL×2). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuum. The residue was purified by reverse phase chromatography (acetonitrile 30-60% / 0.1% NH4OH in water) to give the title compound 45* (first peak in HPLC (basic), 40.6 mg, 0.0793 mmol, 27.6% yield) and the title compound 46* (second peak in HPLC (basic), 30.3 mg, 0.0562 mmol, 19.5% yield). LCMS (ESI) [M+H] + =507.3. Relative stereochemistry was arbitrarily assigned for both compounds.

[0334] Compound 45*: 1 H NMR(400MHz,CD3OD)δ 8.78(d,J=1.6Hz,1H),8.30(d,J=2.4Hz,1H),7.96(d,J=2.0Hz,1H),6.99(t,J=33.2Hz,1H),6.37(s,1H),4.80-4.74(m ,1H),3.91(s,4H),2.49-2.08(m,7H),1.97-1.91(m,4H),1.87-1.79(m,2H),1.75-1.74(m,3H),1.52(d,J=6.8Hz,6H).

[0335] Compound 46*: 1H NMR(400MHz,CD3OD)δ 8.77(s,1H),8.30(d,J=2.8Hz,1H),7.95(s,1H),6.99(t,J=33.2Hz,1H),6.32(s,1H),4.82-4.77(m,1H),3.91(s,4H), 3.04-3.02(m,1H),2.49-2.38(m,6H),1.94-1.89(m,4H),1.75-1.72(m,3H),1.62-1.57(m,2H),1.54(d,J=6.5Hz,6H).

[0336] Example V: 7-((1R,3s,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 47), and 7-((1R,3r,5S,6r)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 48) The title compound was synthesized in the same manner as for Compound 45 using (6-(trifluoromethyl)pyridin-2-yl)boronic acid. [ka]

[0337] The isomers were purified by preparative HPLC (water (0.05% FA)-ACN, 40-60%) to give the title compound 47 (first peak in SFC, 48.1 mg, 0.0936 mmol, 23.4% yield) and the title compound 48 (second peak in SFC, 50.7 mg, 0.0986 mmol, 24.6% yield). LCMS (ESI) [M+H] + =509.2.Relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0338] Compound 47: 1H NMR(400MHz,CD3OD)δ 8.16(d,J=8.0Hz,1H),7.98(t,J=8.0Hz,1H),7.63(d,J=8.0Hz,1H),6.56(s,1H),4.82-4.73(m,1H),4.04(s,4H),3.30-3.25( m,2H),3.14(brs,3H),2.52(dd,J=7.6,12.8Hz,2H),2.23-2.02(m,6H),1.88(s,2H),1.82-1.77(m,1H),1.54(d,J=6.4Hz,6H).

[0339] Compound 48: 1 H NMR(400MHz,CD3OD)δ 8.16(d,J=8.0Hz,1H),7.97(d,J=8.0Hz,1H),7.62(d,J=8.0Hz,1H),6.50(s,1H),4.85-4.75(m,1H),4.02(s,4H),3. 63-3.52(m,1H),3.21-2.69(m,4H),2.68-2.53(m,2H),2.10-2.04(m,4H),1.88-1.72(m,5H),1.56(d,J=7.2Hz,6H).

[0340] Example W: 7-((1R,3s,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 49), and 7-((1R,3r,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 50) [ka] Step 1: 1-[3-[tert-butyl(diphenyl)silyl]oxy-6-bicyclo[3.1.0]hexanyl]-3-[2-(trifluoromethyl)pyrimidin-4-yl]propane-1,3-dione [ka]

[0341] To a solution of 1-[3-[tert-butyl(diphenyl)silyl]oxy-6-bicyclo[3.1.0]hexanyl]ethanone (500 mg, 1.32 mmol) in THF (10 mL) was added NaH (60% in mineral oil, 79 mg, 1.98 mmol) in portions at 0° C. under N2. The reaction mixture was stirred for 0.5 h. Then, a solution of methyl 2-(trifluoromethyl)pyrimidine-4-carboxylate (327 mg, 1.58 mmol) in THF (1 mL) was added at 0° C. under N2. The resulting mixture was stirred at 20° C. for 2 h. The reaction mixture was quenched with a saturated aqueous solution of NH4Cl (20 mL), diluted with water (30 mL), and extracted with ethyl acetate (30 mL×3). The combined organic layers were concentrated in vacuo. The residue was purified by silica flash chromatography (petroleum ether) to give the title compound (0.530 g, 73% yield). LCMS (ESI) [M+H] + =553.1.

[0342] Step 2: tert-Butyl-[[6-[2-isopropyl-5-[2-(trifluoromethyl)pyrimidin-4-yl]pyrazol-3-yl]-3-bicyclo[3.1.0]hexanyl]oxy]-diphenyl-silane and tert-Butyl-[[6-[1-isopropyl-5-[2-(trifluoromethyl)pyrimidin-4-yl]pyrazol-3-yl]-3-bicyclo[3.1.0]hexanyl]oxy]-diphenyl-silane [ka]

[0343] To a solution of 1-[3-[tert-butyl(diphenyl)silyl]oxy-6-bicyclo[3.1.0]hexanyl]-3-[2-(trifluoromethyl)pyrimidin-4-yl]propane-1,3-dione (1.2 g, 2.17 mmol) in ethanol (40 mL) was added isopropylhydrazine hydrochloride (240 mg, 2.39 mmol) and triethylamine (0.35 mL, 2.39 mmol). The reaction mixture was stirred at 25 °C for 15 h. The mixture was concentrated in vacuo and the residue was then purified by silica flash chromatography (0-5% ethyl acetate in petroleum ether) to give the title compound (first peak, less polar) (330 mg, 26% yield). LCMS (ESI) [M+H] + =591.2; 1 H NMR (400 MHz, CDCl3) δ 8.78 (d, J = 5.2 Hz, 1H), 8.11 (d, J = 5.2 Hz, 1H), 7.70-7.61 (m, 4H), 7.49-7.36 (m, 6H), 6.63 (s, 1H), 4.89-4.74 (m, 1H), 4.46-4.40 (m, 1H), 2.43 (t, J = 3.2 Hz, 1H), 2.10-1.97 (m, 4H), 1.69-1.66 (m, 2H), 1.62-1.52 (m, 8H), 1.09 (s, 9H). 2D NMR confirmed the regioselectivity of the pyrazole.

[0344] Other isomer (second peak, more polar) (400 mg, 31% yield). LCMS (ESI) [M+H] + =591.2; 1 H NMR(400MHz,CDCl3)δ 8.75(d,J=4.4Hz,1H),8.05(d,J=4.8Hz,1H),7.74-7.63(m,4H),7.48-7.35(m,7H),6.62-6.55(m,1H),4.62-4.42(m,1H) ),4.09-4.02(m,1H),2.18-2.13(m,2H),2.07-1.95(m,2H),1.65-1.62(m,2H),1.46-1.44(m,6H),1.05(d,J=1.2Hz,9H).

[0345] Step 2: 6-[2-isopropyl-5-[2-(trifluoromethyl)pyrimidin-4-yl]pyrazol-3-yl]bicyclo[3.1.0]hexan-3-ol [ka]

[0346] To a solution of tert-butyl-[[6-[2-isopropyl-5-[2-(trifluoromethyl)pyrimidin-4-yl]pyrazol-3-yl]-3-bicyclo[3.1.0]hexanyl]oxy]-diphenyl-silane (330 mg, 0.56 mmol) in tetrahydrofuran (10 mL) was added triethylamine trihydrofluoride (2.2 mL). The reaction mixture was stirred at 70° C. for 15 h. The reaction was concentrated in vacuum and the residue was quenched with aqueous NaOH (2N). The resulting mixture was extracted with ethyl acetate (50 mL×3). The combined organic layers were concentrated in vacuum and the resulting residue was purified by silica flash chromatography (0-50% ethyl acetate in petroleum ether) to give the title compound (150 mg, 76% yield). LCMS (ESI) [M+H]+=353.1.

[0347] Step 3: 6-[2-isopropyl-5-[2-(trifluoromethyl)pyrimidin-4-yl]pyrazol-3-yl]bicyclo[3.1.0]hexan-3-one [ka]

[0348] To a solution of 6-[2-isopropyl-5-[2-(trifluoromethyl)pyrimidin-4-yl]pyrazol-3-yl]bicyclo[3.1.0]hexan-3-ol (150 mg, 0.43 mmol) in anhydrous dichloromethane (7 mL) was added Dess-Martin periodinane (270 mg, 0.64 mmol) at 0° C., and the reaction mixture was stirred at 25° C. for 4 h. The reaction mixture was diluted with aqueous Na2SO3 (10 mL) and aqueous NaHCO3 (5 mL). The mixture was then extracted with ethyl acetate (30 mL×3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica flash chromatography (0-40% ethyl acetate in petroleum ether) to give the title compound (125 mg, 84% yield). 1 H NMR(400MHz,CDCl3)δ 8.80(d,J=5.2Hz,1H),8.11(d,J=5.2Hz,1H),6.75(s,1H),4.72-4.60(m,1H),2.86-2.72(m, 2H),2.46(s,1H),2.41(s,1H),2.04-2.00(m,2H),1.60-1.52(m,6H),1.41(t,J=3.6Hz,1H).

[0349] Step 3: 7-((1R,3s,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 49) and 7-((1R,3r,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 50). To a solution of 6-[2-isopropyl-5-[2-(trifluoromethyl)pyrimidin-4-yl]pyrazol-3-yl]bicyclo[3.1.0]hexan-3-one (110 mg, 0.31 mmol) and 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide hydrochloride (100 mg, 0.47 mmol) in anhydrous methanol (6 mL) was added acetic acid (57 mg, 0.94 mmol) and sodium cyanoborohydride (59 mg, 0.94 mmol) at 20° C., and the reaction mixture was then stirred at 60° C. for 15 h. The reaction was purified by preparative HPLC (25-55% acetonitrile / 0.05% NH4OH in water) to give the title compound 49 (2nd peak, 56.25 mg, 34% yield) and the title compound 50 (1st peak, 39.7 mg, 24% yield). LCMS(ESI)[M+H] + =510.3. Relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0350] Compound 49: 1 H NMR(400MHz,CD3OD)δ 8.84(d,J=5.2Hz,1H),8.13(d,J=5.2Hz,1H),6.64(s,1H),4.85-4.78(m,1H),3.91(s ,4H),2.85-2.12(m,6H),1.98-1.89(m,4H),1.87-1.72(m,5H),1.54(d,J=6.4Hz,6H).

[0351] Compound 50: 1H NMR(400MHz,CD3OD)δ 8.86(d,J=5.2Hz,1H),8.15(d,J=5.2Hz,1H),6.61(s,1H),4.89-4.82(m,1H),3.93(s,4H),3.08-2.99(m,1H),2.9 6-2.03(m,6H),1.98-1.88(m,4H),1.83-1.78(m,1H),1.77-1.72(m,2H),1.66-1.59(m,1H),1.58(d,J=6.4Hz,6H).

[0352] Example X: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 51), and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 52) [ka] Step 1: 5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazole [ka]

[0353] To a solution of (1R,5S)-3-[tert-butyl(diphenyl)silyl]oxybicyclo[3.1.0]hexane-6-carboxylic acid (2.0 g, 5.26 mmol) and 3-(trifluoromethyl)benzamidine (1.48 g, 7.88 mmol) in N,N-dimethylformamide (20 mL), HATU (2.2 g, 5.78 mmol) and N,N-diisopropylethylamine (2.75 mL, 15.8 mmol) were added. The reaction mixture was stirred at 20° C. for 1 h. To the reaction mixture, isopropylhydrazine hydrochloride (872 mg, 7.88 mmol) and acetic acid (3156 mg, 52.6 mmol) were added. The reaction mixture was then stirred at 80° C. for 1.5 h. The reaction mixture was diluted with ethyl acetate (200 mL) and washed with saturated NaHCO3 (50 mL) and brine (50 mL×3). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was purified by silica flash chromatography (0-10% ethyl acetate in petroleum ether) to give the title compound (2780 mg, 4.71 mmol, 89.7% yield). LCMS (ESI) [M+H] + =590.3.

[0354] Step 2: (1R,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-ol [ka]

[0355] To a stirred solution of tert-butyl-[[(1R,5S)-6-[2-isopropyl-5-[3-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]-3-bicyclo[3.1.0]hexanyl]oxy]-diphenyl-silane (2780 mg, 4.71 mmol) in tetrahydrofuran (23 mL) was added triethylamine trihydrofluoride (23 mL, 142 mmol). The reaction mixture was stirred at 70° C. for 16 h. The reaction was quenched with saturated aqueous NaOH and extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (20 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica flash chromatography (10% ethyl acetate in petroleum ether) to give the title compound (1.06 g, 3.017 mmol, 64% yield). LCMS(ESI)[M+H]+=352.3.

[0356] Step 3: (1R,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0357] To a solution of (1R,5S)-6-[2-isopropyl-5-[3-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]bicyclo[3.1.0]hexan-3-ol (1.06 mg, 3.02 mmol) in anhydrous dichloromethane (20 mL) was added Dess-Martin periodinane (1.93 g, 4.54 mmol) at 0° C. The reaction mixture was stirred at 25° C. for 16 h. The reaction mixture was then diluted with water (10 mL), followed by aqueous Na2SO3 (50 mL) and aqueous NaHCO3 (50 mL). The resulting residue was extracted with ethyl acetate (100 mL×3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The resulting residue was purified by silica flash chromatography (0-30% ethyl acetate in petroleum ether) to give the title compound (950 mg, 2.72 mmol, 90% yield). LCMS (ESI) [M+H] + =350.1.

[0358] Step 4: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 51) and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 52). To a solution of "(1R,5S)-6-[2-isopropyl-5-[3-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]bicyclo[3.1.0]hexan-3-one (100 mg, 0.28 mmol) in methanol (4 mL) was added acetic acid (0.12 mL, 1.44 mmol), 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide hydrochloride (60 mg, 0.38 mmol) and sodium cyanoborohydride (90 mg, 1.44 mmol). The reaction mixture was stirred at 70 °C for 6 h. The mixture was diluted with ethyl acetate (40 mL × 2) and the combined organic layer was washed with NaHCO3 (15 mL × 3). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by reverse phase chromatography (water (0.05% NH3H2O ​​+ 10 nM NH4HCO3)-ACN) to give the title compound 51 (43.32 mg, 0.085 mmol, 30% yield) and compound 52 (52.6 mg, 0.104 mmol, 36.5% yield). LCMS (ESI): [M+H] + =495.3.The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0359] Compound 51: 1H NMR(400MHz,CDCl3)δ 8.31(s,1H),8.22(d,J=7.2Hz,1H),7.59(d,J=8.4Hz,1H),7.52-7.49(m,1H),4.67-4.61(m,1H),4.08(s,4H),2.79(s,2H),2.67(t,J= 7.2Hz,2H),2.48-2.40(m,1H),2.23-2.16(m,4H),2.09(brs,2H),1.90(t,J=9.6Hz,2H),1.69(t,J=2.8Hz,1H),1.57(d,J=6.4Hz,6H).

[0360] Compound 52: 1 H NMR(400MHz,CDCl3)δ 8.30(s,1H),8.22(d,J=7.2Hz,1H),7.58(d,J=6.8Hz,1H),7.52-7.48(m,1H),4.62-4.59(m,1H),4.09-4.05(m,4H),2.9 3(s,1H),2.81(s,2H),2.70(t,J=6.8Hz,2H),2.22-2.15(m,5H),2.04(s,2H),1.97-1.94(m,2H).1.58(d,J=6.4Hz,6H).

[0361] Example Y - Compounds 53* and 54*: 7-((1R,3s,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide, and 7-((1R,3r,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide. [ka] Step 1: 3-(5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyridine [ka]

[0362] To a mixture of tert-butyl-[[(1R,5S)-6-(3-iodo-1H-pyrazol-5-yl)-3-bicyclo[3.1.0]hexanyl]oxy]-diphenyl-silane (2 g, 3.78 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)pyridine (1.55 g, 5.68 mmol) in 1,4-dioxane (16 mL) and water (4 mL) was added K2CO3 (1.57 g, 11.35 mmol) and Pd(dppf)Cl2 (280 mg, 0.40 mmol). The reaction mixture was stirred at 75 °C for 5 h under nitrogen atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica flash chromatography (0-30% ethyl acetate in petroleum ether) to give the title compound (1.9 g, 3.47 mmol, 92% yield). LCMS (ESI) [M+H] + =548.2.

[0363] Step 2: 3-(5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-ethyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyridine [ka]

[0364] To a solution of 3-(5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyridine (1.9 g, 3.47 mmol), Cs2CO3 (2.26 g, 6.94 mmol) in DMF (15 mL) was added iodoethane (1.39 mL, 17.35 mmol) dropwise. The reaction mixture was stirred at 25 °C for 3 h. The reaction was quenched with water (30 mL) and extracted with ethyl acetate (60 mL x 2). The combined organic layers were washed with brine (40 mL x 2), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica flash chromatography (0-15% ethyl acetate in petroleum ether) to give the title compound (1.7 g, 2.95 mmol, 85% yield). LCMS (ESI) [M+H] + =576.2.

[0365] Step 3: (1R,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol [ka]

[0366] To 3-(5-((1R,5S,6r)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-ethyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)pyridine (1.7 g, 2.95 mmol) was added tetrabutylammonium fluoride (23.6 mL, 1 M in THF, 23.6 mmol). The reaction mixture was stirred at 25° C. for 5 h. The mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica flash chromatography (0-50% ethyl acetate in petroleum ether) to give the title compound (830 mg, 2.46 mmol, 83% yield). LCMS (ESI) [M+H] +=338.1.

[0367] Step 4: (1R,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0368] To a solution of (1R,5S,6r)-6-[2-ethyl-5-[5-(trifluoromethyl)-3-pyridyl]pyrazol-3-yl]bicyclo[3.1.0]hexan-3-ol (830 mg, 2.46 mmol) in anhydrous dichloromethane (15 mL) was added Dess-martine periodinane (1.57 g, 3.69 mmol) and stirred at 25 °C for 16 h. The mixture was then diluted with H2O (20 mL), followed by aqueous Na2SO3 (20 mL) and aqueous NaHCO3 (20 mL). The resulting mixture was extracted with dichloromethane (50 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to give the title compound (600 mg, 1.79 mmol, 73% yield). 1 H NMR(400MHz,CDCl3)δ 9.12(d,J=1.6Hz,1H),8.77(d,J=1.2Hz,1H),8.30(s,1H),6.28(s,1H),4.25(m,2H),2.85- 2.74(m,2H),2.49-2.39(m,2H),2.00(s,2H),1.51(t,J=7.2Hz,3H),1.40(t,J=3.6Hz,1H).

[0369] Step 5: 7-((1R,3s,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 53) and 7-((1R,3r,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 54). To a solution of 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide hydrochloride (57 mg, 0.27 mmol) and (1R,5S,6r)-6-(1-ethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one (60 mg, 0.18 mmol) in anhydrous methyl alcohol (3 mL) was added NaBH3CN (34 mg, 0.54 mmol) and acetic acid (0.01 mL, 0.18 mmol) at 20° C. The reaction mixture was stirred at 70° C. for 5 h. The reaction mixture was diluted with NaHCO3 (10 mL) and extracted with dichloromethane (20 mL×3). The combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to give the crude product (100 mg). The crude product was purified by reverse phase chromatography (30-60% acetonitrile / 0.05% ammonia hydroxide in water) to give the title compound 53* (second peak, 45.56 mg, 0.09 mmol, 50.5% yield) and the title compound 54* (first peak, 34.31 mg, 0.068 mmol, 38% yield). LCMS (ESI) [M+H] + = 495.1. Relative stereochemistry arbitrarily assigned.

[0370] Compound 53*: 1H NMR(400MHz,CD3OD)δ 9.15(d,J=2.0Hz,1H),8.76(d,J=1.2Hz,1H),8.41(s,1H),6.46(s,1H),4.28(q,J=7.2Hz,2H),3.91(s, 4H),2.61-2.34(m,4H),2.29-2.27(m,2H),1.97-1.79(m,7H),1.77-1.74(m,3H),1.46(t,J=7.2Hz,3H).

[0371] Compound 54*: 1 H NMR(400MHz,CD3OD)δ 9.14(d,J=1.6Hz,1H),8.76(d,J=1.2Hz,1H),8.41(s,1H),6.41(s,1H),4.32(q,J=7.2Hz,2H),3.91(s,4H),3.07 -3.03(m,1H),2.49-2.04(m,6H),1.94-1.89(m,4H),1.79-1.72(m,3H),1.64-1.56(m,2H),1.48(t,J=7.6Hz,3H).

[0372] Example Z: 7-((1R,3s,5S,6r)-6-(1-(tert-butyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 55), and 7-((1R,3r,5S,6r)-6-(1-(tert-butyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 56) The title compound was synthesized in the same manner as for compound 43 using the above. [ka]

[0373] The mixture of diastereomers was purified by reverse phase chromatography (acetonitrile 30-60% / 0.1% NH4OH in water) to give the title compound 55 (first peak by HPLC, 38.79 mg, 0.0845 mmol, 24.2% yield) and the title compound 56 (second peak by HPLC, 30.9 mg, 0.0672 mmol, 19.2% yield). LCMS (ESI) [M+H] + =446.1.The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0374] Compound 55: 1 H NMR(400MHz,CD3OD)δ 6.22(s,1H),3.91(s,4H),2.45-2.33(m,4H),2.29-2.24(m,2H),1.92-1.89(m,4H),1.88-1.72(m,6H),1.69(s,9H).

[0375] Compound 56: 1 H NMR(400MHz,CD3OD)δ 6.14(s,1H),3.90(s,4H),3.00-2.93(m,1H),2.45-2.26(m,5H),2.07-2.05(m,1H),1.91-1.89(m,4H),1.72(s,9H),1.70-1.64(m,5H).

[0376] Example AA: 6-((1R,3s,5S,6r)-6-(1-(tert-butyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 57), and 6-((1R,3r,5S,6r)-6-(1-(tert-butyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 58) The title compound was synthesized analogously to compound 43 using tert-butylhydrazine hydrochloride. [ka]

[0377] The mixture of diastereoisomers was purified by reverse phase chromatography to give the title compound 57* (first peak by HPLC, 23.3 mg, 0.050 mmol, 18% yield) and the title compound 58* (second peak by HPLC, 43.11 mg, 0.094 mmol, 34% yield). LCMS (ESI) [M+H] + =432.1.The relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0378] Compound 57: 1 H NMR(400MHz,CD3OD)δ 6.22(s,1H),4.08(s,4H),2.85(s,2H),2.72-2.70(m,2H),2.58-2.48(m,1 H),2.27-2.15(m,4H),1.92-1.81(m,3H),1.78-1.73(m,2H),1.70(s,9H).

[0379] Compound 58: 1 H NMR(400MHz,CD3OD)δ 6.13(s,1H),4.08(s,4H),2.90-2.86(m,1H),2.82(s,2H),2.71-2.69(m,2H),2.58- 2.54(m,1H),2.18-2.12(m,4H),2.06-2.01(m,2H),1.71(s,9H),1.70-1.69(m,2H).

[0380] Example BB - Compounds 62* and 63*: 7-((1R,3s,5S,6r)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide, and 7-((1R,3r,5S,6r)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide. [ka] Step 1: 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-3-(trifluoromethyl)-1H-pyrazole [ka]

[0381] To a solution of hydrazine (140.0 mg, 4.37 mmol) in ethanol (10 mL) was added 1-[3-[tert-butyl(diphenyl)silyl]oxy-6-bicyclo[3.1.0]hexanyl]-4,4,4-trifluoro-butane-1,3-dione (2000 mg, 4.21 mmol) and triethylamine (0.63 mL, 4.39 mmol). The reaction mixture was stirred at 80° C. for 15 h. The mixture was concentrated in vacuo and the residue was purified by silica flash chromatography (0-10% ethyl acetate in petroleum ether) to give the title compound (1.63 g, 3.46 mmol, 82% yield). LCMS (ESI), [M+H]+=471.3.

[0382] Step 2: 5-(3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazole [ka]

[0383] To a solution of tert-butyl-diphenyl-[[6-[3-(trifluoromethyl)-1H-pyrazol-5-yl]-3-bicyclo[3.1.0]hexanyl]oxy]silane (1500 mg, 3.19 mmol) in N,N-dimethylformamide (15 mL) was added cesium carbonate (3116 mg, 9.56 mmol) and 2,2-difluoroethyl trifluoromethanesulfonate (1024 mg, 4.78 mmol). The reaction mixture was stirred at 25 °C for 12 h. Ethyl acetate (120 mL) was added to the reaction mixture and the resulting mixture was washed with brine (30 mL × 3). The organic layer was dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica flash chromatography (0-10% ethyl acetate in petroleum ether) to give the title compound (1280 mg, 2.39 mmol, 75.1% yield). LCMS(ESI), [M+H]+=535.1.

[0384] Step 3: 6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-ol [ka]

[0385] To a stirred solution of tert-butyl-[[6-[2-(2,2-difluoro-1-methyl-ethyl)-5-(trifluoromethyl)pyrazol-3-yl]-3-bicyclo[3.1.0]hexanyl]oxy]-diphenyl-silane (1.22 g, 2.22 mmol) in THF (10 mL) was added triethylamine trihydrofluoride (5.46 mL, 33.52 mmol). The reaction mixture was stirred at 70° C. for 16 h. The reaction mixture was quenched with saturated NaOH solution and extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (20 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica flash chromatography (10% ethyl acetate in petroleum ether) to give the title compound (620 mg, 1.998 mmol, 90% yield). LCMS (ESI), [M+H] + =297.1.

[0386] Step 4: (1R,5S,6r)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0387] To a solution of 6-[2-(2,2-difluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl]bicyclo[3.1.0]hexan-3-ol (520 mg, 1.76 mmol) in anhydrous dichloromethane (10 mL) was added Dess-Martin periodinane (1121 mg, 2.64 mmol) under N2 at 0 °C and stirred at 25 °C for 16 h. The reaction mixture was diluted with H2O (10 mL), then diluted with aqueous Na2SO3 (100 mL) and aqueous NaHCO3 (100 mL) and extracted with ethyl acetate (100 mL × 3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica flash chromatography (0-30% ethyl acetate in petroleum ether) to give the title compound (250 mg, 0.85 mmol, 48.4% yield). LCMS(ESI), [M+H]+=295.0.

[0388] Step 5: 7-((1R,3s,5S,6r)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 62), and 7-((1R,3r,5S,6r)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 63). To a solution of 6-[2-(2,2-difluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl]bicyclo[3.1.0]hexan-3-one (80 mg, 0.27 mmol) in methanol (4 mL) was added acetic acid (0.11 mL, 1.36 mmol), 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide hydrochloride (69 mg, 0.33 mmol) and sodium cyanoborohydride (85 mg, 1.36 mmol) and stirred at 70 °C for 12 h.

[0389] The mixture was diluted with ethyl acetate (40 mL) and washed with NaHCO3 (15 mL x 3). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by reverse phase chromatography (water (0.05% NH3H2O ​​+ 10 mM NH4HCO3) -ACN) to give the title compound 62* (31.84 mg, 0.0667 mmol, 24.5% yield) and the title compound 63* (31.57 mg, 0.0675 mmol, 24.8% yield). LCMS (ESI), [M+H]+ = 454.3. The relative stereochemistry of both compounds was arbitrarily assigned.

[0390] Compound 62*: 1 H NMR(400MHz,DMSO-d6)δ 6.53-6.24(m,2H),4.79-4.72(m,2H),3.91(s,4H),2.44-2.29(m,4H), 2.11-2.07(m,3H),1.86(s,1H),1.76-1.75(m,4H),1.66-1.61(m,4H).

[0391] Compound 63*: 1 H NMR(400MHz,DMSO-d6)δ 6.55-6.26(m,2H),4.79-4.72(m,2H),3.88(s,4H),2.81-2.76(m,1H),2. 36-2.21(m,3H),2.13-2.07(m,3H),1.98-1.97(m,1H),1.74-1.60(m,8H).

[0392] Example CC - Compounds 64* and 65*: 6-((1R,3s,5S,6r)-6-(1-ethyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide and 6-((1R,3r,5S,6r)-6-(1-ethyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide The title compound was synthesized in the same manner as for compounds 53 and 54 using 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine. [ka]

[0393] The mixture of isomers was purified by reverse phase chromatography (30-60% acetonitrile / 0.05% ammonia hydroxide in water) to give the title compound 64* (second peak) and the title compound 65* (first peak). LCMS (ESI) [M+H]+ = 413.2. The relative stereochemistry of both compounds has been arbitrarily assigned.

[0394] Compound 64*: 1 H NMR(400MHz,CD3OD)δ 8.89(s,1H),8.43(d,J=3.6Hz,1H),8.16-8.14(m,1H),7.44(dd,J=8.0,5.2Hz,1H),6.34(s,1H),4.27(q,J=7.2Hz,2H),4.17-4.07(m,4H) ),2.86(s,2H),2.71(t,J=7.2Hz,2H),2.63-2.51(m,1H),2.31-2.15(m,4H),1.91-1.81(m,2H),1.79-1.72(m,3H),1.46(t,J=7.2Hz,3H).

[0395] Compound 65*: 1 H NMR(400MHz,CD3OD)δ 8.89(s,1H),8.43(d,J=3.6Hz,1H),8.15-8.13(m,1H),7.44(dd,J=7.6,5.2Hz,1H),6.29(s,1H),4.27(q,J=7.2Hz,2H),4.14-4.05(m,4 H),2.96-2.92(m,1H),2.82(s,2H),2.71(t,J=7.2Hz,2H),2.24-2.13(m,5H),1.97-1.91(m,2H),1.71(brs,2H),1.46(t,J=7.2Hz,3H).

[0396] Example DD - Compounds 66* and 67*: 7-((1R,5S,6r)-6-(1-ethyl-3-(5-fluoropyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide, and 7-((1R,5S,6r)-6-(1-ethyl-3-(5-fluoropyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide The title compound was synthesized in the same manner as for compounds 53 and 54 using 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine. [ka]

[0397] The mixture of isomers was purified by reverse phase chromatography (30-60% acetonitrile / 0.05% ammonia hydroxide in water) to give the title compound 66* (2nd peak, 39.1 mg, 0.0862 mmol, 31% yield) and the title compound 67* (1st peak, 43.58 mg, 0.097 mmol, 35% yield). LCMS (ESI) [M+H] + = 445.2. The relative stereochemistry of both compounds has been arbitrarily assigned.

[0398] Compound 66*: 1 H NMR(400MHz,CD3OD)δ 8.76(s,1H),8.35(s,1H),7.93(d,J=9.6Hz,1H),6.39(s,1H),4.27(q,J=7.2Hz,2H),3.91 (s,4H),2.68-2.48(m,4H),2.34-2.29(m,2H),1.96-1.70(m,10H),1.45(t,J=7.2Hz,3H).

[0399] Compound 67*: 1H NMR(400MHz,CD3OD)δ 8.76(s,1H),8.35(s,1H),7.93(d,J=9.6Hz,1H),6.33(s,1H),4.30(q,J=7.2Hz,2H),3.91(s,4H),3.06-3.0 2(m,1H),2.66-2.40(m,6H),1.93-1.91(m,4H),1.79-1.73(m,3H),1.62-1.60(m,2H),1.47(t,J=7.2Hz,3H).

[0400] Example EE - Compounds 68* and 69*: 6-((1R,3s,5S,6r)-6-(1-ethyl-3-(5-fluoropyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide, and 6-((1R,3r,5S,6r)-6-(1-ethyl-3-(5-fluoropyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide The title compound was synthesized in the same manner as compounds 53 and 54 using 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine and 2-thia-6-azaspiro[3.4]octane 2,2-dioxide. [ka]

[0401] The mixture of isomers was purified by reverse phase chromatography (30-60% acetonitrile / 0.05% aqueous ammonia hydroxide) to give the title compound 68* (second peak, 49.4 mg, 0.112 mmol, 40.1% yield) and the title compound 69* (first peak, 40.9 mg, 0.090 mmol, 32.2% yield). LCMS (ESI) [M+H] + = 431.1. The relative stereochemistry of both compounds has been arbitrarily assigned.

[0402] Compound 68*: 11H NMR (400 MHz, CD3OD) δ 8.76 (s, 1H), 8.35 (d, J = 2.4 Hz, 1H), 7.95 - 7.92 (m, 1H), 6.39 (s, 1H), 4.27 (q, J = 7.2 Hz, 2H), 4.17 - 4.07 (m, 4H), 2.86 (s, 2H), 2.71 (t, J = 7.2 Hz, 2H), 2.62 - 2.52 (m, 1H), 2.30 - 2.20 (m, 4H), 1.92 - 1.86 (m, 2H), 1.80 - 1.73 (m, 3H), 1.46 (t, J = 7.2 Hz, 3H).

[0403] Compound 69*: 1 1H NMR (400 MHz, CD3OD) δ 8.76 (s, 1H), 8.35 (d, J = 2.4 Hz, 1H), 7.97 - 7.88 (m, 1H), 6.33 (s, 1H), 4.27 (q, J = 7.2 Hz, 2H), 4.16 - 4.04 (m, 4H), 2.96 - 2.93 (m, 1H), 2.83 (s, 2H), 2.71 (t, J = 7.2 Hz, 2H), 2.25 - 2.13 (m, 5H), 1.98 - 1.95 (m, 2H), 1.71 (brs, 2H), 1.47 (t, J = 7.2 Hz, 3H).

[0404] Example FF - Compounds 70* and 71*: 7-((1R,3R,5S,6r)-6-(1-((S)-1,1-difluoropropan-2-yl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide; 7-((1R,3S,5S,6r)-6-(1-((R)-1,1-difluoropropan-2-yl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide ,2-dioxide;7-((1R,3S,5S,6r)-6-(1-((S)-1,1-difluoropropan-2-yl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide, and 7-((1R,3R,5S,6r)-6-(1-((R)-1,1-difluoropropan-2-yl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide The title compound was synthesized in the same manner as for Compound 62 using 1,1-difluoropropan-2-yl trifluoromethanesulfonate. [ka] [ka]

[0405] The mixture of isomers was purified by reverse phase chromatography (water (0.05% NH3H2O ​​+ 10 nM NH4HCO3)-ACN) to give compound 70* (as a mixture of isomers) (82 mg, 0.1754 mmol, 36% yield, HPLC peak 1) and compound 71* (as a mixture of isomers) (63 mg, 0.1348 mmol, 27.7% yield, HPLC peak 2). LCMS (ESI), [M+H]+ = 468.2.

[0406] Compound 70*: 1 H NMR(400MHz,CDCl3)δ 6.15-5.86(m,2H),4.70-4.61(m,1H),3.86(s,4H),2.56-2.32(m,4H),2.26 -2.21(m,2H),1.93-1.69(m,7H),1.66-1.64(m,3H),1.53(t,J=3.2Hz,3H).

[0407] Compound 71*: 1 H NMR(400MHz,CDCl3)δ 6.15-5.85(m,2H),4.70-4.61(m,1H),3.85(s,4H),2.90-2.87(m,1H),2.68-2.44( m,3H),2.30-2.13(m,3H),1.90(brs,4H),1.77-1.68(m,5H),1.56(t,J=3.2Hz,3H).

[0408] Example GG: 6-((1R,3s,5S,6r)-6-(1-ethyl-3-(pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 72) and 6-((1R,3r,5S,6r)-6-(1-ethyl-3-(pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 73) The title compound was synthesized in the same manner as for compounds 53 and 54 using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine. [ka]

[0409] The mixture of isomers was purified by reverse phase chromatography (30-60% acetonitrile / 0.05% ammonia hydroxide in water) to give the title compound 72 (compound 72, 30.5 mg, 0.0732 mmol, 28% yield) and the title compound 73 (compound 73, 33.96 mg, 0.0815 mmol, 31.1% yield). LCMS (ESI) [M+H] + =413.2. Relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0410] Compound 72: 1 H NMR(400MHz,CDCl3)δ 8.59(d,J=4.8Hz,1H),7.89(d,J=8.0Hz,1H),7.68(t,J=2.0Hz,1H),7.18-7.13(m,1H),6.38(s,1H),4.31-4.18(m,2H),4.08(s,4H),2.78( brs,2H),2.71-2.62(m,2H),2.45-2.41(m,1H),2.18-2.14(m,4H),1.88-1.83(m,2H),1.76-1.71(m,2H),1.57(brs,1H),1.53-1.46(m,3H).

[0411] Compound 73: 1 H NMR(400MHz,CDCl3)8.59(d,J=4.8Hz,1H),7.89(d,J=8.0Hz,1H),7.68(t,J=2.0 Hz,1H),7.18-7.13(m,1H),6.38(s,1H),4.25(q,J=7.2Hz,2H),4.09-4.01(m,4H ),2.97-2.87(m,1H),2.80(s,2H),2.69(t,J=7.2Hz,2H),2.19-2.12(m,4H),2.0 5(t,J=3.2Hz,1H),1.92-1.91(m,2H),1.67-1.64(m,2H),1.49(t,J=7.2Hz,3H).

[0412] Example HH: 7-((1R,3r,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 74), and 7-((1R,3s,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 79) [ka] Step 1: 5-((1R,5S)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazole [ka]

[0413] The general procedure of J. Org. Chem. 2011, 76, 1177 was followed to give the title compound 5-((1R,5S)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazole (1.3 g, 84.5% yield) after flash column chromatography (IprOAc / heptane). LCMS (ESI) [M+H] + =590.3.

[0414] Step 2: (1R,5S)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-ol [ka]

[0415] To a mixture of 5-((1R,5S)-3-((tert-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazole (1.3 g, 2.22 mmol) in THF (22 mL) was added Et3N.3HF (7.8 mL 44.4 mmol) slowly and the reaction was then heated to 70° C. for 14 h. The reaction mixture was cooled to room temperature and quenched with saturated NaHCO3 (200 mL) and then extracted with IprOAc (100 mL×2). The combined organic layers were washed with brine (100 mL), dried over anhydrous MgSO, filtered, concentrated, and purified by Siliflash chromatography (0-100% heptane to IprOAc gradient) to give (750 mg, 96% yield). LCMS (ESI) [M+H] + =352.2.

[0416] Step 3: (1R,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-one [ka]

[0417] To a stirred solution of (1R,5S)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-ol (750 mg, 2.13 mmol) in DCM (21 mL) was added Dess-Martin reagent (1.36 g, 3.2 mmol). The reaction mixture was stirred at room temperature for 2 h. Saturated aqueous NaHCO3 (100 mL) and sodium sulfite (100 mL) were slowly added to the reaction mixture and the resulting reaction mixture was stirred at room temperature for 0.5 h. The organic layer was separated and the aqueous layer was extracted with DCM (100 mL x 2). The combined organic layers were washed with brine over anhydrous Mg2SO4, filtered, concentrated in vacuo, and purified by silica flash chromatography (IprOAc / heptane) to give the product (710 mg, 2 mmol). LCMS(ESI)[M+H] + =350.1.

[0418] Step 4: 7-((1R,3r,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 74) and 7-((1R,3s,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 74) Bi[3.5]nonane 2,2-dioxide (compound 79): To a mixture of (1R,5S,6r)-6-(1-isopropyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-one and 2-λ-6-thia-7-azaspiro[3.5]nonane-2,2-dione hydrochloride (133 mg, 0.61 mmol) in methanol (4.1 mL) was added acetic acid (203 μL, 3.54 mmol) and sodium cyanoborohydride (51 mg, 0.81 mmol). The reaction mixture was stirred at 50° C. for 2 h, cooled, then diluted with DCM, washed with saturated aqueous NaHCO3, dried over anhydrous Mg2SO4, filtered, and concentrated in vacuo. The mixture of cis and trans isomers was separated by reversed phase HPLC (interchim HPLC, Solvent A: 0.1% formic acid in water, Solvent B: acetonitrile, Column: XSelect CSH Prep C18, 50×30 mm (5 μm), Method: 5-50% B over 10 min at 60 mL / min) and chiral SFC (PIC 200 Chiral, Solvent B: 0.1% ammonium hydroxide in methanol, Chiralcel OX Column 250×30 mm (5 μm), 40° C., isocratic 30% B gradient over 4 min at 70 mL / min) to give the title compounds (trans: 26 mg, 16% yield and cis: 30.6 mg, 19% yield). LCMS (ESI) [M+H] + =509.2.Relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0419] Compound 74: 1H NMR DMSO-d6)δ 8.23-8.16(m,1H),8.16-8.11(m,1H),7.78-7.71(m,1H),7.71-7.63(m,1H),4.83(p,J=6.6Hz,1H),3.92(s,4H),2.84(p,J=7.4Hz,1H),2.5 4(s,1H),2.41-2.22(m,4H),2.22-2.09(m,2H),1.93-1.86(m,2H),1.80-1.73(m,4H),1.69(dd,J=13.6,6.9Hz,2H),1.47(d,J=6.5Hz,6H).

[0420] Compound 79:(400MHz,DMSO-d6)δ 8.23-8.16(m,1H),8.16-8.11(m,1H),7.78-7.72(m,1H),7.72-7.63(m ,1H),4.87(p,J=6.6Hz,1H),3.92(s,4H),3.28-3.17(m,1H),2.48-2.1 9(m,4H),2.12(dd,J=12.4,7.0Hz,2H),2.05(t,J=3.1Hz,1H),1.96-1.87(m,2H),1.81-1.74(m,4H),1.75-1.65(m,2H),1.45(d,J=6.5Hz,6H).

[0421] Example II: 6-((1R,3s,5S,6r)-6-(1-(tert-butyl)-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 75), and 6-((1R,3s,5S,6r)-6-(1-(tert-butyl)-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 76) The title compound was synthesized analogously to compound 51 using tert-butylhydrazine hydrochloride. [ka]

[0422] The mixture of isomers was purified by reverse phase chromatography (water (0.05% NH3H2O ​​+ 10 nM NH4HCO3)-ACN) to give the title compound 75 (60.2 mg, 0.13 mmol, 37% yield, first peak) and the title compound 76 (16 mg, 0.04 mmol, 11% yield, second peak). LCMS (ESI) [M+H] + =509.2.Relative stereochemistry is 1 Assigned based on 1 H NMR analysis.

[0423] Compound 75: 1 H NMR(400MHz,CDCl3)δ 8.29(s,1H),8.21(d,J=8.0Hz,1H),7.59(d,J=8.4Hz,1H),7.42(d,J=8.0Hz,1H),4.08(s,4H),2.81( s,2H),2.71(t,J=7.2Hz,2H),2.46-2.38(m,1H),2.23-2.15(m,6H),1.90-1.87(m,3H),1.57(s.9H).

[0424] Compound 76: 1 H NMR(400MHz,CDCl3)δ 8.29(s,1H),8.21(d,J=8.0Hz,1H),7.59(d,J=8.4Hz,1H),7.42(d,J=8.0Hz,1H),4.05(s,4H),2.83- 2.81(m,1H),2.76(s,2H),2.71(t,J=7.2Hz,2H),2.58-2.56(m,1H),2.17-2.02(m,8H),1.57(s.9H).

[0425] Example JJ - Compounds 77* and 78*: 6-((1R,3s,5S,6r)-6-(1-(tert-butyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide, and 6-((1R,3r,5S,6r)-6-(1-(tert-butyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide The title compound was synthesized in the same manner as for Compound 51 using tert-butylhydrazine hydrochloride and 2,2,2-trifluoroacetimidamide. [ka]

[0426] The mixture of isomers was purified by reverse phase chromatography (water (0.05% NH3H2O ​​+ 10 mM NH4HCO3)-ACN, 50%-80%) to give title compound 77* (23.1 mg, 29.8% yield, 1st peak in HPLC / 2nd peak in SFC) and title compound 78* (32.72 mg, 42.6% yield, 2nd peak in HPLC / 1st peak in SFC). LCMS (ESI) [M+H] + = 433.2. The relative stereochemistry of both compounds has been arbitrarily assigned.

[0427] Compound 77*: 1 H NMR(400MHz,CD3OD)δ 4.15-4.07(m,4H),2.86(s,2H),2.72(t,J=7.2Hz,2H),2.63-2.57(m,1H ),2.27-2.18(m,4H),2.07(s,3H),1.88(t,J=10.4Hz,2H),1.72(s,9H).

[0428] Compound 78*: 1 H NMR(400MHz,CD3OD)δ 4.13-4.06(m,4H),2.92-2.89(m,1H),2.86(t,J=3.2Hz,1H),2.83(s,2H),2 .72(t,J=7.2Hz,2H),2.17(t,J=7.2Hz,2H),2.12(d,J=3.6Hz,4H),2.01(br s,2H),1.73(s,9H).

[0429] Example KK-Compounds 80* and 81*: (S)-7-((1R,3s,5S,6S)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide and (R)-7-((1R,3s,5S,6S)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide [ka] The title compound was synthesized in a similar manner to compounds 3 and 4 using 2-thia-7-azaspiro[4.5]decane 2,2-dioxide and 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)pyridine. The relative stereochemistry of both compounds was arbitrarily assigned.

[0430] This mixture of isomers was purified by chiral SFC (Daicel Chiralpak AD (250mm*50mm, 10μm); 0.1% NH3H2O; EtOH; 30%; 60mL / min) to give the title compound 80* (first peak, 36.2mg, 0.0686mmol, 45% yield) and the title compound 81* (second peak of SFC, 40.8mg, 0.0757mmol, 55% yield). LCMS (ESI) [M+H] + =523.1.

[0431] Compound 80*: 1H NMR(400MHz,CD3OD)δ 8.16(d,J=8.0Hz,1H),7.97(t,J=8.0Hz,1H),7.62(d,J=7.6Hz,1H),6.47(s,1H),4.84-4.77(m,1H),3.20(dd,J=8.4,7.2Hz,2H),2.9 8-2.68(m,4H),2.27-2.19(m,2H),2.16-1.91(m,5H),1.88-1.82(m,2H),1.76-1.65(m,5H),1.55(d,J=6.8Hz,6H),1.51-1.38(m,2H).

[0432] Compound 81*: 1 H NMR(400MHz,CD3OD)δ 8.15(d,J=8.0Hz,1H),7.97(t,J=8.0Hz,1H),7.62(d,J=7.6Hz,1H),6.46(s,1H),4.84-4.80(m,1H),3.24-3.17(m,2H),2.98-2. 66(m,4H),2.28-2.19(m,2H),2.16-1.91(m,5H),1.89-1.81(m,2H),1.77-1.64(m,5H),1.55(d,J=6.8Hz,6H),1.52-1.36(m,2H).

[0433] Example LL - Compounds 82* and 83*: (S)-7-((1R,3r,5S,6S)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide and (R)-7-((1R,3r,5S,6S)-6-(1-isopropyl-3-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide [ka] The title compound was synthesized in the same manner as compounds 3 and 4 using 2-thia-7-azaspiro[4.5]decane 2,2-dioxide and 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)pyridine.

[0434] This mixture of isomers was separated using chiral SFC (Daicel Chiralpak AD (250mm*50mm, 10μm); 0.1% NH3 in H2O; EtOH; 30%; 60mL / min) to give the title compound 82* (first peak, 43.5mg, 0.08mmol, 32.1% yield) and the title compound 83* (second peak, 36.7mg, 0.0688mmol, 27.7% yield). LCMS (ESI) [M+H] + =523.2. The relative stereochemistry of both compounds has been arbitrarily assigned.

[0435] Compound 82*: 1 H NMR(400MHz,CD3OD)δ 8.15(d,J=8.0Hz,1H),7.97(t,J=8.0Hz,1H),7.62(d,J=7.6Hz,1H),6.50(s,1H),4.81-4.75(m,1H),3.18(t,J=7.2Hz,2H),2.95-2.92(m,1H) ),2.71-2.62(m,2H),2.57-2.45(m,1H),2.26-1.97(m,6H),1.87-1.77(m,2H),1.72-1.56(m,6H),1.53(d,J=6.8Hz,6H),1.51-1.36(m,2H).

[0436] Compound 83*: 1H NMR(400MHz,CD3OD)δ 8.15(d,J=8.0Hz,1H),7.97(t,J=8.0Hz,1H),7.62(d,J=7.6Hz,1H),6.50(s,1H),4.81-4.75(m,1H),3.18(t,J=7.6Hz,2H),2.95-2.92(m,1H) ),2.75-2.70(m,2H),2.57-2.45(m,1H),2.31-2.00(m,6H),1.89-1.78(m,2H),1.75-1.59(m,6H),1.53(d,J=6.8Hz,6H),1.51-1.38(m,2H).

[0437] Example MM - Compounds 86* and 87*: (S)-7-((1R,3s,5S,6S)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide and (R)-7-((1R,3s,5S,6S)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide The title compound was synthesized in the same manner as compounds 62 and 63 using 2-thia-7-azaspiro[4.5]decane 2,2-dioxide. [ka]

[0438] The mixture of two cis isomers was purified by chiral SFC (Daicel Chiralpak AD (250mm*30mm, 10μm); 0.1% NH3 in H2O; EtOH; 25%; 60mL / min) to give the title compound 86* (first peak in SFC, 41.4mg, 34.5% yield) and the title compound 87* (second peak in SFC, 44.8mg, 37.3% yield). LCMS (ESI) [M+H] + = 468.2. The relative stereochemistry of both compounds has been arbitrarily assigned.

[0439] Compound 86*: 1 H NMR(400MHz,CD3OD)δ 6.37-6.08(m,2H),4.68-4.64(m,2H),3.20-3.14(m,2H),2.93(d,J=13.6Hz,1H),2.71(s,2H),2.54-2.46(m,1H), 2.26-2.21(m,2H),2.19-2.11(m,2H),2.10-1.97(m,2H),1.83-1.76(m,3H),1.75-1.72(m,3H),1.64-1.44(m,4H).

[0440] Compound 87*: 1 H NMR(400MHz,CD3OD)δ 6.37-6.08(m,2H),4.68-4.64(m,2H),3.20-3.16(m,2H),2.93(d,J=13.6Hz,1H),2.72(s,2H),2.54-2.46(m,1H), 2.26-2.21(m,2H),2.19-2.11(m,2H),2.10-1.99(m,2H),1.83-1.76(m,3H),1.75-1.69(m,5H),1.58-1.44(m,2H).

[0441] Example NN - Compounds 88* and 89*: (S)-7-((1R,3r,5S,6S)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide, and (R)-7-((1R,3r,5S,6R)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide. [ka] The title compound was synthesized in a similar manner to compounds 62 and 63 using 2-thia-7-azaspiro[4.5]decane 2,2-dioxide. The mixture of trans isomers was separated using chiral SFC (Daicel Chiralpak AD (250 mm*30 mm, 10 μm); 0.1% NH3 in H2O; ethanol; 25%; 60 mL / min) to give the title compound 88* (first peak in SFC, 54.7 mg, 45.1% yield) and the title compound 89* (second peak in SFC, 50.9 mg, 42% yield). LCMS (ESI) [M+H] + = 468.2. The relative stereochemistry of both compounds has been arbitrarily assigned.

[0442] Compound 88*: 1 H NMR(400MHz,CD3OD)δ 6.39-6.10(m,2H),4.70-4.65(m,2H),3.21-3.17(m,2H),2.93-2.87(m,2H),2.85-2.78(m,2H),2.23-2.09(m,4H),2 .07-2.01(m,2H),1.98(t,J=3.2Hz,1H),1.90-1.84(m,2H),1.73-1.64(m,5H),1.56-1.50(m,1H),1.47-1.34(m,1H).

[0443] Compound 89*: 1 H NMR(400MHz,CD3OD)δ 6.39-6.10(m,2H),4.70-4.65(m,2H),3.21-3.17(m,2H),2.93-2.78(m,4H),2.23-2.16(m,2H),2.13-2.0 7(m,2H),2.05-1.97(m,3H),1.90-1.84(m,2H),1.71-1.64(m,4H),1.58-1.47(m,2H),1.41-1.29(m,1H).

[0444] Example OO - Compounds 90* and 91*: 6-((1R,3s,5S,6r)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide, and 6-((1R,3r,5S,6r)-6-(1-(2,2-difluoroethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide. The title compound was synthesized in the same manner as compounds 62 and 63 using 2-thia-6-azaspiro[3.4]octane 2,2-dioxide. [ka]

[0445] The mixture of diastereoisomers was purified by reverse phase chromatography (water (0.05% NH3H2O ​​+ 10 mM NH4HCO3); ACN) to give the title compound 90* (2nd peak in SFC, 48.0 mg, 45.1% yield) and the title compound 91* (1st peak in SFC, 42.4 mg, 27.3% yield). LCMS (ESI) [M+H] + =440.2.

[0446] Compound 90*: 1 H NMR(400MHz,CD3OD)δ 6.38-6.08(m,2H),4.69-4.64(m,2H),4.15-4.08(m,4H),2.85(s,2H),2.72-2.66( m,2H),2.58-2.50(m,1H),2.28-2.18(m,4H),1.86-1.81(m,3H),1.75-1.74(m,2H).

[0447] Compound 91*: 1H NMR(400MHz,CD3OD)δ 6.38-6.09(m,2H),4.67-4.62(m,2H),4.11-4.05(m,4H),2.97-2.90(m,1H),2.80(s,2H),2.7 0(t,J=7.2Hz,2H),2.31(t,J=3.2Hz,1H),2.17-2.11(m,4H),2.01-1.97(m,2H),1.69(s,2H).

[0448] Example PP - Compounds 92* and 93*: (R)-7-((1R,3s,5S,6R)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide, and (S)-7-((1R,3s,5S,6S)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide. The title compound was synthesized in the same manner as for compounds 43 and 44 using 2-thia-7-azaspiro[4.5]decane 2,2-dioxide. [ka]

[0449] The mixture of diastereoisomers was separated using chiral SFC (Daicel Chiralpak AD (250 mm x 30 mm, 10 μm); HO, 0.1% NH in EtOH, 20%; 60 mL / min) to give the title compound 92* (46.1 mg, 38% yield, first peak on SFC) and title compound 93* (56.2 mg, 46% yield, second peak on SFC). LCMS (ESI) [M+H]+ = 446.1. The relative stereochemistry of both compounds has been arbitrarily assigned.

[0450] Compound 92*: 1H NMR(400MHz,CD3OD)δ 6.15(s,1H),4.80-4.75(m,1H),3.19-3.14(m,2H),2.93(d,J=13.6Hz,1H),2.71(brs,2H),2.54-2.46(m,1H),2.25-2.20(m ,2H),2.14-1.98(m,4H),1.83-1.77(m,2H),1.72-1.68(m,4H),1.65-1.62(m,1H),1.58-1.51(m,1H),1.47(d,J=6.8Hz,8H).

[0451] Compound 93*: 1 H NMR(400MHz,CD3OD)δ 6.15(s,1H),4.82-4.75(m,1H),3.19-3.15(m,2H),2.93(d,J=13.6Hz,1H),2.71(brs,2H),2.52-2.46(m,1H),2.25-2.20(m ,2H),2.18-1.99(m,4H),1.83-1.79(m,2H),1.72-1.68(m,4H),1.65-1.64(m,1H),1.58-1.52(m,1H),1.47(d,J=6.8Hz,8H).

[0452] Example QQ - Compounds 94* and 95*: (R)-7-((1R,3r,5S,6R)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide and (S)-7-((1R,3r,5S,6S)-6-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[4.5]decane 2,2-dioxide [ka] The title compound was synthesized in a similar manner to compounds 43 and 44 using 2-thia-7-azaspiro[4.5]decane 2,2-dioxide. The mixture of trans isomers (100 mg, 0.22 mmol) was separated using chiral SFC (Daicel Chiralpak AD (250 mm x 30 mm, 10 μm); 0.1% NH3 in H2O; EtOH; 15%; 60 mL / min) to give the title compound 94* (46.3 mg, 45.8% yield, first peak on SFC) and the title compound 95* (40.4 mg, 39.6% yield, second peak on SFC). LCMS (ESI) [M+H]+ = 446.1. The relative stereochemistry of both compounds was arbitrarily assigned.

[0453] Compound 94*: 1 H NMR(400MHz,CD3OD)δ 6.11(s,1H),4.84-4.79(m,1H),3.22-3.18(m,2H),2.94-2.86(m,4H),2.24-2.16(m,2H),2.13-1.99(m, 4H),1.92(t,J=3.2Hz,1H),1.88-1.83(m,2H),1.71-1.52(m,6H),1.49(d,J=6.8Hz,6H),1.44(brs,1H).

[0454] Compound 95*: 1 H NMR(400MHz,CD3OD)δ 6.11(s,1H),4.83-4.80(m,1H),3.22-3.18(m,2H),2.94-2.86(m,4H),2.24-2.18(m,2H),2.16-1.99(m, 4H),1.92(t,J=3.2Hz,1H),1.88-1.83(m,2H),1.70-1.52(m,6H),1.49(d,J=6.8Hz,6H),1.44(brs,1H).

[0455] Example RR: 7-((1R,3s,5S,6r)-6-(1-(2,2-difluoroethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 96), and 7-((1R,3r,5S,6r)-6-(1-(2,2-difluoroethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-7-azaspiro[3.5]nonane 2,2-dioxide (compound 97) The title compound was synthesized in the same manner as compounds 62 and 63 using 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide. [ka]

[0456] The mixture of diastereoisomers was purified by reverse phase chromatography (water (0.05% NH3H2O ​​+ 10 mM NH4HCO3)-ACN, 50-80%) to give the title compound-96 (second peak, 11.2 mg, 6.8% yield) and title compound-97 (first peak, 19.2 mg, 11.7% yield). LCMS (ESI) [M+H] + = 454.3. The relative stereochemistry of both compounds has been arbitrarily assigned.

[0457] Compound 96*: 1 H NMR(400MHz,CDCl3)δ 6.28-5.98(m,2H),4.47-4.40(m,2H),3.85(s,4H),2.35-2.16(m,7H),1.93-1.90(m,4H),1.81-1.74(m,3H),1.68-1.65(m,2H).

[0458] Compound 97*: 1 H NMR(400MHz,CDCl3)δ 6.28-5.98(m,2H),4.47-4.40(m,2H),3.84(s,4H),2.93-2.85(m,1H),2.63 -2.24(m,7H),1.90(t,J=5.2Hz,4H),1.80-1.79(m,1H),1.57-1.51(m,3H).

[0459] Example SS - Compounds 98* and 99*: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide, and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide [ka] The title compound was synthesized similarly to compounds 11 and 12 using 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)pyridine. The mixture of diastereoisomers was purified by reverse phase chromatography (Xtimate C18, 150×25 mm×5 μm; water (NH3H2O+NH4HCO3)-ACN, 30-60%) to give the title compound. LCMS (ESI) [M+H] + =481.2.

[0460] Compound 98*: 1 H NMR(400MHz,DMSO-d6)δ ppm 9.21(s,1H),8.84(s,1H),8.36(s,1H),6.63(s,1H),5.75(s,1H),4.74(quin,J=6.5Hz,1H),4.30(s,4H),3.28(s,4H),2.64-2.7 2(m,1H),2.07(s,1H),2.00(dd,J=12.3,6.9Hz,2H),1.74-1.79(m,1H),1.62(brs,2H),1.49-1.59(m,2H),1.44(d,J=6.6Hz,6H),

[0461] Compound 99*: 1H NMR(400MHz,DMSO-d6)δ ppm 9.22(d,J=1.6Hz,1H),8.85(s,1H),8.37(s,1H),6.60(s,1H),5.76(s,1H),4.66(quin,J=6.6Hz,1H),4.30(s,4H),3.21(s,4H),2.84(b rt,J=6.9Hz,1H),2.56(t,J=3.2Hz,1H),2.08(s,1H),1.82-1.93(m,2H),1.72(d,J=13.8Hz,2H),1.64(brs,2H),1.49(d,J=6.6Hz,6H).

[0462] Example TT: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 102), and 6-((1R,3r,5S,6r)-6-(1-isopropyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 103) The title compound was synthesized in a similar manner to compounds 45 and 46 using (2-(trifluoromethyl)pyrimidin-5-yl)boronic acid and 2-thia-6-azaspiro[3.4]octane 2,2-dioxide. [ka]

[0463] The mixture of diastereoisomers was purified by reverse phase chromatography (water (0.05% NH3H2O ​​+ 10 mM NH4HCO3)-ACN, 60-90%) to give title compound 102 (45.7 mg, 0.09 mmol, 40% yield, first peak in basic HPLC) and title compound 103 (58.1 mg, 0.12 mmol, 51% yield, second peak in basic HPLC). LCMS (ESI) [M+H] +=496.3. (Relative stereochemistry is 1 (Assigned based on H NMR analysis)

[0464] Compound 102: 1 H NMR(400MHz,CD3OD)δ 9.27(s,2H),6.51(s,1H),4.84-4.77(m,1H),4.16-4.09(m,4H),2.86(s,2H),2.72(t,J=7.2Hz,2H),2.60-2. 53(m,1H),2.29-2.19(m,4H),1.89-1.83(m,2H),1.79-1.78(m,1H),1.76-1.74(m,2H),1.53(d,J=6.8Hz,6H).

[0465] Compound 103: 1 H NMR(400MHz,CD3OD)δ 9.27(s,2H),6.46(s,1H),4.83-4.76(m,1H),4.13-4.07(m,4H),2.98-2.96(m,1H),2.84(s,2H),2. 72(t,J=7.2Hz,2H),2.20-2.15(m,5H),1.97-1.94(m,2H),1.74-1.71(m,2H),1.55(d,J=6.8Hz,6H).

[0466] Example UU - Compounds 104* and 105*: 6-((1R,3S,5S,6r)-6-(3-((1s,4S)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide, and 6-((1R,3S,5S,6r)-6-(3-((1r,4R)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka] Step 1: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0467] To a mixture of potassium carbonate (183 mg, 1.33 mmol) and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (31 mg, 0.040 mmol) in 1,4-dioxane (20 mL) and water (3 mL) was added 6-((1R,3s,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (210 mg, 0.44 mmol) and 4,4,5,5-tetramethyl-2-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane (235 mg, 0.88 mmol). The reaction mixture was stirred at 75° C. under N2 for 16 h. The reaction mixture was then filtered and concentrated in vacuo. The crude residue was purified by silica flash chromatography (0-50% ethyl acetate in petroleum ether) to give the title compound (220 mg, 0.36 mmol, 82% yield) as a white solid. LCMS (ESI) [M+H]+=488.3.

[0468] Step 2: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0469] To a solution of 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (200 mg, 0.41 mmol) in ethanol (20 mL) was added 10% wt. Pd / C (175 mg, 0.16 mmol) at 25° C. The reaction mixture was stirred under H2 (15 psi) at 25° C. for 2 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give the title compound (190 mg, 0.388 mmol, 94.6% yield) as a yellow oil. LCMS (ESI) [M+H] + =490.3.

[0470] Step 3: 4-(5-((1R,3s,5S,6r)-3-(2,2-dioxo-2-thia-6-azaspiro[3.4]octan-6-yl)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazol-3-yl)cyclohexanone [ka]

[0471] 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (190 mg, 0.388 mmol) was added to aqueous HCl (3.0 mL, 3 mmol, 1 M). The reaction mixture was stirred at 25 °C for 1 h. The pH of the reaction mixture was adjusted to 8 at 0 °C using saturated aqueous NaHCO3 solution (40 mL). The reaction mixture was extracted with ethyl acetate (40 mL x 3) and the combined layers were washed with brine (10 mL x 3) and dried over anhydrous Na2SO4. The mixture was filtered, concentrated in vacuo, and the residue was purified by silica flash chromatography (0-10% methanol in dichloromethane) to give the title compound (165 mg, 0.370 mmol, 95% yield) as a colorless oil. LCMS (ESI) [M+H] + =446.3.

[0472] Step 4: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0473] Cesium fluoride (112.0 mg, 0.74 mmol) was added to a solution of 4-(5-((1R,3s,5S,6r)-3-(2,2-dioxo-2-thia-6-azaspiro[3.4]octan-6-yl)bicyclo[3.1.0]hexan-6-yl)-1-isopropyl-1H-pyrazol-3-yl)cyclohexanone (60.0 mg, 0.13 mmol) in tetrahydrofuran (4 mL) at 0° C. Trifluoromethyltrimethylsilane (115 mg, 0.81 mmol) was added slowly and the reaction mixture was stirred at 0° C. for 20 min. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (50 mL×2). The combined organic layers were dried over anhydrous Na2SO, filtered, and concentrated in vacuo. The residue was purified by silica flash chromatography (0-2% dichloromethane in methanol) to give the title compound (50 mg, 63.2% yield) as a white solid. LCMS (ESI) [M+H] + =588.3

[0474] Step 5: 6-((1R,3S,5S,6r)-6-(3-((1s,4S)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide and 6-((1R,3S,5S,6r)-6-(3-((1r,4R)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0475] Triethylamine trihydrofluoride (1 mL, 6.13 mmol) was added to a solution of 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (50.0 mg, 0.08 mmol) in tetrahydrofuran (3 mL). The reaction mixture was stirred at 20° C. for 1 h. The reaction mixture was quenched at 0° C. by the addition of saturated aqueous NaHCO3 solution (10 mL) and extracted with ethyl acetate (50 mL×2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica flash chromatography (0-5% dichloromethane in methanol) to give the title compound (35 mg, 79% yield) as a colorless oil. SFC showed two peaks LCMS (ESI) [M+H]+=516.3.

[0476] The mixture of diastereoisomers was separated using chiral SFC (Daicel Chiralcel AD (250 mm x 30 mm, 10 μm); 0.1% NH in H2O; EtOH; 30%; 60 mL / min) to give title compound 104* (22 mg, 62% yield, first peak in SFC) and title compound 105* (6.4 mg, 16.8% yield, second peak in SFC). LCMS (ESI) [M+H] + = 516.3. The relative stereochemistry of both compounds has been arbitrarily assigned.

[0477] Compound 104*: 1 H NMR(400MHz,CD3OD)δ 5.71(s,1H),4.68-4.63(m,1H),4.16-4.09(m,4H),2.89-2.87(m,3H),2.74-2.71(m,2H),2.58 -2.52(m,1H),2.27-2.19(m,4H),2.02-1.81(m,8H),1.68-1.56(m,5H),1.43(d,J=6.8Hz,6H).

[0478] Compound 105*:1 H NMR(400MHz,CD3OD)δ 5.69(s,1H),4.69-4.62(m,1H),4.15-4.08(m,4H),2.86(s,2H),2.73-2.71(m,2H) ,2.58-2.52(m,2H),2.25-2.18(m,4H),1.89-1.64(m,13H),1.43(d,J=6.8Hz,6H).

[0479] Example VV: 6-((1R,3S,5S,6r)-6-(1-isopropyl-3-((1s,4S)-4-(trifluoromethyl)cyclohexyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 106), and 6-((1R,3S,5S,6r)-6-(1-isopropyl-3-((1r,4R)-4-(trifluoromethyl)cyclohexyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 107), and [ka] Step 1: 6-((1R,3s,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide and 6-((1R,3r,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0480] To a mixture of 2-thia-6-azaspiro[3.4]octane 2,2-dioxide (586 mg, 3.63 mmol) and sodium cyanoborohydride (571.0 mg, 9.09 mmol) in methanol (10 mL) was added (1R,5S)-6-(5-iodo-2-isopropyl-pyrazol-3-yl)bicyclo[3.1.0]hexan-3-one (1.0 g, 3.03 mmol) and acetic acid (909 mg, 15.14 mmol). The reaction mixture was stirred at 60° C. for 3 h. The reaction mixture was quenched with water (10 mL) and the pH was adjusted to 8 with aqueous NaOH (1 M). The reaction mixture was extracted with ethyl acetate (100 mL×3). The combined organic layers were washed with brine (25 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica flash chromatography (0-60% ethyl acetate in petroleum ether) to give 6-((1R,3s,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (more polar by TLC, 400 mg, 0.816 mmol, 26.9% yield) and 6-((1R,3r,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (less polar by TLC, 1000 mg, 2.0 mmol, 66% yield). Both isomers were obtained as white solids. LCMS(ESI)[M+H] + =476.2.

[0481] Step 2: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0482] To a mixture of potassium carbonate (174 mg, 1.26 mmol) and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (60 mg, 0.08 mmol) in 1,4-dioxane (10 mL) and water (2 mL) was added 6-((1R,3s,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (200.0 mg, 0.420 mmol) and 4,4,5,5-tetramethyl-2-[4-(trifluoromethyl)-1-cyclohexan-1-yl]-1,3,2-dioxaborolane (232 mg, 0.84 mmol). The reaction mixture was stirred under N2 at 75°C for 3 h. The reaction mixture was concentrated in vacuo and the residue was purified by silica flash chromatography (0-100% ethyl acetate in petroleum ether) to give the title compound (200 mg, 0.366 mmol, 86.9% yield) as a yellow oil. LCMS (ESI) [M+H] + =488.3.

[0483] Step 3: 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)cyclohexyl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0484] To a solution of 6-((1R,3s,5S,6r)-6-(1-isopropyl-3-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (200 mg, 0.40 mmol) in ethanol (10 mL) was added 10% wt. Pd / C (171 mg, 0.16 mmol) under H2 (15 psi) for 16 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give the title compound (140 mg, 0.280 mmol, 70% yield) as a white solid. LCMS (ESI) [M+H] + =490.3.

[0485] The mixture of diastereoisomers was separated using chiral SFC (Daicel Chiralpak AD (250mm*30mm, 10μm); 0.1% NH3 in H2O; EtOH; 20%; 70mL / min) to give title compound 106 (62.9mg, 0.1257mmol, 56% yield, first peak) and title compound 107 (38.4mg, 0.075mmol, 44% yield, second peak in SFC). LCMS (ESI) [M+H] + = 500.2. The relative stereochemistry of both compounds was arbitrarily assigned.

[0486] Compound 106: 1 H NMR(400MHz,CD3OD)δ 5.66(s,1H),4.73-4.62(m,1H),4.08(s,4H),3.00-2.92(m,1H),2.91-2.85(m,1H),2.82(s,2H),2.70-2.68(m,2H),2 .28-2.12(m,5H),2.09-1.97(m,3H),1.89-1.84(m,2H),1.77-1.68(m,6H),1.62-1.60(m,2H),1.46(d,J=6.8Hz,6H).

[0487] Compound 107: 1H NMR(400MHz,CD3OD)δ 5.64(s,1H),4.64-4.59(m,1H),4.07(s,4H),3.01-2.90(m,1H),2.81(s,2H),2.70-2.68(m,2H),2.55-2.45(m,1H) ),2.24-2.09(m,5H),2.05-1.98(m,5H),1.91-1.76(m,2H),1.62-1.60(m,2H),1.44(d,J=6.8Hz,9H),1.29(s,1H).

[0488] Example WW: 6-((1R,3s,5S,6r)-6-(3-(4,4-difluorocyclohexyl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (compound 108) [ka] Step 1: 6-((1R,3s,5S,6r)-6-(3-(4,4-difluorocyclohex-1-en-1-yl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0489] To a mixture of potassium carbonate (87 mg, 0.63 mmol) and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (30 mg, 0.040 mmol) in 1,4-dioxane (5 mL) and water (1 mL) was added 6-((1R,3s,5S,6r)-6-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (100 mg, 0.21 mmol) and 2-(4,4-difluorocyclohexen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (103 mg, 0.42 mmol). The reaction mixture was then stirred at 75° C. under N for 3 h. The reaction mixture was concentrated in vacuo and the residue was purified by silica flash chromatography (0-10% methanol in dichloromethane) to give the title compound (40 mg, 0.0851 mmol, 40.4% yield) as a yellow solid. LCMS (ESI) [M+H] + =466.3.

[0490] Step 2: 6-((1R,3s,5S,6r)-6-(3-(4,4-difluorocyclohexyl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide [ka]

[0491] To a solution of 6-((1R,3s,5S,6r)-6-(3-(4,4-difluorocyclohex-1-en-1-yl)-1-isopropyl-1H-pyrazol-5-yl)bicyclo[3.1.0]hexan-3-yl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide (40.0 mg, 0.09 mmol) in ethanol (4 mL) was added 10% wt. Pd / C (37 mg, 0.03 mmol) under H2 (15 psi) for 32 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The crude product was purified by reverse phase chromatography (Xtimate C18, 150×40 mm×5 μm; water (NH3H2O+NH4HCO3)-ACN, 40-70%) to give the title compound (23 mg, 0.05 mmol, 70% yield). LCMS (ESI) [M+H] + = 468.2. (Relative stereochemistry assigned based on 1H NMR analysis)

[0492] Compound 108: 1 H NMR(400MHz,CDCl3)δ 5.56(s,1H),4.72-4.53(1H),4.03(s,4H),2.96-2.87(m,2H),3.08-2.83(m,2H),2.77-2.67(m,4H) ),2.59-2.54(m,5H),2.09-2.02(m,4H),1.96(brs,3H),1.88-1.59(m,3H),1.47(d,J=6.4Hz,6H).

[0493] Biological Assay Examples Preparation of mouse OPCs To assess the effect of treatments on OPCs, all treatments were assayed on two or more independent plates of epiblast stem cell-derived OPCs (EpiSCs). EpiSC-derived OPCs were obtained using a previously described in vitro differentiation protocol and culture conditions (Najm et al., 2011, Nature Methods). OPCs were expanded and frozen in aliquots. OPCs were thawed to proliferation conditions for at least one passage before use in further assays.

[0494] EC of the compound50 Determining Values In vitro phenotypic screening of OPCs EpiSC-derived OPCs were grown and expanded in poly-L-ornithine (PO) and laminin-coated flasks in N2B27 medium (DMEM / F12 (Gibco), N2-MAX (R&D Systems), B-27 (ThermoFisher), GlutaMax (Gibco)) supplemented with FGF2 (10 μg / mL, R&D systems, 233-FB-025) and PDGF-AA (10 μg / mL, R&D systems, 233-AA-050) before harvesting for experiments. Cells were plated at 150,000 / cm in growth factor-free N2B27 medium on poly-L-ornithine or poly-D-lysine-coated Cell Carrier Ultra plates (PerkinElmer) coated with laminin (Sigma, L2020). 2 Cells were seeded at a density of 1:1000. For dose-response testing, 1000x compound stocks in dimethyl sulfoxide (DMSO) were added to the assay plates to obtain an 8-point dose curve with final concentrations ranging from 1000 nM to 0.5 nM. A positive control and a DMSO vehicle control were included in each assay plate. Cells were incubated under standard conditions (37 °C, 5% CO) for 3 days and fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for 20 min. Fixed plates were washed with PBS, permeabilized with 0.1% Triton X-100, and blocked with 10% donkey serum (v / v) in PBS for 40 min. Cells were then labeled with MBP antibody (Abcam, ab7349; 1:200) for 2 h at room temperature, washed with PBS, and stained with Alexa Fluor-conjugated secondary antibody (1:500) for 45 min. Nuclei were visualized by DAPI staining (Sigma; 1 g / ml) followed by a further PBS wash.

[0495] High-Content Imaging and Analysis Cells and cell culture plates were imaged with an Operetta High Content Imaging and Analysis system (PerkinElmer). Analysis (PerkinElmer Harmony and Columbus software) began by identifying intact nuclei stained by DAPI. The perinuclear area of ​​each cell was then cross-referenced with mature myelin protein (MBP) staining to identify oligodendrocyte nuclei, from which the percentage of oligodendrocytes was calculated. EC 50 Values ​​were calculated using the Levenberg-Marquardt algorithm to fit the Hill equation to dose-response data (0.5 nM to 1000 nM). Results are shown in Table 4 (OPC EC 50 ) as shown in

[0496] Determination of potency and enzyme target GC / MS-based sterol profiling Sterols were monitored using a modified Folch wash protocol (Hubler et al., 2018, Nature). EpiSC-derived OPCs were seeded at 100,000 cells / well on PO and laminin-coated 96-well plates in growth factor-free N2B27 medium. After 24 h, cells were rinsed with saline and plates were frozen. Cholesterol-d7 standards were then added to each well, followed by drying under a stream of nitrogen and derivatization with 55 μl of bis(trimethylsilyl)trifluoroacetamide. After derivatization, 2 μl was analyzed by gas chromatography / mass spectrometry using an Agilent 5973 networked mass selective detector equipped with a 6890 gas chromatograph system and an HP-5MS capillary column (30 m × 0.25 mm × 0.25 mm). Samples were analyzed in full scan mode using electron impact ionization, ion fragment peaks were integrated to calculate sterol abundance, and quantification was compared to cholesterol-d7. The following ion fragments were used to quantify each metabolite: cholesterol-d7 (465), FF-Mas (482), cholesterol (368), zymostenol (458), zymosterol (456), desmosterol (456, 343), 7-dehydrocholesterol (456, 325), lanosterol (393), lanosterol (458), 14-dehydrozymostenol (456, 351). For reference, Table 2 shows the sterol GC-MS analytes and their relationship to inhibitors of cholesterol biosynthesis. All standards were obtained from Avanti Polar Lipids unless otherwise indicated. A calibration curve was generated by injecting various concentrations of sterol standards and maintaining a constant amount of cholesterol-D7. For normalized timostenol accumulation results, the total amount of timostenol measured after drug treatment was divided by the total amount of timostenol accumulated after 24 h treatment with 100 nM positive control standard. EC 50 Values ​​were calculated using the Levenberg-Marquardt algorithm to fit the Hill equation to dose-response data (8 doses from 0.15 nM to 333 nM). EC 50 Value (Zymo GCMS EC 50 ) are shown in Table 4. [Table 2]

[0497] Determination of binding affinity Lysate preparation: To investigate compound binding affinity to EBP, human EBP was overexpressed in human embryonic kidney 293 cells. Cell pellets were lysed in 10x weight binding buffer (50mM Tris, 5mM MgCl2, 0.1mM EDTA, 1x protease inhibitor cocktail, pH 7.5) on ice using a dounce homogenizer. The solution was centrifuged at 25,000g for 50 min at 4°C. Membrane pellets were resuspended in binding buffer and passed through a 25 5 / 8 gauge needle. After confirming the concentration by Bradford assay, the total cell membrane solution was adjusted to 20mg / mL and stored at -80°C.

[0498] Determination of the equilibrium dissociation constant Kd of the radioligand: Membranes prepared as above were pre-incubated with PVT-WGA SPA beads (PerkinElmer Cat. No. RPNQ0003) in a ratio of 0.3 mg beads / 25 μL binding buffer containing 5 μg membranes for 2 hours at 20° C. with shaking. The binding solution was centrifuged at 400 g for 5 minutes to recover the bead / membrane mixture. After resuspending the pellet in the same calculated volume of binding buffer containing 0.01% BSA (Sigma A1933), the bead / membrane mixture was added at 25 μl / well to a 384-well low binding surface plate (Perkin Elmer Cat. No. 6057480). Different concentrations of radioligand with and without 5 uM of the same non-radiolabeled ligand (for non-specific and total signals, respectively) were added to a final volume of 50 μl / well with 0.1% DMSO concentration. At equilibrium (3 h after ligand addition), the radiometric signal CPM was counted using a Microbeta2 microplate counter (Perkinelmer). Kd was determined by nonlinear regression fitting of specific signal plots against the concentration of the radioligand [3H]-Ifenprodil (Table 3). [Table 3]

[0499] [L], concentration of radioligand used in the assay Competitive binding assay to determine compound affinity: The same conditions of the radioligand Kd test were used for compound single dose percentage inhibition and equilibrium dissociation constant Ki tests, except that 50 nL of compound DMSO stock was pre-added by Echo 550 (Labcyte) to 384-well low binding surface plates (PerkinElmer catalogue no. 6057480) to reach final concentrations for single dose tests at 1 uM and dose response tests from 0.06 nM to 5 uM (8 doses, 5-fold dilutions). The pre-incubated bead / membrane mixture was added to the compound plate at 0.3 mg beads and 5 μg membrane / well. Radioligand [3H]-Ifenprodil was added to reach the optimized concentration [L], bringing the assay volume to 50 μl. At equilibrium (3 h after ligand addition), the radiometric signal was counted as above. Percent inhibition of compound at each test concentration was calculated by normalizing the CPM readout for each condition to the complete block (5 uM non-radiolabeled ligand) and unblocked (DMSO) control conditions. Compound binding inhibition IC 50 was determined by nonlinear regression fitting of the percentage inhibition plot against compound concentration. Compound Ki was calculated according to the formula Ki=IC 50 Calculated from / (1+[L] / Kd), where [L] was the radioligand concentration used in the assay. All studies had an N of ≥ 2. Data from this experiment are shown in Table 4 (hEBP SPA Ki). Determination of binding affinity to EBP-7-dehydrocholesterol reductase

[0500] [Table 5]

[0501] [Table 6]

[0502] [Table 7]

[0503] Membrane preparation: Human emopamil-binding protein and human 7-dehydrocholesterol reductase co-expressing cells were generated by transiently transfecting host human embryonic kidney (HEK) 293 cells with two DNA constructs containing the coding sequence of each protein. Cells were cultured in suspension at 37°C in FREESTYLE 293 expression medium (Thermofisher) with 5% CO2. Total cell membranes were prepared by harvesting the cell pellet, adding 10x the cell pellet weight volume of cold membrane buffer (50mM Tris, pH 7.5, 1x Roche COMPLETE EDTA-free protease inhibitor cocktail), lysing the cell pellet on ice using a Dounce homogenizer, spinning at 200g for 15 minutes at 4°C, collecting the supernatant, spinning again at 25000g for 50 minutes at 4°C, transferring the pellet to a Dounce homogenizer, resuspending the pellet by homogenizing in membrane buffer on ice to reach approximately 25mg / mL, and then keeping the total cell membrane aliquot at -80°C.

[0504] Compounds were prepared in 96-well U-bottom plates using an Echo550 instrument and 10 mM compound DMSO stock solutions, followed by backfilling DMSO to 100 nL / well and performing an 8-dose 5-fold serial dilution protocol with final test compound concentrations ranging from 0.06 to 5000 nM, n=2. 5 uM wells of DMSO and Ifenprodil were added to each plate as 0 and 100% inhibition controls, n=8 for each condition. UniFilter-96 GF / B plates were pretreated by adding 50 μl / well of 0.3% (v / v) PEI to the UniFilter-96 GF / B plates. Plates were sealed and incubated at 4 °C for 3 hours. Plates were then washed 3 times with ice-cold assay buffer. Radioligand binding assays were prepared by adding hEBP-DHCR7 membranes diluted in assay buffer to 96-well compound plates at 66.7 μg / ml × 150 μl / well to reach 10 μg membranes per well. [3H]-((S)-6-(2-methyl-3-(6-(trifluoromethyl)pyridin-3-yl)propyl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide or (R)-6-(2-methyl-3-(6-(trifluoromethyl)pyridin-3-yl)propyl)-2-thia-6-azaspiro[3.4]octane 2,2-dioxide) diluted in assay buffer was then added at 25 nM × 50 μl / well. After incubation, plates were centrifuged at 1000 rpm for 30 min. The plates were then sealed and agitated at 600 rpm for 5 min at 22° C., then incubated for 3 h at 22° C. The incubation was stopped by transferring the binding solution to a pretreated UniFilter-96 GF / B plate, vacuum filtered, and then washed 4 times with ice-cold assay buffer. After this, the plates were dried at 37° C. for 45 min. The plates were then sealed at the bottom. 40 μl / well of scintillation cocktail was added to the plate. The plates were then read using a MicroBeta2 microplate counter, and the data was analyzed.For reference and test compounds, results are expressed as % inhibition using the following normalization formula: N=100-100×(U-C2) / (C1-C2), where U is the unknown, C1 is the mean of the high controls, and C2 is the mean of the low controls. IC50 was determined by fitting the percent inhibition as a function of compound concentration with the Hill equation using XLfit. Results are expressed as hEBP-DHCR7 Ki (uM) in Table 4. Ki was calculated as above, and * indicates one or more isomers that have been isolated but have not been assigned stereochemistry. [Table 4-1] [Table 4-2] [Table 4-3]

[0505] Efforts have been made to ensure accuracy with respect to numbers used (eg, amounts, temperature, etc.) but some experimental errors and deviations should be accounted for.

[0506] One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the subject matter described herein, and the present disclosure is in no way limited to only the methods and materials described.

[0507] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter belongs and are consistent with Singleton et al (1994) Dictionary of Microbiology and Molecular Biology, 2nd Ed., J. Wiley & Sons, New York, NY; and Janeway, C., Travers, P., Walport, M., Shlomchik (2001) Immunobiology, 5th Ed., Garland Publishing, New York.

[0508] Throughout this specification and the claims, the words "comprise," "comprises," and "comprising" are used in their non-exclusive sense, unless the context otherwise requires. It is understood that the embodiments described herein include "consisting of" and / or "consisting essentially of" embodiments.

[0509] When a range of values ​​is provided, it is understood that the upper and lower limits of the range include each intervening value, to one-tenth of the unit of the lower limit, between the range and any other value or intervening value stated within the range, unless the context dictates otherwise. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also included, subject to any specifically excluded limit within the stated range. When the stated range includes one or both of the limits, ranges excluding one or both of the included limits are also included.

[0510] Many modifications and other embodiments of what is described herein will come to mind to one skilled in the art to which this subject matter pertains having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. It is to be understood, therefore, that the subject matter is not limited to the specific embodiments disclosed, and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, these terms are used in a generic and descriptive sense only and not for purposes of limitation.

Claims

1. Formula I 【Chemistry 141】 or a pharma- ceutically acceptable salt thereof, wherein j 1 and m 1 are each independently 1, 2 or 3; j 2 and m 2 are each independently 0, 1, 2, or 3; Here, j 1 and 2 The sum of and m 1 And 2 The sum of each is 5 or less, and j 1 and 2 And 1 And 2 The sum of m is 9 or less, and 2 and 2 when one of is 0, the other is 1, 2, or 3; Ring A is a 5-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from the group consisting of O, N and S; R y is, if present, in each occurrence, halogen, C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 Alkoxy, C 3 ~C 7 Cycloalkyl, C 3 ~C 7 independently selected from the group consisting of halocycloalkyl, and -CN; n is 0, 1, 2, or 3; R x is halogen, C 1 ~C 10 Alkyl, halo-C 1 ~C 6 Alkyl, C 1 ~C 10 Alkenyl, halo-C 1 ~C 6 Alkenyl, C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 Alkoxy, 5- to 7-membered heterocyclyl, C 3 ~C 7 Cycloalkyl, C 6 ~C 10 selected from the group consisting of aryl, 5- to 6-membered heteroaryl, and -CN; wherein the heterocyclyl, cycloalkyl, aryl or heteroaryl is (R xA ) q wherein q is 0, 1, 2, 3, 4, or 5; Each R xA is halogen, C 1 ~C 6 Alkyl, Hydroxy, C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 Alkyl, -SO 2 (C 1 ~C 6 The compound of formula I, or a pharma- ceutically acceptable salt thereof, optionally substituted with -N, -N independently selected from the group consisting of -N, -N-alkyl, and -CN.

2. 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein ring A contains 1, 2 or 3 N.

3. 3. The compound according to claim 1 or 2, or a pharma- ceutically acceptable salt thereof, wherein Ring A is selected from the group consisting of pyrazolyl, triazolyl and imidazolyl.

4. The compound has the formula Ia 【Chemistry 142】 or a pharma- ceutically acceptable salt thereof, 1 , X 2 , X 3 , and X 4 are respectively N, NH, and R x Or R y N, R substituted with x Or R y or CH substituted with X 1 , X 2 , X 3 , and X 4 The compound of claim 1 , wherein one, two or three of are N, NH or substituted N.

5. X 2 is C-R x 5. The compound of claim 4, wherein:

6. X 3 6. The compound of claim 4 or 5, or a pharma- ceutically acceptable salt thereof, wherein:

7. The compound according to any one of claims 1 to 6, wherein n is 1, or a pharma- ceutically acceptable salt thereof.

8. The compound has the formula Ib 【Chemistry 143】 or a pharma- ceutically acceptable salt thereof, wherein X 1 is CH or N, R y is C 1 ~C 6 Alkyl or C 3 ~C 5 The compound of claim 4 which is cycloalkyl.

9. R y or a pharma- ceutically acceptable salt thereof. The compound according to any one of claims 1 to 8, wherein each occurrence of is selected from the group consisting of methyl, ethyl, propyl, butyl and cyclobutyl.

10. R y 10. The compound of claim 9, or a pharma- ceutically acceptable salt thereof, wherein is propyl.

11. R y 11. The compound of claim 10, or a pharma- ceutically acceptable salt thereof, wherein is isopropyl.

12. R x But, C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, C 1 ~C 10 Alkenyl, halo-C 1 ~C 6 Alkenyl, halo-C 1 ~C 6 Alkoxy, C 3 ~C 7 Cycloalkyl, C 6 ~C 10 aryl and 5-6 membered heteroaryl, wherein said cycloalkyl, aryl or heteroaryl is selected from the group consisting of (R xA ) q wherein q is 0, 1, 2 or 3, and, if present, each R xA is halogen, C 1 ~C 6 Alkyl, Hydroxy, C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 Alkoxy and halo-C 1 ~C 6 12. The compound of claim 1, wherein the aryl group is substituted with aryl, aryl or aryl alkyl, or a pharma- ceutically acceptable salt thereof.

13. R x But, Hello-C 1 ~C 6 13. The compound of claim 12, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

14. R x 14. The compound of claim 13, or a pharma- ceutically acceptable salt thereof, wherein is selected from the group consisting of trifluoromethyl, difluoromethyl, fluoromethyl, trifluoroethyl, difluoroethyl, and fluoroethyl.

15. R x 15. The compound of claim 14, or a pharma- ceutically acceptable salt thereof, wherein is trifluoromethyl.

16. R x But, C 6 ~C 10 Aryl, or (R xA ) q wherein q is 0, 1, 2, or 3, and, if present, each R xA is halogen, C 1 ~C 6 Alkyl, Hydroxy, C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 Alkoxy, and halo-C 1 ~C 6 13. The compound of claim 12, or a pharma- ceutically acceptable salt thereof, wherein the heteroaryl is 5-6 membered heteroaryl substituted with (independently selected from the group consisting of alkyl).

17. R x is phenyl or (R xA ) q 17. The compound of claim 16, wherein R is a 6-membered heteroaryl substituted with R, or a pharma- ceutically acceptable salt thereof.

18. The compound has the formula Ic 【Chemistry 144】 or a pharma- ceutically acceptable salt thereof, wherein E 1 , E 2 , E 3 , E 4 , and E 5 are each independently N, R XA C or CH when bonded to E 1 , E 2 , E 3 , E 4 , and E 5 9. The compound of claim 8, wherein up to three of are N and q is 1 or 2.

19. E 1 is CH, and E 2 is N and E 3 is C-R XA And E 4 is C-R XA And E 5 20. The compound of claim 18, or a pharma- ceutically acceptable salt thereof, wherein:

20. E 1 , E 2 , E 3 , and E 5 is CH, and E 4 is C-R XA 20. The compound of claim 18, wherein:

21. E 1 is CH, and E 2 is N and E 3 is CH, and E 4 is C-R XA And E 5 20. The compound of claim 18, or a pharma- ceutically acceptable salt thereof, wherein:

22. E 1 , E 2 , E 4 , and E 5 is CH, and E 3 is C-R XA 20. The compound of claim 18, wherein:

23. E 1 is CH, and E 2 is N and E 3 is C-R XA And E 4 is N and E 5 20. The compound of claim 18, or a pharma- ceutically acceptable salt thereof, wherein:

24. E 1 , E 2 , and E 3 is CH, and E 4 is C-R XA And E 5 is N, or a pharma- ceutically acceptable salt thereof.

25. E 1 is CH, and E 2 is N and E 3 is C-R XA And E 4 and E 5 20. The compound of claim 18, or a pharma- ceutically acceptable salt thereof, wherein:

26. E 1 is CH, and E 2 is CH, and E 3 is N and E 4 is C-R XA And E 5 is N, or a pharma- ceutically acceptable salt thereof.

27. E 1 is CH, and E 2 is CH, and E 3 is N and E 4 is C-R XA And E 5 20. The compound of claim 18, or a pharma- ceutically acceptable salt thereof, wherein:

28. E 1 is N and E 2 is CH, and E 3 is CH, and E 4 is C-R XA And E 5 20. The compound of claim 18, or a pharma- ceutically acceptable salt thereof, wherein:

29. R XA But, Hello-C 1 ~C 6 29. The compound of any one of claims 18 to 28, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

30. R XA 30. The compound of claim 29, or a pharma- ceutically acceptable salt thereof, wherein is selected from the group consisting of trifluoromethyl, difluoromethyl, fluoromethyl, trifluoroethyl, difluoroethyl, and fluoroethyl.

31. R XA 31. The compound of claim 30, or a pharma- ceutically acceptable salt thereof, wherein is trifluoromethyl.

32. X 1 The compound according to any one of claims 4 to 31, or a pharma- ceutically acceptable salt thereof, wherein is CH.

33. j 1 and 2 The sum of and m 1 And 2 The sum of each is 4 or less, and j 1 and 2 And 1 And 2 The compound according to any one of claims 1 to 32, or a pharma- ceutically acceptable salt thereof, wherein the sum of: is 7 or less.

34. j 1 and 2 The sum of and m 1 And 2 The sum of each is 3 or less, and j 1 and 2 And 1 And 2 The compound according to any one of claims 1 to 32, or a pharma- ceutically acceptable salt thereof, wherein the sum of: is 5 or less.

35. m 1 and m 2 The compound according to any one of claims 1 to 34, wherein one of the following is 1 and the other is 2, or a pharma- ceutically acceptable salt thereof.

36. m 1 and m 2 and R 1 is 0, R 2 is 1, or a pharma- ceutically acceptable salt thereof.

37. m 1 and m 2 The compound according to any one of claims 1 to 34, wherein one of is 3 and the other is 1, or a pharma- ceutically acceptable salt thereof.

38. m 1 and m 2 The compound according to any one of claims 1 to 34, or a pharma- ceutically acceptable salt thereof, wherein each of

39. m 1 is 3, m 2 The compound according to any one of claims 1 to 34, or a pharma- ceutically acceptable salt thereof, wherein:

40. j 1 and j 2 The compound according to any one of claims 33 to 39, wherein one of the following is 1 and the other is 2, or a pharma- ceutically acceptable salt thereof.

41. j 1 and j 2 40. The compound according to any one of claims 33 or 35 to 39, wherein one of is 3 and the other is 1, or a pharma- ceutically acceptable salt thereof.

42. j 1 and j 2 and R is 0, R is 1, or a pharma- ceutically acceptable salt thereof.

43. j 1 and j 2 and n is 1 or 2; and n is 2 or 3. The compound according to any one of claims 33 or 35 to 39, or a pharma- ceutically acceptable salt thereof.

44. j 1 is 3, and j 2 The compound according to any one of claims 33 to 38, or a pharma- ceutically acceptable salt thereof, wherein

45. j 1 is 1, j 2 is 1, m 1 is 1, m 2 is 1 or j 1 is 1, j 2 is 1, m 1 is 2, m 2 is 1 or j 1 is 1, j 2 is 1, m 1 is 1, m 2 is 2 or j 1 is 1, j 2 is 1, m 1 is 2, m 2 is 2 or j 1 is 2, and j 2 is 1, m 1 is 2, m 2 is 1 or j 1 is 2, and j 2 is 1, m 1 is 1, m 2 is 3 or or j 1 is 2, and j 2 is 1, m 1 is 3, m 2 is 1, 35. The compound according to any one of claims 1 to 34, or a pharma- ceutically acceptable salt thereof.

46. The compound is of formula Ic or a pharma- ceutically acceptable salt thereof, wherein: E 1 , E 2 , E 3 , E 4 , and E 5 are each independently N, C-R XA or CH, 1 , E 2 , E 3 , E 4 , and E 5 at most three of are N; X 1 is N or CH, G is O, S and C(R 30 R 40 ) selected from the group consisting of R 30 is hydrogen, halo-C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, halogen, halo-C 1 ~C 6 selected from the group consisting of alkoxy and hydroxy; R 40 is halogen, halo-C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 selected from the group consisting of alkoxy and hydroxy; q is 1 or 2; Each R XA is halogen, C 1 ~C 6 Alkyl, Hydroxy, C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 Alkoxy and halo-C 1 ~C 6 independently selected from the group consisting of alkyl, m 1 and m 2 one of m is 2 and the other is 1, or m 1 and m 2 are each 1 or m 1 and m 2 are 2, j 1 and j 2 are each 1 or j 1 and j 2 one of j is 2 and the other is 1, or 1 and j 2 20. The compound of claim 18, wherein each is 2.

47. The central bicyclic 3.1.0 ring is 【Chemistry 145】 47. The compound according to any one of claims 1 to 46, wherein:

48. 48. The compound of any one of claims 1 to 47, selected from the group consisting of the compounds of Table 1 or a pharma- ceutically acceptable salt thereof.

49. 49. A pharmaceutical composition comprising a compound according to any one of claims 1 to 48 or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

50. 50. A method of treating a disorder in a subject in need thereof, comprising administering to said subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 48 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 49.

51. A compound according to any one of claims 1 to 48, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 49, for use in treating a disorder in a subject in need thereof.

52. 50. Use of a compound according to any one of claims 1 to 48 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 49, in the manufacture of a medicament for treating a disorder in a subject in need thereof.

53. 50. A method of promoting myelination in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 48 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 49.

54. A compound according to any one of claims 1 to 48, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 49, for use in promoting myelination in a subject in need thereof.

55. 50. Use of a compound according to any one of claims 1 to 48 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 49, in the manufacture of a medicament for promoting myelination in a subject in need thereof.

56. 56. The method, compound or use of any one of claims 50 to 55, wherein the subject has a myelin-related disorder.

57. The myelin-related disorder is multiple sclerosis (MS), neuromyelitis optica (NMO), optic neuritis, childhood leukodystrophy, neonatal white matter injury, age-related dementia, schizophrenia, progressive multifocal leukoencephalopathy (PML), encephalomyelitis (EPL), central pontine myelinolysis (CPM), adrenoleukodystrophy, Alexander disease, Pelizaeus-Merzbacher disease (PMD), vanishing white matter disease, Wallerian degeneration, transverse myelitis, amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, and the like.

57. The method or use of claim 56, wherein the condition is selected from the group consisting of glaucoma, Parkinson's disease, spinal cord injury, traumatic brain injury, post-radiation injury, neurological complications of chemotherapy, stroke, acute ischemic optic neuropathy, vitamin E deficiency, isolated vitamin E deficiency syndrome, Bassen-Kornzweig syndrome, Marchiafaver-Bignami syndrome, metachromatic leukodystrophy, trigeminal neuralgia, acute disseminated encephalitis, Guillain-Barré syndrome, Charcot-Marie-Tooth disease, Bell's palsy, and radiation-induced demyelination.

Citation Information

Patent Citations

  • Pyrazole derivatives and their use as inhibitors of dlk

    JP2017504605A

  • Compounds and methods for promoting myelination

    JP2019525938A

  • Triazoles for the treatment of demyelinating diseases

    WO2016197009A1

  • Substituted oxazolidinones for the treatment of mammalian infections

    WO2020021468A1